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Chapter 1  
 
INTRODUCTION   
 
 
Motivation 
Current treatment for moderate and severe mitral regurgitation (MR), due to degenerative 
mitral valve (MV) disease, is open-chest surgical repair or replacement, as there are no 
known pharmacologic therapies that directly affect the disease process [1, 2]. 
Approximately one third of MV replacements are performed in lieu of repair due to lack of 
expertise and not the complexity of the lesions, indicating a need for MV repair techniques 
that can be more broadly adopted [3]. Additionally, it is estimated that up to 50% of high-
risk patients with severe symptomatic MR are not referred for surgery due to co-
morbidities that may confer high perioperative risk [4]. As a result, percutaneous 
approaches to MV repair have received a great deal of interest. Depending on the lesions 
present, current MV repairs may include annuloplasty, leaflet resection, or chordal transfer 
or replacement. While there are several percutaneous annuloplasty and chordal repair 
devices currently in development [5], there are currently no percutaneous techniques to 
perform leaflet resection, which is used in 70-80% of all surgical MV repairs [6, 7]. Thus, 
there is a need for a percutaneous leaflet resection technique in the expanding MV repair 
armamentarium [8].  
Radiofrequency (RF) ablation is a well-developed technique that has been used to 
treat cardiac electrophysiology abnormalities and uses electrical energy to form thermal 
lesions by resistive heating. The primary structural component of MV leaflets is collagen, 
which denatures and contracts when heated to >65°C. As a result, RF ablation can be used 
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to reduce the size of enlarged myxomatous MV leaflets [9, 10], providing a percutaneous 
alternative to open-chest surgical leaflet resection (Fig. 1.1). However, application of RF 
ablation to MV leaflets in a dynamic hemodynamic environment is difficult without 
additional catheter stability. To address this, we have developed cryo-anchoring, a 
technique similar to cryoablation that uses pressurized nitrous oxide to provide cooling of a 
catheter tip [11]. The sub-freezing temperatures provide adhesion, allowing stable and 
reversible attachment of a catheter tip to a moving MV leaflet. 
The objective of this work is to translate a combined RF ablation and cryo-
anchoring (RFC) catheter for treatment of degenerative MV disease from concept to in vivo 
animal models. The work that follows will describe the design and development of the RFC 
catheter system and will evaluate the performance of the RFC catheter according to three 
specific aims. 
 
 
 
Fig. 1.1: RFC Catheter Concept 
The combined radiofrequency ablation and cryo-anchoring catheter concept to treat 
enlarged MV leaflets percutaneously.  
 
MV Prolapse Normal Closure
RF Ablation
Cryo-Anchor
MR
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Specific Aims 
The hypothesis of this investigation is that a combined RF ablation and cryo-anchoring 
catheter can reversibly adhere to MV leaflets in a beating heart environment without 
negatively affecting hemodynamics, and that RF ablation can be used to thermally shrink 
enlarged MV leaflet tissue.  
 
1. Develop an RFC catheter prototype and assess treatment feasibility in static bench 
experiments. The goals of this aim are (1) to quantify the magnitude of the thermal 
shrinkage lesions generated by the RFC catheter and (2) to evaluate cryo-anchor 
effectiveness in the presence of RF ablation 
 
2. Quantify the mechanical and morphological changes of healthy porcine mitral valve 
leaflets exposed to simultaneous cryo-anchoring and radiofrequency ablation in a 
physiologic flow environment. The goals of this aim are (1) to identify indicators of MV 
leaflet thermal alteration and (2) to demonstrate that combined cryo-anchoring and 
radiofrequency ablation effectively alters mitral valve leaflet morphology and compliance 
in a hemodynamic environment that mimics in vivo conditions. 
 
3. Develop a 2D echocardiographic technique for clinically-relevant measurement of 
MV leaflet shrinkage and assess procedural efficacy in a porcine animal model. The goals of 
this aim are (1) to identify clinically measurable qualitative and quantitative indicators of 
MV thermal shrinkage and (2) to assess treatment efficacy in vivo.   
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Chapter 2  
 
BACKGROUND AND SIGNIFICANCE 
 
 
Mitral Valve Anatomy and Function 
The mitral valve (MV) is a bi-leaflet heart valve which sits between the left atrium and left 
ventricle of the heart. The complex anatomy of the MV consists of five primary 
components: (1) the annulus, a fibrous ring of tissue located at the base of the atrium, (2) 
two leaflets, consisting of the anterior and posterior leaflets, (3) commissures, which are the 
sites of separation between the leaflets, (4) chordae tendineae, which act to tether the free 
edges of the MV leaflets to the ventricular wall, and (5) the papillary muscles, the sites of 
chordae tendineae attachment (Fig. 2.1). The anterior leaflet is the larger of the two leaflets, 
and is approximately twice the height of the posterior leaflet [12]. The posterior leaflet 
consists of three distinct scallops, with the central scallop being the largest in 
approximately 90% of normal hearts [12].  
During normal functioning of the heart, the MV opens during diastole in order to 
allow passive filling of the left ventricle. During systole, when the heart is pumping blood 
to the systemic circulation of the body, the MV is closed and must resist large pressures 
(>120 mmHg) exerted on it to prevent reverse blood flow. Abnormalities of any of the 
primary components of the MV, as well as problems associated with left atrial or left 
ventricular dysfunction, can lead to malfunctioning of the MV [13], and the type and 
severity of the diseased structure determines whether surgical techniques are needed to 
treat the defect. 
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Fig. 2.1: Mitral Valve Anatomy 
A: Anatomy of the mitral valve, indicating the five major structural components: the 
annulus, leaflets, commissures, chordae tendineae, and papillary muscles. Reproduced 
with permission from [1], Copyright Massachusetts Medical Society. B: A comparison of 
the larger, anterior leaflet and the three scallops that form the posterior leaflet.  
 
 
 
anterior
posteriorB
A
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Mitral Regurgitation and Mitral Valve Prolapse 
Problems associated with the MV result in a “leaky” valve, in which reverse blood flow 
occurs across the MV during systole. This is termed mitral regurgitation (MR), and severe 
cases of MR can lead to left ventricular dysfunction and congestive heart failure [14]. Poor 
leaflet coaptation is the endpoint through which MR occurs, and one specific syndrome 
that may result in MR is termed mitral valve prolapse (MVP), which is found in 
approximately 2% of the population [15] and is defined as superior displacement greater 
than 2 mm of one or both leaflets into the atrium during systole [16] (Fig. 2.2). The severity 
and underlying cause of MR dictates the type of treatment administered, and open-chest 
replacement or repair is the current gold standard for treatment of moderate-to-severe and 
 
 
Fig. 2.2: Mitral Valve Prolapse 
MV prolapse can affect one or both leaflets. Shown above is a MV with enlarged leaflet 
billowing into the left atrium during systole (top left) and significant MR (top right) and 
imaged with 2D transesophageal echocardiography. 3D transesophageal 
echocardiography (bottom left) and the surgical view (bottom right) further demonstrate 
leaflet billowing. Reproduced with permission from [17], Copyright Nature Publishing 
Group. 
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severe MR in patients with symptoms of left ventricular dysfunction [18]. This represents a 
significant problem in older patients who are more at-risk when undergoing invasive 
surgical procedures, a population that is currently growing, as the population of Americans 
aged 65+ is estimated to more than double – from 34 to 79 million – over the next 50 years 
[19].  
 
Degenerative MV Disease: Common Characteristics 
Dysfunction of the MV is classified into one of two distinct categories: (1) degenerative 
disease, a primary dysfunction due to abnormalities of the MV itself, and (2) functional 
disease, dysfunction that is secondary to diseases of the left ventricle or other areas of the 
heart [20]. While percutaneous MV repair devices are currently being developed to treat 
lesions arising from each of these sub-types, the RFC catheter is a leaflet repair device, and 
therefore targets lesions of degenerative disease. Degenerative disease of the MV apparatus 
occurs across a spectrum of conditions (Fig. 2.3), and the ends of this spectrum are termed 
Barlow’s disease and fibroelastic deficiency. Little is known about the underlying 
molecular mechanisms of degenerative diseases of the MV, thus no pharmacologic 
therapies currently exist [2, 21].  
Fibroelastic deficiency results from impaired production of connective tissue and 
typically presents late in life (>60 years) with only a short history of known disease. The 
primary lesion in fibroelastic deficiency is chordal rupture, due to the frail, thin nature of 
the chordae and MV leaflets [22]. Additionally, MV leaflets with fibroelastic deficiency 
often contain a region of thickening with excess tissue in the area of prolapse, most often 
present in the central segment of the posterior leaflet. Otherwise, MV leaflets with 
fibroelastic deficiency are typically normal in size.  
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Fig. 2.3: Classification of Degenerative MV Disease 
Degenerative disease of the MV occurs across a spectrum of conditions, with the ends of 
the spectrum termed fibroelastic deficiency (FD, or FED in above figure) and Barlow’s 
disease. Reproduced with permission from [23]. Copyright Learned Society and Oxford 
University Press. 
 
 
In contrast to fibroelastic deficiency, Barlow’s disease presents earlier in life (<60 
years) with myxoid infiltration as the primarily pathology [22]. Patients presenting with 
Barlow’s disease may go many years before symptoms become severe enough to require 
treatment [24]. On echocardiography, Barlow’s leaflets appear thick and voluminous, with 
multi-segmental prolapse [25, 26]. Surgical lesions may include excess tissue, enlarged 
leaflets, elongated or ruptured chords, and calcification of the chords, papillary muscles, or 
annulus. While myxomatous infiltration is not well characterized at the cellular and 
molecular levels, histological analysis of myxomatous MVs has revealed leaflets with 
disrupted and compromised collagen architecture and an increase in proteoglycans; 
chordae can be similarly affected [2]. Previous morphologic analysis of myxomatous MV 
leaflets demonstrated a two-fold increase in valvular surface area, due to significant 
increases in both anterior and posterior leaflet surface areas [27]. Additionally, mechanical 
testing has shown that myxomatous leaflets are twice as extensible as normal MV leaflets 
[28]. Similar changes in size and extensibility have been shown in MV chordae [29]. Given 
9 
 
the variety and severity of lesions, surgical repair of Barlow’s disease is generally more 
complex than that of fibroelastic deficiency [30].  
 
Surgical Repair of the MV Due to Degenerative MR 
The current standard in long-term treatment of MR due to degenerative disease is open-
chest surgical repair or replacement, depending on the severity and structure affected. 
Repair of the MV is generally preferred over replacement due to lower rates of 
thromboembolism, resistance to endocarditis, the avoidance of a prosthetic valve and 
associated long-term anticoagulation therapy, as well as the excellent durability of repairs – 
as long as 25 years – compared to valve replacement [20]. Half of all patients undergoing 
MV replacement, with either a mechanical or bioprothesis, die within 10-15 years, with 
most deaths being valve or cardiac related [31-33]. Further, 20% of all patients receiving a 
MV replacement require reoperation within 20 years [31]. For comparison, MV repair using 
Carpentier’s techniques offers a mortality rate comparable to that of the general population 
[34], with 6% incidence of reoperation within the first 20 years [34-36]. One benefit of MV 
repair is that it preserves the sub-valvular apparatus, consisting of the chords and papillary 
muscles, as removal of these structures has been associated with detrimental effects on left 
ventricular shape and performance [37-39].  
The differentiation of degenerative MV disease into Barlow’s and fibroelastic 
deficient sub-types when comparing long-term repair outcomes has only recently been 
made [22, 40]. One reason is that degenerative disease of the MV can frequently present in 
the middle of the spectrum of disease (Fig. 2.3), with lesions that are characteristic of each 
sub-type. Thus, when describing MV repair due to degenerative disease, the type of lesion 
and repair techniques are often reported without regard for disease sub-type [30]. 
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There are a variety of surgical repair techniques employed by the cardiac surgeon, 
and the techniques used depend largely on the individual lesions present. Repairs of 
degenerative sub-types of MV disease frequently include a combination of leaflet resection 
and implantation of an annuloplasty ring [41]. Resection of excess leaflet tissue typically 
involves removal of a triangular or quadrangular section of tissue near the location of 
prolapse [42], while annuloplasty involves implantation of a rigid or flexible ring around 
the MV annulus at the base of the atrium. Implantation of annuloplasty rings are frequently 
used to correct an enlarged MV annulus, but their use in the normal-sized MV annulus has 
also been associated with improved long-term clinical outcomes [6, 43]. While it us 
unknown why annuloplasty usage in MVs with a normal-sized annulus improves 
outcomes, it is believed to be due to the progressive nature of the disease [6, 7]. Only about 
70% of patients are free from MR > grade 2 (moderate) 15 years after treatment [7, 35], 
indicating the need for possible re-treatment in the later stages of life. In addition to leaflet 
resection and annuloplasty repair techniques, chordal repairs are also commonly 
performed and can include chordal shortening, chordal transfer, or implantation of 
synthetic PTFE chords [44, 45]. For an analysis of the frequency of usage for the most 
common repair techniques used to treat degenerative disease, see Table 2.1. 
 
Clinical Significance of Less Invasive Techniques 
In 2003, 43,000 MV valve procedures were performed in the U.S. alone, with 2,800 deaths 
due directly and another 6,600 due in part to MV disease [46]. Recently, less-invasive, 
percutaneous techniques have been in development to treat MV disease. Percutaneous 
techniques are often preferred over surgical procedures because they have been shown to 
reduce the need for blood transfusions, decrease rates of infection, and reduce recovery 
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time [10, 47]. These benefits have the potential to reduce procedure cost and time 
dramatically. Additionally, approximately one third of MV replacements are performed in 
lieu of repair due to lack of expertise and not the complexity of the lesions, indicating a 
need for MV repair techniques that can be more broadly adopted [3]. Further, it is 
estimated that up to 50% of high-risk patients with severe symptomatic MR are not referred 
for surgery due to co-morbidities [4]. As a result, percutaneous approaches to MV repair 
have received a great deal of interest. 
Due to the variety of lesions that may be present, and the multitude of techniques that 
may be used in surgery, attempts to percutaneously repair degenerative MVs may be best 
served by a combination of different repair devices, each with a specialized function. One 
example is the sub-optimal repair rates of the MitraClip device. Repair is sufficiently 
efficacious in some patients, but not in a majority [48]. There will likely be no percutaneous 
repair strategy that is ideal for all patients, and a combination of approaches with different 
percutaneous devices may best replicate the combination of repair strategies currently 
employed by surgeons. While there are several percutaneous annuloplasty and chordal 
repair devices currently in development [5, 8], there are currently no percutaneous 
techniques to perform leaflet resection, which is used in 70-80% of all surgical MV 
repairs[6, 7]. Thus, there is a need for a percutaneous leaflet resection technique in the 
expanding MV repair armamentarium [8]. 
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Table 2.1: General classification of MV repairs for correction of degenerative disease. 
 
 
 
 
 
 
 
 
 
Percutaneous Application of Radiofrequency Ablation to Treat MVP 
One possible method to replace leaflet resection with a percutaneous technique is 
radiofrequency ablation (RF), an established technique for treating cardiac arrhythmias that 
has been around since the mid-1980s. RF ablation utilizes electrical signals at around 300-
700 kHz in order to generate resistive heating for ablation of tissue. It is dependent on 
power, electrode-tissue interface temperature, electrode size, and contact pressure [49]. The 
target of RF ablation is the collagen architecture of the MV leaflets, which contributes to 
much of the strength and mechanical properties of the tissue [50]. Previously, the fibrillar 
structure of collagen has been shown to denature and contract when heated to greater than 
65°C [51]. Additionally, transmission electron microscopy has shown an increase in 
collagen fiber diameter and a loss of cross-striations with increasing application of RF 
power [52]. The goal of using RF ablation to treat enlarged MV leaflets is to induce 
permanent changes in leaflet geometry via resistive heating of collagen and subsequent 
shortening. 
  Flameng [6]   David [7] 
Total repairs 348   649 
Leaflet Repair 
     
Segmental resection 274 79% 
 
431 66% 
Other leaflet intervention 13 4%   0 0% 
Chordal Repair 
     
Chordal shortening 22 6% 
 
39 6% 
Chordal transfer 27 8% 
 
40 6% 
Chordal replacement (PTFE) 48 14%   380 59% 
Annuloplasty Rings 
     
Rigid ring 326 94% 
 
96 15% 
Flexible ring 11 3% 
 
141 22% 
Incomplete ring 0 0% 
 
379 58% 
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In MV leaflets, collagen is preferentially aligned with the circumference of the MV 
annulus, which causes an anisotropic loading response in normal leaflets (Fig. 2.4A-B). This 
collagen alignment can affect the response of MV tissue to application of RF energy. 
Following treatment with RF ablation, collagenous tissues undergo shortening primarily in 
the direction of collagen alignment. Prior treatment of porcine MV leaflets with RF ablation 
in vitro has demonstrated directional length changes that are dependent on RF power, with 
the circumferential direction shortening much more than the radial direction [9]. 
 
History of RF Ablation of the MV 
The history of utilizing percutaneous application of RF ablation to alter the MV apparatus 
is brief and began with two animal studies published in 2008. The first of these studies used 
the QuantumCor device, which uses a circular RF ablation probe to reduce the MV annulus 
diameter and is intended as a treatment for functional MR [53]. Use of the QuantumCor 
device in 16 sheep reduced the anterior-posterior dimension of the MV annulus by more 
than 20%, and these changes remained durable for the duration of the 180-day study, with 
 
 
Fig. 2.4: Anisotropic Mechanical Response of MV Leaflets 
A: Collagen is preferentially aligned with the circumferential (circ) direction in MV leaflets. 
B: Due to this collagen alignment, MV leaflets are more stiff in the circumferential 
direction than the radial direction.  
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tissue fibrosis and necrosis present at the endpoint [54]. This study was performed in 
normal sheep, with little to no traces of MR at the beginning of the study. 
The second study used a standard RF ablation catheter to apply RF energy directly 
to MV leaflets in order to reduce leaflet size and alter biomechanical properties and was 
performed on two separate treatment groups [10]. The first was an acute procedure 
performed on n=3 canines with severe MR in which RF ablation was applied under open-
chest surgery. An average of 4 ablations at a power of 16 W for 40 seconds produced 
anywhere from 44% to 60% reduction in MR, as measured by echocardiography. An 
additional chronic study was performed on n=3 healthy canines, and RF ablation was 
applied percutaneously until structural and/or functional alteration of the MV was 
demonstrated by echocardiography. It took an average of 20 ablations for 60 seconds at a 
power of 50-60 W to induce noticeable changes, due largely to the difficulty in maintaining 
adequate contact between the RF ablation catheter tip and the MV leaflets. While open-
chest application of RF ablation demonstrated significant reductions in post-ablation MR, 
the number of ablations required in the percutaneous procedure indicates that a method to 
stabilize catheter contact with the moving MV apparatus is clearly warranted. Further, 
while leaflets experience small areas of coagulation necrosis and areas of fibroblast 
proliferation, leaflets remained durable over 6 weeks. 
 
Cryo-Anchoring for MV Attachment 
In order to enable more reliable application of RF energy to MV leaflets, the RF electrode on 
the catheter device must remain in direct contact with the target tissue area. The 
requirements for an anchoring device are to enable reversible attachment to either the 
posterior or anterior MV leaflet, depending on the desired ablation target. Anchoring to the 
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chords for RF ablation represents another potential target. Cryoablation is one technology 
that has been used to percutaneously treat cardiac arrhythmias since 1999 [55], which uses 
pressurized liquid nitrogen to cool a catheter tip to temperatures as low as -80°C. A 
technique termed cryo-mapping was developed for use with these cryoablation catheters, 
which cools the catheter tip to temperatures as low as -30°C to temporarily induce 
electrophysiological changes in cardiac tissues [49]. This is performed with minimal cellular 
damage and little effect on the structural properties of the tissue [56]. Given the negligible 
amount of tissue damage induced at temperatures as low as -30°C, and the temporary, 
reversible tissue attachment that can be created, this cryo-anchoring technique represents 
one potential strategy to maintain attachment to moving MV leaflets. 
 
Potential Complications 
In designing the RFC catheter treatment strategy and studying the effects of RFC catheter 
treatment on the MV, it is important to consider the potential complications that may arise 
as a result of the procedure. Potential complications of percutaneous treatment of the MV 
with the RFC catheter can be classified according to one of three categories, which are 
discussed further below: 1) complications arising as a result of RF ablation and cryo-
anchoring delivery, or catheter manipulation, within the heart and vasculature generally, 2) 
complications arising from ablation of the MV structure specifically, and 3) complications 
that compromise long-term treatment efficacy, or re-dilation of the MV leaflet after 
treatment.  
 
General Complications of RF Ablation and Catheter Manipulation in the Heart. 
Complications that may result due to administration of RF energy, cryo-anchoring, or 
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general manipulation of a catheter within the vasculature and heart are well-known. RF 
ablation and cryoablation catheters have been used safely and successfully since the 1980s 
and 1990s [49, 55], respectively, to treat a variety of arrhythmias in the heart. A primary 
concern of RF ablation is tissue charring and thrombus formation due to the high 
temperatures produced during treatment, and the associated risk of embolization [57-59]. 
When ablation is performed within a cardiac chamber, thromboembolic risk is as high as 
2% [57, 58]; however, the risk of cerebral embolization is much lower, around 0.1% [57]. 
Thromboembolic risk can be minimized by limiting RF ablation temperatures to minimize 
excessive charring, the use of heparin protocols, and post-procedure antithrombotic 
protocols [58-60]. An additional risk of RF ablation is damage to the surrounding 
structures, especially as thermal alterations due to RF ablation are permanent [61]. 
Pulmonary vein stenosis [62], coronary sinus injury or thrombus formation [63], coronary 
artery stenosis [64], and arrhythmogenicity of ablating critical electricity-conducting 
structures such as the AV node are all risks that must be considered. Cryo-anchoring was 
developed partly in response to this risk: the significant catheter stability provided by cryo-
achoring combined with echocardiographic visualization of the RFC catheter tip minimizes 
the risk of off-target ablations. Additionally, cryoablation and cryo-anchoring are 
associated with minimal thrombus formation compared to RF ablation [65]. 
 
Specific Complications Involving the MV Following RF Ablation. A second subset of 
possible complications resulting from RFC catheter treatment of the MV leaflets is 
undesired structural damage secondary to leaflet shrinkage. MV leaflet perforation or 
ruptured chords are a possible concern, which may arise due to excessive heat generation 
(>100°C) or due to the possible frail nature of diseased tissue. There is a small body of 
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literature on valvular lesions occurring following RF ablation of accessory atrioventricular 
conduction pathways in the left ventricle. These ablations are performed using a 
retrograde, transaortic catheter approach. A few studies have used transthoracic 
echocardiography to assess the incidence of valvular regurgitation following ablation of 
these accessory conduction pathways and found that mild MR developed in 6.7%, 5.4%, 
and 0.01% of cases within 24 hours in studies of 59 [66], 355 [67], and 179 patients [68], 
respectively. When followed long-term, findings were unchanged over 15-36 months. It is 
still unclear if MR results from RF energy delivery or catheter manipulation, or both [66, 
67]. Two case studies of young patients undergoing routine RF ablation for treatment of 
Wolff-Parkinson-White syndrome provide evidence for both causes. In one, a 14 year old 
male developed a 3 mm by 5 mm perforation in the center of the posterior leaflet, 
discovered 20 months post-procedure after presentation with sudden chest pain with no 
other abnormal findings, suggesting catheter manipulation as the cause [69]. In another 
case, a 39 year old female developed severe MR 2 weeks post-procedure and was found to 
present with a ruptured anterior leaflet chord with surrounding reddened and thickened 
areas with partially necrotic tissue, suggesting excessive RF energy delivery [70]. Given the 
transaortic approach, any ablations near the MV annulus within the ventricle, where 
convective heat transfer away from the RF electrode is reduced, must be carefully 
monitored to avoid excessive heat generation. 
Given the possibility of leaflet or chordal structural damage, RF energy delivery will 
have to be carefully titrated during RFC catheter treatment in order to avoid excessive 
tissue temperatures. Further, the proposed atrial access route of the RFC catheter, as 
opposed to the retrograde approach used in the ventricular ablations described above, will 
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likely avoid many of the possible complications of ventricular access such as chordal 
entanglement or excessive ablation of the ventricular side of the annulus.  
 
Long-Term Thermal Shrinkage Efficacy. A third subset of potential complications of RFC 
catheter treatment is the possibility of leaflet re-dilation post-treatment, which would 
compromise the efficacy of the procedure. The potential for thermal shrinkage lesions to re-
dilate has been assessed in other tissues previously. For example, RF ablation to reduce the 
size of infarct area to improve left ventricular volumes found that tissue re-dilated back to 
baseline after 30 days [71]. However, the QuantumCor device, with is designed to 
thermally shrink the MV annular diameter, has been shown to produce reductions in 
annular diameter that remain durable 6 months post-treatment [54]. Given the disparity in 
the literature, the potential for MV leaflet re-dilation following RF ablation will be studied 
in Chapter 6 and Chapter 7. 
 
The RFC Catheter as an Alternative to Surgical Leaflet Resection 
Surgical resection of the MV leaflets is commonly used to address lesions in both 
fibroelastic deficiency and Barlow’s disease and is a mainstay of the most commonly used 
methodology of degenerative MV repair: the methodology described by Carpentier [42]. 
Leaflet resection is just one of the repair techniques described by Carpentier, but as several 
of the other repair techniques were discussed earlier in this chapter and the RFC catheter is 
intended as a leaflet resection device, only leaflet resection will be discussed here.  
The goal of the so-called French correction, which is still the most commonly used 
repair framework and has been shown to be highly successful [23], is to restore the MV 
structure to as close to normal anatomy as possible. In fibroelastic deficient valves, this 
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often means resection of the P2 leaflet segment, since this segment is often enlarged, or 
contains ruptured chords, or both (Fig. 2.3, left side). In Barlow’s valves, resection could be 
required in any of the MV segments, as leaflets are generally much enlarged with lots of 
billowing into the atrium (Fig. 2.3, right side). Leaflet resection, when used to treat either of 
these subtypes, can be carried out to varying degrees. The resection takes place in the area 
of leaflet enlargement, or if present, on the portion of the leaflet segment containing a 
ruptured chord (as on the chordal rupture and prolapsing segments seen in Fig. 2.3). 
Depending on the lesion and severity, leaflet resection may be triangular, quadrangular, or 
could be a sliding-plasty or butterfly resection (Fig. 2.5) [42, 72]. In the case of quadrangular 
resection, up to 30% of the leaflet area is often cut out and removed [73]. The opposing 
leaflet edges on either side of the resection are then sutured together using an interrupted 
stitch, and any cuts through the annulus are often sutured with a mattress stitch to plicate 
the annulus in an effort to reduce valve circumference in the case of enlarged valves.  
 
 
 
Fig. 2.5: Common Leaflet Resection Incisions 
Geometric differences between the common leaflet resection techniques shown on a 
healthy porcine posterior leaflet.  
 
Triangular
Quadrangular
Sliding-Plasty
Butterfly
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The goal of the RFC catheter is to approximate surgical leaflet resection by 
thermally shrinking the prolapsing leaflet segments. Instead of physically cutting excess 
tissue or removing segments with detached chords, the goal is to shrink enough of the 
enlarged leaflet and surrounding area to replicate the results of leaflet resection. The work 
presented in the following chapters will show that RFC catheter treatment has to ability to 
reduce leaflet area by up to 40%, which is within the range of leaflet areas commonly 
resected surgically [73]. 
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Chapter 3  
 
THE STATE OF PERCUTANEOUS MV REPAIR 
 
Text and figures for Chapter 3 taken from: 
Boronyak SM, Merryman WD: “The once and future state of percutaneous mitral valve repair.” 
Future Cardiology, Vol. 8, Issue 5, 779-93, 2012. 
 
Introduction 
Many surgical techniques exist to repair the MV and reduce MR. In any given surgical 
repair, a combination of techniques may be used, and thus, percutaneous MV repair is not 
one size fits all. In this chapter, percutaneous MV repair devices currently in use or in 
development will be discussed, with a focus on those through human or animal trials. 
Several devices have been in development for percutaneous repair of the MV in the 
past decade [5]. These percutaneous techniques offer potential improvement over current, 
conventional surgical procedures in that they have been shown to reduce the need for 
blood transfusions, decrease rates of infection, and reduce hospital and recovery time 
significantly [10, 47]. As demonstrated by the recent enrollment in clinical trials for new 
percutaneous repair devices, patients are taking an interest despite the fact that long-term 
durability remains to be proven. Additionally, these new percutaneous approaches have 
the potential to greatly benefit the growing elderly population, who are more at-risk when 
undergoing invasive surgical procedures.  
While some percutaneous techniques in development involve replicating repairs 
that have previously been performed surgically, such as the MitraClip edge-to-edge repair, 
many percutaneous devices in development alter the MV apparatus using entirely new 
approaches, such as direct leaflet ablation and coronary sinus (CS) annuloplasty. As a 
22 
 
result, the long-term efficacy and durability of these repairs is unknown. Evaluation of how 
these devices affect the mechanics of the MV, either in vitro or in animal models, might 
offer the possibility to predict long-term efficacy. For example, analysis of the effect of 
various annuloplasty devices on MV leaflet strains could predict repair durability or 
indicate that some devices may be more suited for certain types of MV disease [74, 75]. 
With many leaflet repairs currently being performed in combination with annuloplasty, in 
the future, multiple percutaneous approaches may be combined to generate a more 
efficacious repair. In this review, we report on several percutaneous annuloplasty and 
leaflet repair devices with prior clinical or animal data, and place the results in context with 
hemodynamic data from in vitro studies.  
 
Subtypes of Mitral Valve Disease 
MV disease can be due to dysfunction of any of the components of the MV apparatus, 
including the annulus, leaflets, chordae, and papillary muscles, but MR can also result due 
to abnormalities of the left ventricle (LV) or left atrium. Most causes of MR can be classified 
into one of two distinct categories, degenerative (primary) and functional (secondary), and 
most current repair techniques target one of these subtypes [20]. In order to understand 
how percutaneous repairs will be required to alter the MV apparatus, degenerative MR and 
functional MR must first be understood in terms of how MV function and morphology is 
affected. For a comphrensive description of degenerative MR (DMR), see Chapter 2.  
 
Functional MR. Another common cause of MR is functional disease due to ischemic left 
ventricular dysfunction or dilated cardiomyopathy. MV leaflets and chordae frequently 
appear normal in hearts with functional MR (FMR), but dysfunction of other components 
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of the heart affect MV function. FMR is therefore secondary to other disease processes in 
the heart, frequently those that result in increased LV size. Left ventricular chamber 
enlargement, regional LV wall motion abnormalities, dilation of the MV annulus, and 
changes in LV shape may all significantly contribute to FMR [76]. Quantitative 
echocardiography has demonstrated an increase in the size of the MV annulus, in addition 
to increased papillary muscle tethering distance as a result of increased LV volume, which 
may contribute to MR [77]. Additionally, dyssynchrony in papillary muscle activation has 
also been shown to be a possible contributor to FMR [78, 79], and recently, it was found that 
it is the impairment of lateral shortening between the papillary muscles during systole, and 
not passive ventricular size, that impairs systolic valve closure in ischemic MR [80].  
Annuloplasty is the dominate mode of repair for FMR, in which implantation of 
either a flexible or rigid ring sutured to the MV annulus reduces the MV orifice and 
enhances leaflet coaptation by bringing the leaflets closer together. Recently, cause-specific 
annuloplasty rings have been developed in order to account for morphologic differences in 
ischemic and dilated cardiomyopathy. Previous studies have shown that even with similar 
severity of MR, less enlargement of the LV and mitral annulus occurs in patients with 
ischemic than with dilated cardiomyopathy. Moreover, leaflet tethering tends to be 
symmetrical in dilated cardiomyopathy, while leaflet tethering occurs primarily on one side 
of the valve in ischemic cases [81]. Due to these morphologic differences between dilated 
and ischemic cardiomyopathy, it may be necessary to develop specialized percutaneous 
annuloplasty devices capable of correcting the different pathologies.   
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Leaflet Repair 
MitraClip Edge-to-Edge Repair. The Alfieri edge-to-edge repair is one alternative surgical 
technique, which creates a double-orifice MV by suturing together the anterior and 
posterior leaflets in the central portion of the valve [82-84]. The suture point of the double-
orifice MV forms a fixed coaptation point, facilitating coaptation of the remainder of the 
leaflet segments. 
The MitraClip (Abbott Vascular) was developed in order to replicate this procedure 
via a percutaneous approach and is currently the most tested percutaneous MV repair 
technique available [18, 48, 85]. The MitraClip has been used for treatment of DMR and 
FMR, with reduced MR demonstrated in both subtypes. In place of the sutures used for 
forced leaflet coaptation, a 4-mm wide implantable, cobalt-chromium clip secures the 
leaflets together (Fig. 3.1A). The MitraClip system utilizes a 24-F steerable guide catheter 
that is introduced via transseptal access. A clip delivery catheter then passes through the 
guide catheter, which can be steered to the delivery site, with the MitraClip attached to the 
distal end. Several barbs on the center portion of the clip facilitate tissue attachment upon 
clip closure. One important benefit of the MitraClip device is that the clip can be opened 
and closed several times during delivery, in order to assess if MR is reduced and that clip 
attachment is secure. If the procedure cannot be completed, or MR not reduced, the 
MitraClip can be fully retracted and removed from the body. However, acute assessment of 
MitraClip efficacy can sometimes be difficult; despite device implantation, 17% of patients 
in a high risk study were discharged without a significant reduction in MR [48]. Further, it 
may be difficult to differentiate the effects of general anesthesia from the effects of 
MitraClip placement on MR during the procedure [85], an issue that may be common to 
other percutaneous devices as well. 
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Fig. 3.1: Percutaneous Repair with the MitraClip 
Detailed drawing of the MitraClip implant, showing the cobalt-chromium clip with barbs 
to enhance tissue attachment. Reprinted from [86]. Also depicted is MitraClip placement at 
the position of the A2-P2 segments of the MV. Reprinted from [87].  
 
 
More clinical data exists for the MitraClip than other percutaneous leaflet repair or 
annuloplasty devices, and two important studies have recently been published from the 
EVEREST II clinical trial. Results from 12-month assessment of a randomized study 
comparing percutaneous MitraClip repair with conventional valve replacement or surgery 
identified a 55% primary end point efficacy for the MitraClip repair group and a 73% 
efficacy in the conventional surgery group [18]. Primary end point efficacy included 
freedom from death, freedom from MV surgery, and 3+ or 4+ MR at 12-months. While the 
MitraClip repair produced less desirable results in terms of efficacy compared with 
conventional surgery, the MitraClip repair was associated with enhanced safety. The rate of 
major adverse clinical events at 30 days was found to be 15% in those receiving the 
MitraClip, compared with 48% in the conventional surgery group. The superior safety 
results of the MitraClip and sub-optimal efficacy indicate that MitraClip treatment may be 
most appropriate in high-risk patients who fail to qualify for conventional surgical repair or 
replacement procedures. 
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In the EVEREST II high-risk study, 12-month survival was found to be 76% in those 
receiving the MitraClip device, compared with 55% of the comparator group, who either 
did not enroll or were anatomically ineligible for MitraClip placement [48]. Additionally, 
78% of patients receiving the MitraClip with matched baseline and 12-month data had MR 
≤2+. However, only 54% of all patients who received the MitraClip had MR of ≤2+ at 12-
months. More recently published results from the German transcatheter mitral valve 
interventions registry demonstrated similar device efficacy, as 313 out of 471 (66%) patients 
who received MitraClip treatment had MR grade 1 or lower upon follow-up [88]. In-
hospital mortality was found to be 2.5%, and post-discharge mortality was 12.5%. Results 
from echocardiographic assessment of patients with MitraClip implantation in the high-
risk study, as well as a study involving 104 patients not amenable for surgery, are included 
in Table 3.1 [48, 89].  
 
Mechanical Studies of Edge-to-Edge Repair. Several in vitro studies have previously been 
performed to analyze the effects of the edge-to-edge repair on MV mechanics and 
functionality, and while they have all used the conventional form of edge-to-edge repair 
with sutures, the results of these studies can be used to aid in prediction of long-term 
MitraClip efficacy.  Many of these in vitro studies, with a focus on valve mechanics and 
hemodynamics, have provided insight into the use of edge-to-edge repair without 
annuloplasty, as prior data has suggested sub-optimal mid-term results from edge-to-edge 
repair alone [90]. Jimenez et al used in vitro testing in a left heart flow simulator to decouple 
the effects of MV annular area, transmitral pressure, and mitral flow rate on the force 
exerted on the suture (stitch force) in the edge-to-edge repair [91]. Results indicated that 
annular dilation negatively impacted the efficacy of edge-to-edge repair, as peak systolic 
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stitch force increased linearly with increasing annular area, and this could lead to a 
reduction in long-term durability of edge-to-edge repair. Additionally, peak diastolic stitch 
force increased with decreasing mitral annular area. These results indicate that combined 
annuloplasty may be necessary in many patients to increase durability of the edge-to-edge 
repair by reducing annular dilation. Further study by Croft et al demonstrated that edge-to-
edge repair alone can reduce, but not completely eliminate, MR due to annular dilation 
[92]. It was also found that edge-to-edge repair alone is ineffective at reducing MR due to 
papillary muscle displacement, providing evidence that in many cases, edge-to-edge repair 
may be secondary to annuloplasty in reduction of MR. 
A more recent in vitro study by Bhattacharya et al demonstrated that the tension 
generated by the MV on the annulus is not completely restored following edge-to-edge 
repair in a chordal elongation model, leading to an imbalance between the inward annular 
tension generated by the MV apparatus and the outward force generated by the left 
ventricular myocardium [93]. This force imbalance at the mitral annulus could be a possible 
mechanism for annular dilation to occur following treatment of MR due to MV prolapse, 
and recurrent MR due to progressive annular dilation is a possibility that must be 
examined. Interestingly, echocardiographic analysis of the patients enrolled in the 
MitraClip EVEREST II high-risk study at 12-months showed decreases in the LV end-
systolic (-10.0%) and end-diastolic volumes (-15.7%), in addition to a decrease in the septal-
lateral diameter (-6.3%) of the mitral annulus (Table 3.1) [48]. These reductions are contrary 
to the results suggested by the in vitro annular tension study and suggest that MitraClip 
treatment may actually result in favorable remodeling of the LV following the first 12-
months after treatment. Favorable LV remodeling was reported to occur in patients with 
FMR, as well as DMR. 
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One possible explanation that might account for some of the reduction in LV end-
systolic volume, LV end-diastolic volume, and the septal-lateral diameter seen in this study 
is that the number of patients with matched data decreased from baseline (n = 72) to 12-
months (n = 56) in the high-risk study. Additionally, when the difference between 
MitraClip repair and surgery was analyzed for FMR and DMR, it was found that surgery 
produced significantly better outcomes for DMR, while there was little difference in 
outcome between MitraClip repair and surgery for FMR. Therefore, while annular dilation 
following treatment of DMR with the MitraClip should be considered a possibility in long-
term outcomes, current clinical data suggests that remodeling of the MV annulus and LV 
due to MitraClip therapy is favorable. Longer follow-up studies will be necessary to 
confirm the effects of MitraClip treatment on LV remodeling.  
 
Annuloplasty Devices 
Coronary Sinus Annuloplasty. Annuloplasty rings have been essential for surgical repair of 
MR due to both functional and degenerative etiologies, and several percutaneous 
annuloplasty approaches are currently in development. Coronary sinus (CS) annuloplasty 
approaches, in particular, have received a great deal of interest, due to ease of access and 
prior history of device implantation in the coronary vessels. As the CS sits within close 
proximity to the MV annulus, shortening of the CS effectively reduces the septal-lateral 
diameter of the annulus by forcing the posterior annulus in the anterior direction. 
The Monarc device (Edwards Lifesciences) is one percutaneous approach that 
utilizes a nitinol implant consisting of distal and proximal self-expanding, stented anchors 
with an interconnecting, spring-like bridge segment that provides shortening tension (Fig. 
3.2A) [94, 95]. Both distal and proximal anchors are held in place by using an anchor 2 mm 
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to 4 mm larger in diameter than the CS. The delivery system of the Monarc device includes 
a 12-F guide catheter and dilator, and a 9-F delivery catheter with access via the internal 
jugular vein. The Monarc also contains a biodegradable element incorporated within the 
spring-like bridge segment, preventing complete spring tension at initial device 
implantation. As the biodegradable element absorbs over the first month, shortening of the 
device continues until full spring tension is achieved. 
Safety and efficacy of the Monarc device were recently reported in the EVOLUTION 
I study, where device implantation was successful in 82% of patients with FMR [94]. 
Implantation of the device could not be completed in the remainder of study patients due 
to tortuosity of the CS or lack of correctly sized devices, indicating that CS devices may not 
be appropriate for all patients. Additionally, 81% of patients experienced a reduction in MR 
grade of ≥1, and average regurgitant volume was reduced by >20% and maintained for 12-
months (Table 3.1). Monarc implantation also seemed to provoke favorable MV and LV 
remodeling, with septal-lateral diameter, LV end-systolic volume, and LV end-diastolic 
volume all decreasing over the 12-month study period. Despite demonstrating safety and 
efficacy, further study of the Monarc device has stopped due to slow patient enrollment. 
The Carillon Mitral Contour System (Cardiac Dimension, Inc.) is another CS 
annuloplasty device that operates on a similar principle [96-98]. The implant is constructed 
out of nitinol wire consisting of expandable distal and proximal anchors, connected by a 
tensioning bridge (Fig. 3.2B). A 9-F delivery catheter is used to place the distal anchor. The 
delivery catheter is retracted to allow expansion of the anchor and then advanced to 
complete anchor expansion. Manual traction on the delivery catheter is used to provide 
tension on the CS and MV annulus, and the proximal anchor is then released and 
expanded. The result of placement of the Carillon device is that the septal-lateral diameter 
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is reduced. Unlike the Monarc device, this septal-lateral diameter reduction occurs 
immediately, and no further changes in bridge tension are designed to occur. The benefit of 
this design is that changes in MR can be immediately assessed, and the device can be 
removed if no improvement occurs. 
Assessment of the Carillon device in the AMADEUS EU trial resulted in successful 
device placement in 30 of 48 patients with FMR, with failed placement in 18 due to a 
combination of CS access complications, slipping of the distal anchor, vessel perforation, 
and insufficient reduction in FMR [96]. By 30-day follow-up, 13% of patients had 
experienced a major adverse event. Echocardiographic assessment of the Carillon device 
indicated favorable changes at 1-month and 6-month time points: regurgitant volume 
decreased by over 30%, and reductions in LV end-systolic volume and LV end-diastolic 
volume, along with a significant decrease in septal-lateral diameter, were also observed 
(Table 3.1). Further clinical trials are currently underway.  
A percutaneous CS annuloplasty device that uses a different approach to reduce the septal-
lateral diameter is the cerclage annuloplasty technique [99]. The cerclage technology uses a 
guide-wire that is looped around the MV annulus and LV outflow tract, which is then 
replaced by a suture (Fig. 3.2C). Tension exerted on the suture constricts the MV annulus, 
reducing the septal-lateral diameter and the annulus circumference. The guide-wire is 
introduced via a 9-F introducer sheath into the right jugular vein. The guide-wire then 
crosses through the CS, enters the proximal great cardiac vein, and then proceeds into the 
first septal perforator vein, where it crosses the myocardium into either the right atrium or 
ventricle. The guide-wire is then ensnared in the right side of the heart and exchanged for a 
suture and tension-fixation device. The resulting implant is a suture, tensioned to 
approximately 400 grams, that encircles both the MV annulus and LV outflow tract. Early 
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results from the cerclage technology in a porcine model demonstrated septal-lateral 
shortening of the MV annulus without introduction of a pressure gradient across the LV 
outflow tract. In order to prevent compression of entrapped coronary arteries located 
between the CS and MV annulus, a rigid-arch protection device was developed to direct 
compressive forces away from the entrapped artery. The rigid-arch protection device is a 
nitinol implant, 1.5 mm in outer diameter, and is placed under coronary angiography. 
Testing of the coronary artery protection device verified that no vessel compression or 
significant pressure gradient was present following implantation and tensioning of the 
Cerlage. Successful implantation of the cerclage occurred in 14 out of 16 consecutive swine 
in an initial feasibility study [99]. The cerclage technology also demonstrated acute 
reductions in septal-lateral diameter, LV end-systolic volume, and LV end-diastolic volume 
in a model of ischemic cardiomyopathy (Table 3.2). The cerclage technology addresses two 
common issues with CS annuloplasty devices: variable vessel anatomy, which can prevent 
placement of a large device in theCS, and coronary artery entrapment, in which vessels 
between the CS and MV are compressed due to the forces generated by the annuloplasty 
device. 
While CS annuloplasty has been shown to reduce MR, induce favorable LV 
remodeling, and reduce the septal-lateral diameter of the MV annulus (Table 3.1), the 
changes in these values are much less than those recorded with surgical annuloplasty. 
Surgical treatment of MR using leaflet, chordal, or papillary muscle repair in combination 
with an annuloplasty ring has produced reductions in the septal-lateral diameter by as 
much as 40-50% and reduced LV end-diastolic and end-systolic volumes by 20-30% (Table 
3.3) [100]. While CS annuloplasty has yet to be used in combination with any other repair, a 
comparison of these results demonstrates that CS annuloplasty may not be as effective as   
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surgically-implanted annuloplasty rings. Challenges and limitations of the various 
percutaneous CS annuloplasty and MV repair techniques are summarized in Table 3.4. 
 
Anatomical and Mechanical Studies of the Coronary Sinus. One of the challenges that must 
be addressed in development of percutaneous CS annuloplasty devices is the variable 
anatomic relationship of the CS and MV annulus between patients. Prior study using multi-
slice computed tomography (CT) has indicated that the CS ostium – the location of the 
proximal anchor in the Monarc and Carillon devices – lies at the same level as the 
atrioventricular groove in only 54.5% of patients at end-systole [101]. This number drops to 
less than 10% for locations midway between the great cardiac vein (GCV) and CS ostium. 
Other studies using cadaveric hearts have indicated that the CS is superior to the MV 
annulus in normal hearts by a mean distance of approximately 9.7 mm from the P2 scallop 
[102]. For maximum effectiveness, the CS should lie within the same plane as the MV 
annulus. As the CS is used to displace the posterior section of the MV annulus, these results 
indicate that efficacy of percutaneous CS annuloplasty devices could be compromised in a 
large group of patients. Moreover, relative positioning of the CS and MV annulus has been 
shown to vary based on the degree of annular dilation, LV and left atrial enlargement, and 
severity of MR. Multi-slice CT has shown that a shift of the CS towards the MV annulus 
occurs with left atrial and LV enlargement [103]. However, some studies indirectly 
contradict these results, indicating that increased MR severity and annular dilation leads to 
an increase in the CS to MV annulus distance [104, 105]. Differences in measurement 
techniques and the longitudinal position along the CS in which the measurement was taken 
could account for these differences. Assessment of CS anatomy of each patient will be 
important in the future to determine eligibility for device placement.  
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Fig. 3.2: Percutaneous Annuloplasty Devices 
A: The Monarc implant located in the coronary sinus. Reprinted from [94]. The device 
consists of two stent-like anchors placed in the CS/GCV and CS ostium and a connecting 
bridge segment. B: The Carillon device operates on a similar principle, with two 
expandable anchors connected by a nitinol bridge. C: The cerclage system uses a wire, 
placed percutaneously, to encircle the MV apparatus and LV outflow tract. Reprinted from 
[99]. D: The QuantumCor device utilizes RF ablation to directly reduce the MV annulus 
circumference, without leaving an implant behind. Reprinted from [106]. 
 
 
 
 
 
C D
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Table 3.3: Echocardiographic Assessment of Surgical MV Repair with Annuloplasty 
 
Another anatomical consideration in design of percutaneous CS annuloplasty 
devices is the possibility of coronary arteries traversing between the CS and MV annulus. 
Estimates vary, but coronary arteries have been determined to traverse between the CS and 
MV annulus in as many as 68-86% of patients [101, 103, 105]. Additionally, when only 
patients with severe MR were analyzed, the number of coronary arteries traversing the CS 
and MV annulus was 97% [103]. Compression of the coronary arteries due to percutaneous 
CS annuloplasty devices could lead to heart failure if severe enough and may exclude   
many patients from being eligible for device placement. The design of the cerclage device 
introduced a rigid-arch protection device that re-distributes the compressive forces exerted 
by the device on the CS, reducing coronary artery compression [99]. Future CS 
annuloplasty approaches may include a similar device. 
As percutaneous CS annuloplasty devices exert considerable force on and around 
the MV apparatus, analysis of how these devices alter MV geometry and mechanics may be 
essential in prediction of the long-term efficacy and durability of repairs. Devices that 
increase leaflet strains, increase chordal elongation, or prevent annular dynamic motion 
may compromise long-term durability. Previous studies have tracked MV annular and/or 
Treatment LVESV (mL)   LVEDV (mL)   Avg S-L Diameter (mL) 
  n Pre Post %Δ   n Pre Post %Δ   n Pre Post %Δ 
                              
3 months 
Carpentier-Edwards Physio 
ring® 23 45 48 6.7   23 138 117 -15.2   23 42.5 22.1 -48.0 
Cosgrove-Edwards band® 21 45 33 -26.7   21 138 96 -30.4   21 41 24.1 -41.2 
6 months 
Carpentier-Edwards Physio 
ring® 23 45 43 -4.4   23 138 110 -20.3   23 42.5 21.8 -48.7 
Cosgrove-Edwards band® 21 45 37 -17.8   21 138 110 -20.3   21 41 23.9 -41.7 
                              
Data were acquired using real-time 3D echocardiograpy.  
LVESV, left-ventricular end-systolic volume; LVEDV, left-ventricular end-diastolic volume; S-L diameter, septal-lateral 
diameter 
Data taken from [100] 
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leaflet motion in animal models using several methods, including: radiopaque, tantalum 
markers sutured to the annulus or leaflet surface and imaged using videofluoroscopy [107, 
108], sonomicrometry using piezoelectric markers sutured to the MV annulus [109, 110], 
and 3-dimensional echocardiography [111, 112]. These studies have been used to determine 
that traditional, rigid annuloplasty rings unfavorably reduce MV annular dynamics by 
reducing the natural, sphincteric motion of the MV [108] and also increase excursion of the 
anterior leaflet, leading to higher bending stresses on the leaflet and possibly reduced 
repair durability [107]. Future assessment of percutaneous CS annuloplasty approaches 
could use these methods to enhance device design and predict long-term outcomes. 
Additionally, use of a technique for non-invasive assessment of MV annular dynamic 
motion using 3-D echocardiography was reported in an ovine model of ischemic 
cardiomyopathy [111]. Results demonstrated that percutaneous CS annuloplasty can 
reduce MV annular area without significantly reducing annular excursion, or its superior-
inferior motion. The use of 3-D echocardiography to assess MV annular dynamic motion 
may play an important role in future assessment of percutaneous annuloplasty devices 
undergoing clinical trials. 
In addition to the forces exerted by CS annuloplasty devices on the left heart, the 
CS/GCV undergoes a significant amount of motion over the course of the cardiac cycle. The 
dynamic motion of the CS/GCV imparts bending stresses on CS annuloplasty implants, and 
this may lead to degradation over time. In initial human trials with an early iteration of the 
Monarc device, separation of the nitinol bridge segment occurred in 3 out of 4 patients, 
necessitating a re-design of the device [95]. In order to better understand interactions 
between percutaneous CS annuloplasty devices and the CS vessel, prior study has analyzed 
the mechanical properties of the porcine and human CS. Pressure-inflation testing of the 
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porcine CS demonstrated that the CS exhibited an S-shaped pressure-radius response – the 
CS is very distensible at low pressures (10-30 mmHg) and much stiffer at high pressures 
(40-80 mmHg) [113]. The CS was also found to dilate up to 88% at a pressure of 80 mmHg, 
and model fitting generated material parameters that can potentially be used for finite 
element simulations of device-tissue interactions. The biaxial mechanical properties of the 
CS were also quantified to compare differences between aged human, porcine, and ovine 
tissues, and the aged human CS was found to be significantly stiffer in both the 
circumferential and longitudinal directions than the porcine or ovine CS [114]. As it is 
generally older individuals who will receive percutaneous MV repairs, these results could 
have important implications in moving from animal to human clinical trials. Previously, the 
dynamics of the CS/GCV have been studied using CT angiography and indicated that the 
distance between the CS/GCV and the MV annulus can change by as much as several 
millimeters over the cardiac cycle, with the greatest distance occurring during end-systole 
[101]. The diameter of the CS/GCV also changes considerably over the cardiac cycle, and 
changes over 2 mm occur near the CS ostium. While motion of the CS/GCV relative to the 
MV annulus can be recorded, no estimates currently exist for the amount of force that may 
be exerted on devices within the CS. Further analysis of the dynamics between the CS/GCV 
and MV annulus may lead to more durable percutaneous CS annuloplasty approaches. 
 
Direct Annuloplasty. In addition to approaches that re-shape the MV annulus via CS 
implants, several devices are currently in development that more directly alter the 
geometry of the MV annulus. These devices place an implant directly into the MV annulus 
in order to cinch the annulus and reduce the septal-lateral diameter. Two devices are of 
note, as they have demonstrated first-in-man results, although these results are yet to be 
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published. The first of these is the Mitralign technology (Mitralign, Inc.), which places a 
pair of pledgets, via LV access, near each of the commissures that are then plicated and 
locked to reduce the septal-lateral diameter. The procedure had been performed in at least 
12 patients thus far. The second device is the Accucinch Annuloplasty System (Guided 
Delivery Systems), also with first-in-man results. The Accucinch system uses an implant 
that encircles the MV annulus from one trigone to the other and uses a circumferential 
cinching force to restrict the annular size. Mechanical analysis of the effects of these devices 
on the MV structure is limited, and further study will be necessary to assess the utility of 
these devices in treating MR.  
 
QuantumCor Direct Annular Ablation. One potential application for RF ablation in 
treatment of MR is direct annular ablation. The QuantumCor device (QuantumCor, Inc.) 
utilizes a circular probe that incorporates 7 RF electrodes around its radius [53, 54, 106]. The 
QuantumCor probe conforms to the annulus shape (Fig. 3.2D), and application of RF 
energy is applied directly to the annulus in order to reach electrode-tissue interface 
temperatures of at least 65°C. Like the MV leaflets, the annulus structure is supported by 
collagen, and application of RF energy to the MV annulus reduces the annulus 
circumference, with the intention of improving leaflet coaptation. 
Acute study of the effects of RF ablation on annular size in an ovine model 
demonstrated a 23.8% reduction in septal-lateral diameter, with no thrombosis or damage 
to nearby coronary arteries, CS, or MV leaflets [53]. However, this study was performed in 
16 healthy sheep with no or natural occurring MR, and the procedure was performed 
under cardiopulmonary bypass via access through the left atrial appendage. A 6-month 
follow-up study of 7 animals demonstrated that the reduction in septal-lateral diameter 
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was durable, with a 26.4% reduction from baseline [54]. The QuantumCor device generated 
the largest percent reduction in septal-lateral diameter of any percutaneous device; 
however, the effect of this change on moderate to severe MR has not been assessed. Further 
study will be needed to determine device efficacy in a model of MR.  
 
Conclusion 
Percutaneous MV repair devices have received a great deal of interest in recent years, and 
several devices have been tested in animal models and clinical trials. Many of these devices 
attempt to mimic repairs that are currently performed surgically, including the MitraClip 
edge-to-edge repair and various percutaneous annuloplasty devices. As several of these 
devices alter the MV apparatus in new ways, including RF ablation treatment and CS 
annuloplasty, knowledge of the long-term efficacy and durability of these repairs is 
unknown. While it is still vitally important to analyze the effect of each device on acute MR 
reduction, MR recurrence rate, and mortality, engineering analysis of these devices can 
serve a role as a predictor of long-term outcomes. In vitro studies and animal testing have 
already led to insights into the changes that various percutaneous MV repair devices effect 
on the MV apparatus, but the amount of published studies in this area is still limited. 
Percutaneous MV repair devices have been demonstrated to be less efficacious than 
surgical repair; in general, current percutaneous techniques have only been able to reduce 
mitral regurgitant volumes by approximately 20-40% and reduce MR by about 1 grade. 
Further mechanical analysis of percutaneous MV repair may be able to reveal the reasons 
for these sub-optimal results. For now, percutaneous MV repair devices are most suitable 
for high-risk patients who are ineligible for open-chest surgery. However, this is still a 
significantly sized group of potential patients, as a 2007 survey found that 49% of patients 
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with severe symptomatic MR were not operated on due to old age, impaired LV function, 
or multiple co-morbidities [4]. Prior data has suggested that treatment with percutaneous 
repair produces superior outcomes in high-risk patients, and when all patients are 
considered, percutaneous treatment reduces the complication rate compared with open-
chest repair or replacement. With safety rates in mind, several percutaneous MV repair 
devices may be used to treat high-risk patients in the near future; however, efficacy of these 
devices must be improved before widespread usage can begin. Finally, current 
percutaneous treatments for MR have been shown to be limited in their usage based on 
variability in patient anatomy and the type of lesion present. Some of these limitations are 
summarized in Table 3.4. As a result, no one percutaneous approach will be correct for all 
patients or causes of MR. 
 
Table 3.4: Challenges and Limitations in Percutaneous MV Repair Devices 
 
 
Edge-to-Edge Repair 
 Limited to treatment of regurgitant jets originating from malcoaptation of the middle scallops 
of the anterior and posterior leaflets [48] 
 Can introduce moderate stenosis in MVs with an annular area <4.0 cm2  [48] 
 Leaflet geometry must meet several requirements: coaptation length ≥2 mm, coaptation 
depth <11 mm, flail gap <10 mm, flail width <15 mm [18, 48] 
RF Ablation (Leaflet, Chordae, and Annulus) 
 Procedure cannot be reversed if too much RF energy is applied or MR is not reduced 
 Introduces the potential for permanent damage to surrounding structures 
 Mechanical strength of ablated tissues may be temporarily reduced [54] 
 Creates detectable regions of coagulation necrosis [10, 54] 
CS Annuloplasty 
 Variable position and size of the CS in relation to the MV annulus between patients limits 
the number of patients who are anatomically eligible for device placement [101-105] 
 The superior position of the CS in relation to the MV annulus reduces the cinching effect of 
percutaneous CS devices on the posterior annulus [102, 103] 
 The CS undergoes significant motion relative to the MV annulus during the cardiac cycle, 
imparting strain on devices implanted in the CS [101] 
 Coronary arteries frequently traverse between the CS and MV annulus and can be 
compressed and restricted by percutaneous CS devices [101, 103, 105] 
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Future Perspective 
Many forms of MV repair currently utilize multiple techniques to reduce MR, especially in 
treatment of DMR. Leaflet resection or edge-to-edge repair is often used in combination 
with an annuloplasty ring in order to enhance leaflet coaptation and prevent annular 
dilation. Future use of percutaneous MV repair devices, several years from now, may take a 
similar approach by combining multiple devices to enhance the efficacy of MR reduction. 
As most published results of percutaneous MV repair devices typically report MR 
reduction by approximately 1 grade, combining multiple devices for enhanced efficacy may 
be likely in the future.  Most percutaneous MV repair devices have gone through their first 
published testing in animal models, but the development of in vitro flow loops and other 
methods of bench-top analysis can permit assessment of many percutaneous repair devices 
before undergoing costly animal testing. In vitro mechanical testing and marker tracking in 
animal models can provide quantitative information about how current and future 
percutaneous repair devices alter MV mechanics and geometry, leading to insights into the 
durability and long-term efficacy of repairs. Additionally, more advanced quantitative 
imaging techniques, including multi-slice CT and 3-D echocardiography will enable better 
clinical assessment of patient eligibility and device function, both acutely and long-term. As 
it is difficult to duplicate the complex surgical repairs that are currently performed under 
open-heart surgery, development of future percutaneous repair devices may be very 
specific to the MV structure affected – including the MV annulus, leaflets, chordae, 
papillary muscles, and the LV. In terms of the capability of treating each of these structures, 
the field of percutaneous MV repair devices is relatively new, but recent developments may 
have the ability to treat many of these structures in the coming years. 
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Executive Summary 
Introduction 
 Current percutaneous devices have the ability to reduce MR by approximately 1 
grade, which is less than that typically achieved by surgical repair or replacement of 
moderate-severe and severe MR 
 Due to reduced rates of efficacy and increased safety compared with open-heart 
surgical repair and replacement, current percutaneous approaches are most suitable 
for high-risk patients who are ineligible for current treatments 
Leaflet Repair 
 The MitraClip facilitates leaflet coaptation by creating a double-orifice MV, and the 
EVEREST II trial has demonstrated a 55% end-point efficacy at 12-months 
 RF ablation, combined with cryo-anchoring for catheter stability, can reduce leaflet 
size with the application of thermal energy. In vivo results are limited, and further 
study is needed 
Annuloplasty Devices 
 The Carillon and Monarc CS annuloplasty devices create septal-lateral shortening 
via placement of a metal implant in the CS; however, variations in patient-to-patient 
anatomy, including the height of the CS relative to the MV annulus and coronary 
arteries that may traverse between the CS and MV will limit the use of this 
technology 
 The cerclage technology uses a suture, threaded around the MV annulus and LV 
outflow tract, to generate cinching, and features a rigid-arch protection device to 
protect against coronary artery compression 
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 The QuantumCor device uses RF ablation to reduce the MV annular circumference, 
demonstrating a >20% reduction in an initial feasibility study 
Future Perspective 
 In the future, percutaneous annuloplasty approaches may be used in combination 
with percutaneous leaflet repair techniques to increase overall efficacy and 
durability 
 Analysis of how novel percutaneous approaches affect MV mechanics may provide 
insight into the long-term efficacy of repairs 
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Chapter 4  
 
THE RFC CATHETER SYSTEM 
 
 
RFC Catheter Design Considerations 
The focal point of this work is the design and performance of the RFC catheter for thermal 
shrinkage of MV leaflet tissue. Throughout the development process, it has been necessary 
to design and build several different RFC catheter prototypes in order to execute different 
experiments and to iteratively improve thermal shrinkage performance. These prototypes 
have been designed for static bench testing (Fig. 4.1A), for bench testing in a dynamic left 
heart flow simulator (Fig. 4.1B), and for in vivo animal studies (Fig. 4.1C). As described in 
previous chapters, the RFC catheter uses an RF ablation element to produce tissue 
temperatures greater than 65°C for tissue shrinkage. To provide constant contact with the 
MV leaflets in a beating heart environment, a cryo-anchoring element is used and cooled to 
temperatures between -20°C and -50°C. The novelty of the RFC catheter is the combination 
of these two elements – resistive heating of the RF electrode and sub-freezing temperatures 
of the cryo-anchor – into one therapeutic device. The design goal is to place these two 
opposing elements on a catheter such that 1) RF electrode contact with the leaflet tissue is 
maximized and 2) the RF ablation and cryo-anchoring elements do not interfere with each 
other. As the RFC catheter is intended as a percutaneous repair device, the final design 
must be optimized for vascular access and maneuverability in the heart. Thus, catheter 
outer diameter must remain small (10 Fr or less) and the distal catheter tip segment must be 
steerable in at least one direction. The prototype for in vivo use described below was 
designed with these considerations in mind. When used percutaneously, the RFC catheter 
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Fig. 4.1: Evolution of Catheter Prototypes 
A: RFC catheter prototype for static bench experiments. B: RFC catheter prototype for 
bench studies in a left heart flow simulator. C: Close view of the RFC catheter prototype 
for non-survival animal studies. D: CAD drawing of the static bench prototype with liquid 
nitrogen or nitrous oxide delivery. E: CAD drawing of a prototype for non-survival animal 
studies showing the positions of the cryo-anchors and RF electrode. 
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is intended for use with a bi-directional steerable sheath via femoral access. The steerable 
sheath is guided up through the vena cava and into the right atrium, where a 
Brockenbrough needle is used to puncture the interatrial septum to pass the sheath into the 
left atrium. The RFC catheter is then passed through the sheath and into the left atrium, 
where it can be guided to the leaflets by transesophageal echocardiography and/or 
fluoroscopy.  
 
Static Bench Prototype for Initial Feasibility Studies 
In order to first demonstrate the feasibility of using cryo-anchoring and RF ablation 
together on a catheter, and to determine the geometrical and mechanical effects of RF 
ablation and cryo-anchoring treatment of MV leaflets, a simple prototype for static bench 
top experiments was developed (Fig. 4.2A). This prototype uses liquid nitrogen to cool the 
catheter tip, delivered through a large (0.05” inner diameter) polyimide tube housed inside 
the main catheter body of Nylon 12. The 1.9 mm long cryo-anchor of the static prototype is 
located at the most distal point on the catheter shaft, with a 1.9 mm long RF electrode 
located just proximal. The outer diameters of the RF electrode and cryo-anchor are 4 mm 
(12 Fr).  A thermocouple is used to monitor the cryo-anchor temperature and liquid 
nitrogen is removed from inside the catheter under vacuum.  
A commercially available RF generator (Osypka) is used to deliver RF energy to the 
catheter (Fig. 4.2B). The cryo canister is electrically controlled in a binary fashion using an 
attached servo motor. Cryogen and RF energy delivery protocols were programmed on an 
Arduino microcontroller for repeatability. This was the first RFC catheter prototype, and it 
enabled the first tests of treatment feasibility to be performed on the lab bench. These 
experiments are described in Aim 1.  
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Fig. 4.2: First RFC Catheter Prototype – Static Bench Prototype 
A: The RFC catheter static bench prototype. B: Complete static bench prototype including 
the RF energy and cryogen delivery systems. The compact design of the static bench 
prototype enables quick and easy experiments to be performed on the lab bench when 
steerability or extended reach are not needed.  
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RFC Catheter Prototype for In Vivo Studies 
The current iteration of the RFC catheter is a custom device built on a steerable Freezer 
MAX Cardiac Cryoablation catheter (Medtronic, Minneapolis, MN). The rationale for using 
the Freezer MAX catheter is that components for a steerable catheter are not readily 
available off the shelf, and using existing components reduces cost and development time. 
Additionally, all cryo components are already integrated into the Freezer MAX catheter. 
Several non-trivial modifications were made to the Freezer MAX catheter, and a 
comprehensive guide to fabricating the RFC catheter can be found in the Appendix. The 
modifications begin with machining of the cryo applicator to provide space for the RF 
electrode by removing a void of material in the middle of the cryo applicator with an end 
mill (Fig. 4.3). The void in the cryo-anchor is then filled with epoxy to provide insulation, 
and a 3.0-3.3 mm (10 Fr) diameter RF electrode is placed over it. This configuration results 
in one cryo-anchor on either side of the RF electrode, providing maximum leaflet contact 
between the RF electrode and MV leaflet (Fig. 4.4A). It has been found through trial and 
error that cryo-anchor size does not need to be significant in comparison to the RF 
electrode. Cryo-anchors with outer diameter 2.3 mm (7 Fr) and 1 mm long on either side of 
the RF electrode are sufficient for robust leaflet cryo-anchoring.  
The completed catheter tip consists of an RF electrode placed between two cryo-
anchors, and the RF electrode is kept electrically insulated (Fig. 4.4A). Liquid nitrous oxide 
delivery to the inside of the catheter tip, which is kept under vacuum, provides the cooling 
power for the cryo-anchors. The catheter steering system, cryo thermocouple, and cryogen 
delivery tubes were retained, largely unmodified. The RF electrode wire and RF 
thermocouple are run outside the Freezer MAX catheter shaft and secured with clear FEP 
shrink tubing. All inputs and outputs to the catheter can be seen in Fig. 4.4B. 
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Fig. 4.3: Cryo-Anchor Dimensions 
Dimensions of the cryo-anchor of the RFC catheter for in vivo use. 
 
 
 
 
Fig. 4.4: RFC Catheter Prototype for In Vivo Use 
A: RFC catheter tip showing the orientation of the RF electrode and cryo-anchors, with ice 
ball formation. B: Modified Freezer MAX catheter handle with new inputs and outputs for 
cryogen delivery, temperature measurement, and RF ablation. C: Complete RFC catheter 
control system with RF generator, cryogen delivery system and nitrous oxide tank, and 
control electronics. 
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To control and measure the outputs to the RFC catheter, control software and 
electronics were developed using LabView and the open-source Arduino platform (Fig. 
4.5). The software controls nitrous oxide delivery to the catheter tip by regulating the duty 
cycle to a cryogenic solenoid based on the temperature desired. Once the nitrous oxide 
delivery lines have been primed, cryo-anchoring temperatures are achieved within 1 
second after the user initiates the cryo-anchor (Fig. 4.6). RF power output to the catheter 
electrode is set on a commercial RF generator (EPT-1000, Boston Scientific). The control 
software records temperature data from the RFC catheter and uses this information to 
regulate the cryogenic solenoid duty cycle to modulate cryo-anchor temperature. During 
ablation treatment, ablation temperature is monitored and RF power is manually throttled 
to maintain ablation temperature within a pre-determined range. For maximum ablation 
effectiveness, it is desirable to use the highest ablation power that does not result in 
excessive tissue charring or coagulum formation [49]. As the RF electrode is in very close 
proximity to the cryo-anchors on the RFC catheter, RF electrode temperature, and the 
measurement junction, are significantly affected by the cryo-anchors. Thus, the ideal RF 
electrode temperature is actually many degrees cooler than the desired tissue temperature. 
Calibration of the desired RF electrode temperature is described in the Appendix. Control 
software, cryo delivery hardware, and control system electrical schematics can also be 
found in the Appendix. 
Key to the RFC catheter treatment strategy is its ability to selectively cryo-anchor to 
the MV leaflets, depending on the location of leaflet enlargement or chordal rupture. In a 
simulated flow environment, leaflet attachment is possible to one (Fig. 4.7A-B) or both 
leaflets (Fig. 4.7C) at a time, depending on the placement of the catheter in relation to the 
leaflet free edge. Cryo-anchoring to regions closer to the free edge are more likely to result 
52 
 
in bi-leaflet attachment, while cryo-anchoring in the leafelt belly region or closer to the 
annulus results in single leaflet attachment. The positions of the cryo-anchors on either side 
of the RF electrode encourage direct contact with the leaflets for enhanced tissue heating.  
The studies that follow in the remaining chapters will report RFC catheter performance 
according to the three specific aims discussed in Chapter 1. 
 
 
Fig. 4.5: RFC Catheter System Key Components and Data Transfer Between Systems 
Schematic representation of RFC catheter system key components. 
 
 
 
Fig. 4.6. Time to Cryo-Anchor 
A: Time to cryo-anchor onset with catheter shown in a left heart flow simulator flowing at 
5 L/min. Left panel: nitrous oxide flow off. Right panel: cryo-anchor temperatures have 
been achieved. B: Typical cryo-anchoring temperature measurements during in vivo use. 
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Fig. 4.7: RFC Catheter Cryo-Anchoring in a Physiologic Flow Environment 
Various RFC catheter cryo-anchoring placements shown in a left heart flow simulator at 
physiologic flow rates and pressure. A: Anterior leaflet attachment in systole (left) and 
diastole (right). B: Posterior leaflet attachment in diastole. C: Bi-leaflet attachment, with the 
catheter cryo-anchors placed close to the leaflet free edge. Bi-leaflet cryo-anchoring forms a 
double-oriface valve, similar to that produced by an edge-to-edge repair. 
  
A: Anterior Leaflet Attachment B: Posterior Attachment
C: Bi-Leaflet Attachment
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Chapter 5  
 
AIM 1 – PART 1: INITIAL RFC CATHETER DEVELOPMENT AND FEASIBILITY 
EXPERIMENTS 
 
Text and figures for Chapter 5 taken from: 
Boronyak SM, Merryman WD: “Development of a Simulataneous Cryo-Anchoring and 
Radiofrequency Ablation Catheter for Percutaneous Treatment of Mitral Valve Prolapse.” Annals of 
Biomedical Engineering Vol. 40. Issue 9, 1971-81, 2012. 
 
 
 
Introduction 
The purpose of this study was to determine the feasibility of using cryo-anchoring and RF 
ablation on the same catheter tip and to quantify the geometrical, biomechanical and 
thermodynamic effects of RF ablation on porcine MV leaflets. We hypothesized that an RF 
ablation catheter that utilizes a cryo-anchor will effectively adhere to and alter MV leaflet 
geometry and compliance, reducing MV leaflet size at maximum systolic load. To test this 
hypothesis, we developed a catheter prototype containing both a cryo-anchor for 
attachment and stability and an RF electrode for ablation. To investigate the effects of using 
cryogenic temperatures and resistive heating in close proximity, we quantified changes in 
biaxial mechanical compliance of MV leaflets and used infrared (IR) thermal imaging to 
discern distinct thermal regions within the tissue. We also quantified the anchor strength of 
the cryo-anchor both with and without RF ablation. These data support our hypothesis that 
simultaneous cryo-anchoring and RF ablation effectively reduces MV leaflet size, while 
further demonstrating that cryo-anchoring and RF ablation can function effectively in close 
proximity on a single catheter tip.  
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Materials and Methods 
Catheter Prototype. A 4 mm (12 French) diameter catheter prototype was developed 
containing both a cryogenically cooled anchor (cryo-anchor) and an RF ablation electrode 
(Fig. 5.1A and Fig. 5.1B). The cryo-anchor and RF electrode reside in-line on the catheter 
shaft and are separated by a 1 mm spacer, with the cryo-anchor on the most distal point of 
the catheter. Both the cryo-anchor and RF electrode are constructed out of hollow copper 
rod and are approximately 1.9 mm in length. The cryo-anchor is thermally connected via a 
solder joint to an inner copper rod containing a lumen which allows liquid nitrogen 
delivery. Teflon is used to insulate the RF electrode from the cryo-anchor and inner copper 
rod, and a thermocouple attached to the outer surface of the cryo-anchor records the 
temperature at the anchor-tissue interface. RF ablation is performed with an Osypka HAT 
300 generator, capable of delivering a 500 kHz electrical signal at powers of up to 50 W to 
the RF electrode on the catheter tip. Liquid nitrogen is contained inside a handheld canister 
(Cry-Ac, Brymill Cryogenic Systems) and delivered to the catheter tip under vacuum by an 
inner lumen housed inside the catheter.  
Control of RF ablation and liquid nitrogen delivery is performed via custom built 
control electronics for synchronization and repeatability (Fig. 5.1C). Liquid nitrogen flow 
control is binary, and a servo motor is used to switch flow on and off. The sequence used 
for liquid nitrogen flow was developed to anchor the catheter tip to the tissue sample prior 
to RF ablation and to maintain anchoring throughout the ablation (Fig. 5.1D). Control of the 
RF generator was performed by interfacing with the footswitch port on the generator, with 
air flow controlled by a solenoid valve and control electronics. For each ablation, one of 
three RF protocols was utilized at 25, 45, or 50 W of power for 15, 20, or 30 s, respectively 
(Fig. 5.1D). Due to the time required for the RF generator to increase the power to the 
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desired set-point (~3 s), the total energy output was lower than that produced by the 
product of time and power (Joules = W s). The final energy delivery to the tissue, as 
recorded by the generator for each of the 25, 45 and 50 W ablations, was 350, 850, and 1250 
Joules (J), respectively.  
 
Tissue Preparation. Healthy porcine MV leaflets were obtained from a local abattoir 
(Hampton Meat Processing, Hopkinsville, KY), excised on-site, and frozen in phosphate 
buffered saline (PBS) at -20°C until testing. Anterior leaflets were chosen for the 
biomechanical and thermal imaging studies due to their larger and more continuous 
surface area compared to posterior leaflets, although it is noted that posterior leaflets are 
more often affected by MVP [20]. The center portion of the leaflets were used and trimmed 
into rectangular sections (Fig. 5.2A) approximately 12 mm in the radial direction and 15 
mm in the circumferential direction. The center portion was used as it experiences the most 
homogenous strains during MV closure [115]. For the anchor strength study, posterior 
leaflets were used for testing.  
 
Biaxial Mechanical Testing. Biomechanical analysis was performed using a custom-
designed biaxial mechanical testing device (Fig. 5.2A) [9]. Samples were loaded in each 
direction up to a membrane tension comparable to that experienced by the leaflet during 
systole (120 mmHg ≈ 90 N/m of membrane tension), and all testing was performed with 
samples fully submerged in PBS at 37°C. Prior to testing, each sample was pre-conditioned 
over ten loading cycles to 90 N/m with a 15 s rise time. Following pre-conditioning, a 
marker reference was recorded and used as the unloaded state. Samples were then tested 
for ten cycles with a 15 s rise time to 90 N/m in order to determine untreated compliance. 
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Fig. 5.1: First Prototype Design and Control Scheme 
A: Solid model cut-away of the catheter prototype design, indicating the relative positions 
of the cryo-anchor, insulating spacer, and RF electrode. B: Catheter prototype tip used for 
all treatments of tissue (scale bar = 1/8”). C: Flow chart representation of the control system 
used to integrate and synchronize cryo-anchoring with RF ablation for treatment of tissue. 
D: Sequence programmed into the controller for performing RF ablation treatments with 
cryo-anchoring. Note that liquid nitrogen delivery to the catheter tip begins prior to RF 
ablation in order to first anchor the catheter tip to the tissue surface. RF power is 
represented as being applied instantaneously; however, it took ~3 s for RF power to reach 
target power. Final RF energy delivery (J=Joules) is indicated on the plot and represents 
total energy delivery of each treatment. 
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Stress-strain behavior has been found to be independent of loading rate for cycles with rise 
times of up to 15 s, thus tissues were not loaded at physiologic rates [116]. 
After determining leaflet biomechanical properties, samples were loaded to 10 N/m 
and subjected to one of the following four treatments with the catheter prototype. In order 
to determine the biomechanical effects of the cryo-anchor alone, samples were kept in 
contact with the cryo-anchor for 30 s at approximately -20 to -30°C (n = 3). To test the 
combined effects of cryo-anchoring and RF ablation, tissues were subjected to one of three 
treatment groups (n = 5) as described earlier and shown in Fig. 5.1D. During treatment, the 
fluid level in the bath was lowered to just below the surface of the sample in order to 
ensure that maximal energy transfer was through the tissue. By performing treatment such 
that all RF energy must pass through the sample, the amount of RF energy required to 
invoke the recorded biomechanical changes can be determined. The alternative is to 
completely submerge leaflets during treatment, but this provides a very low resistive path 
to ground, which bypasses the target tissue via direct conduction through the PBS bath. 
Four ground electrodes were placed in the bath, approximately 13 cm away from the tissue, 
to complete the electrical circuit for RF ablation. Following treatment, samples were 
returned to their unloaded state, a new marker reference was recorded to determine 
changes in unloaded geometry, and samples were loaded for ten cycles to 90 N/m. All data 
reported is from the tenth loading cycle of each experiment.  
All analysis of biaxial mechanical data was performed using MATLAB 
(Mathworks). Marker positions recorded just prior to loading were used to determine 
geometric changes of the unloaded tissues due to treatment with the catheter prototype. 
Unloaded marker area was calculated as the area enclosed by the polygon connecting the 
four markers. Additionally, the percent change in the determinant of the deformation 
59 
 
gradient tensor, F (% change in det(F)) was used to provide a quantitative assessment of the 
biomechanical changes of the tissue at maximum systolic load. The determinant of F is the 
ratio of the deformed marker area to the marker area of the reference state, where: 
 
𝑭 =  [
𝐹11 𝜅1
𝜅2 𝐹22
] 
 
F11 and F22 represent the stretch ratios in the circumferential and radial directions, 
respectively, and κ1 and κ2 provide a measure of shear. det(F) was determined at 90 N/m 
before and after treatment, and the unloaded marker reference state recorded just after pre-
conditioning was used for all calculations. Because the same marker reference state is used 
to determine F in both the untreated and treated conditions, % change in det(F) provides a 
direct comparison of systolic leaflet deformation before and after treatment. Therefore, we 
refer to % change in det(F) at 90 N/m as % change in areal systolic deformation. In addition 
to reporting changes in det(F) due to treatment, we also report % change in axial systolic 
deformations which are changes in F11 and F22 at 90 N/m. For a more complete description 
of the calculation of F from biaxial mechanical testing, see Humphrey [117]. 
 
Infrared Thermal Imaging. Thermal imaging of simultaneous cryo-anchoring and RF 
ablation was performed using an IR camera (ThermoVision A20M, FLIR Systems) with a 
measurement range of -20°C to 250°C and accuracy of ±2°C. Previous studies have used IR 
imaging to identify the lethal isotherm of RF lesions [118, 119]. Leaflets were imaged in a 
custom built bath, and the camera was placed below the bath for imaging of full thickness 
changes in temperature distribution (Fig. 5.2B). An IR window (IR Material Window, 
Edmund Optics Inc.) was placed at the bottom of the bath to allow imaging through the 
bottom surface by allowing transmission of IR wavelengths. Prior to treatment, an image 
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Fig. 5.2: Static Ex Vivo Experimental Set-Ups 
A: Mitral valve anatomy with marker placement and biaxial testing device with leaflet 
tissue in place. B: Set-up for full thickness thermal imaging. The IR camera is placed below 
in order to measure the temperature distribution throughout the entire surface of the 
tissue. An IR window allows transmission of IR wavelengths for unimpeded temperature 
measurement. C: Set-up for measurement of anchor strength of the cryo-anchor. Leaflets 
are clamped into the load cell assembly, and the maximum load is recorded. 
 
was taken of a calibration phantom to determine the x and y distance scales. Testing was 
performed in PBS at room temperature, and the fluid level was lowered to just below the 
top surface of the tissue to allow maximal energy transfer through the leaflet. Four ground 
electrodes were placed in the bath in a circular pattern, each approximately 13 cm from the 
center of the leaflet. During ablation, a non-conductive plate was placed over the leaflet in 
order to maintain contact of the entire leaflet surface with the IR window. This was done to 
ensure that the temperatures measured were of the leaflet itself and not the fluid between 
the leaflet and IR window. All samples were then treated using one of the ablation 
sequences in Fig. 5.1D (n = 3 for each of the 350, 850, and 1250 J sequences), and images of 
the treatment were recorded at 1 Hz beginning at the onset of RF ablation using 
ThermaCAM Researcher software and synchronized with the ablation sequence using the 
control electronics. Images were then analyzed in MATLAB to produce thermal contour 
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plots of the tissue. Additionally, the area of tissue heated to > 65°C was quantified in order 
to provide a measure of the extent of thermal contracture of the extracellular matrix 
collagen, and the tissue area < 0°C was also quantified to provide an estimate of the 
attachment area of the catheter prototype. 
 
Anchor Strength. In order to assess the anchor strength of the cryo-anchor both with and 
without RF ablation, a submersible load cell was used (Model 31 Mid, Honeywell). 
Posterior MV leaflets were clamped onto the load cell assembly and completely submersed 
in PBS at 37°C (Fig. 5.2). Leaflets were completely submersed during treatment in order to 
test the anchor strength of the cryo-anchor in an environment that more closely mimics the 
in vivo case. The output from the load cell was amplified using a custom built amplifier 
circuit and read into LabView using a data acquisition card (NI 9205, National 
Instruments). Anchor strength was tested at one of two protocols (n = 5 for each protocol). 
For the “Cryo Only” protocol, liquid nitrogen was pumped under vacuum to the catheter 
tip continuously for 10 s, and the catheter was then immediately pulled from the leaflet 
surface until separation. To determine the loss of anchor strength resulting from 
application of RF energy, the “RF + Cryo” protocol consisted of 5 s of continuous liquid 
nitrogen delivery, followed by 10 s of RF ablation at 50 W with continuous liquid nitrogen 
delivery. The catheter was then pulled away from the leaflet surface until separation. In 
both cases, the maximum load during separation was recorded. Maximum load was 
converted to anchor strength by dividing the load by 0.12 cm2, the approximate area of the 
cryo-anchor in contact with the tissue. 
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Statistics. Data are presented as mean ± SE. To analyze significance of changes due to 
combined RF ablation and cryo-anchoring for the biomechanical and anchor strength 
studies, data were analyzed using a one way ANOVA (α = 0.05) for multiple pair wise 
comparison (Holm-Sidak method).  
 
Results 
Tissue Geometry and Compliance. Prior to treatment, leaflets displayed a typical, 
anisotropic mechanical response to loading [50], with the radial direction much more 
compliant than the circumferential direction (Fig. 5.3A and Fig. 5.3B). This is due to 
collagen fibers being preferentially aligned in the circumferential direction. Following 30 s 
of cryo-anchoring, MV leaflets experienced negligible changes in geometry and mechanical 
response (Fig. 5.3A). However, after 1250 J of RF ablation with cryo-anchoring, leaflets 
underwent significant changes. In the circumferential direction, changes in systolic 
deformation were attributable primarily to shrinkage of the tissue, as indicated by a large 
shift in stretch ratio in the unloaded state (membrane tension = 0 N/m), while the radial 
direction underwent a decrease in systolic deformation with little geometric changes.  
There was a consistent trend of decreasing marker area with increasing RF energy 
(Fig. 5.3C), due primarily to decreases in length in the circumferential direction (Fig. 5.3D). 
Change in systolic deformation was analyzed at maximum load, 90 N/m (Fig. 5.3E and Fig. 
5.3F), with all deformations referenced to the marker reference state recorded just after pre-
conditioning. Similarly to geometric changes, the areal systolic deformation decreased with 
increasing RF energy (Fig. 5.3E), due primarily to shrinkage in the circumferential 
direction. Additionally, there was a consistent trend of decreasing axial systolic 
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Fig. 5.3: Biaxial Mechanical Characterization of RF Ablation-Treated MV Leaflets 
Biaxial, membrane tension vs. stretch ratio following 30 s of cryo-anchoring without RF 
ablation (A) and with 1250 J of RF ablation (B). C: % Change in unloaded marker area for 
each treatment group (0 J represents cryo-anchoring without RF ablation). % Change in 
unloaded marker lengths (D), areal systolic deformation (E), and axial systolic deformation 
(F) for each treatment group. + Significant decrease vs. 0 J (p<0.001) and ** significant 
decrease vs. 850 J (p<0.05). 
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deformation in both the circumferential and radial directions with increasing RF energy 
(Fig. 5.3F), although the changes in the radial direction were not significant.  
 
Temperature Distribution. Leaflet tissue > 65°C was quantified to identify the area of the 
leaflet exposed to temperatures that cause thermal damage to collagen. The area > 65°C was 
found to increase with increasing RF energy, from 0.51 ± 0.13 cm2 to 1.9 ± 0.13 cm2 at 
energies of 350 J and 1250 J, respectively (Fig. 5.4A). The tissue area below 0°C was used to 
determine the degree of cryo-anchoring present during ablation and was approximately 
0.14 ± 0.05 cm2 at the end of the 1250 J ablations. For comparison, the area of the cryo-
anchor in contact with the leaflet during the procedure is approximately 0.12 cm2. Thermal 
contours at the end of each treatment indicate distinct regions of cryo-anchoring and tissue 
ablation (Fig. 5.4B). The thermal contour plots at the end of the 350 J treatment shows 
minimal tissue > 65°C, while the majority of the leaflet tissue is > 65°C in the 1250 J 
treatment.  
 
Anchor Strength. Following cryo-anchoring for 10 s, anchor strength was found to be 1020 ± 
23 kPa (Fig. 5.5). As expected, application of RF ablation at 50 W for 10 s with cryo-
anchoring reduced the anchor strength significantly (p<0.005) to 668 ± 79 kPa; however, the 
adherence is still robust.  
 
Discussion 
We have previously shown that RF ablation directionally alters MV leaflet geometry and 
compliance [9]. The therapeutic effect of our percutaneous treatment strategy is to restore 
competence to diseased or prolapsed MV leaflets by reducing leaflet size, and therefore, 
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Fig. 5.4: Characteristic Thermal Contours of RFC Catheter Treatment 
A: Tissue areas heated to > 65°C by RF ablation (red bars) and cooled to < 0°C by cryo-
anchoring, as measured at the end of treatment. + Significant increase vs. 350 J (p<0.005) 
and ** significant increase vs. 850 J (p<0.05). B: Infrared thermal contour images prior to 
(time = 0) and following RF ablations of 350 J, 850 J, and 1250 J RF, with simultaneous cryo-
anchoring. 
 
 
 
Fig. 5.5: Typical Cryo-Anchor Holding Strength 
Cryo-anchor strength following 10 s of attachment (blue bar) and 10 s of cryo-anchoring 
with 50 W of RF ablation (red bar). + Significant decrease vs. cryo only (p<0.005). 
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displacement of leaflets into the atrium during systole. However, any device that aims to 
percutaneously treat MVP must do so in a highly dynamic mechanical environment. 
Additionally, due to the high rate of blood flow across the MV and the resulting potential 
for heat convection, application of RF energy must be performed with the RF electrode in 
direct contact with the target tissue. Thus, we have introduced cryo-anchoring as a means 
to potentially maintain direct catheter contact with a moving MV leaflet and to enhance 
stability during the procedure. During cryo-anchoring, tissue is cooled to < 0°C, which 
interferes with the resistive heating that is the therapeutic mechanism behind RF ablation. 
However, due to the small size of MV leaflets, cryo-anchoring must be utilized in close 
proximity to the RF electrode. In this study, we demonstrate the effects of using two 
competing energy modalities and the feasibility of RF ablation performed with cryo-
anchoring.  
 
More RF Energy Required with Cryo-Anchoring. Biaxial mechanical data following 
treatment with the catheter prototype demonstrates that RF ablation remains a valid 
therapy, even with sub-freezing temperatures on the cryo-anchor in close proximity on the 
MV leaflet (Fig. 5.3). To determine the extent to which cryo-anchoring reduces the 
biomechanical effects of RF ablation, we re-analyzed previous biaxial data from treatment 
with a commercially available RF catheter (7F, Blazer II, Boston Scientific) without cryo-
anchoring [9], plotting the % change in areal systolic deformation alongside our data 
presented here (Fig. 5.6). While RF ablation with cryo-anchoring altered unloaded MV 
leaflet geometry and deformation at systolic loading, it took significantly more energy 
versus RF ablation alone to produce the same effect. Previous treatments using the 
commercially available RF catheter reduced areal systolic deformation by approximately 
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Fig. 5.6: Comparison of Shrinkage Deformations in RF Only and RF+Cryo Treatments 
% change in areal systolic deformation with RF ablation alone (black bars) [9] and RF + 
cryo-anchoring (gray bars), demonstrating that more RF energy is needed when cryo-
anchoring is utilized to produce the same therapeutic effect as RF ablation alone. 
 
 
25% when 350 J of energy was applied at a power of 25 W [9]. In treatments utilizing cryo-
anchoring, areal systolic deformation decreased by only 2.8 ± 0.6% under the same RF 
conditions. However, when 1250 J of energy was applied at a power of 50 W, our catheter 
prototype was able to produce changes similar to the commercially available catheter at 350 
J. These results indicate that even though RF power must be increased significantly when 
cryo-anchoring is used, the catheter prototype can still achieve the same therapeutic effect.  
 
Thermally-Related Collagen Contracture. RF ablation introduces both geometric and 
biomechanical changes in MV leaflets; specifically, changes in areal systolic deformation 
are primarily due to length changes in the circumferential direction (Fig. 5.3D). This 
shortening of the collagen fibers in the circumferential direction is due to thermal rupture 
of heat-sensitive bonds and uncoiling of the collagen triple helix. This uncoiling of collagen 
fibers and transition from a crystalline state to a random coil is responsible for collagen 
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shortening, and transmission electron microscopy of collagenous tissues treated with RF 
ablation show collagen fibrils that increase in average diameter with increasing RF power 
[120]. Additionally, aligned collagen fibers fuse together in the orthogonal directions after 
treatment with RF ablation [120, 121], leading to modest changes seen in the radial 
direction here (Fig. 5.3D). Therefore, the use of a cryo-anchor for stability during the RF 
ablation procedure reduces the therapeutic effect of RF energy, but this effect can be 
mitigated by increasing RF power. 
 
Heat Distribution of RF Ablation with Cryo-Anchoring. In addition to determining 
biomechanical changes induced by RF ablation, we have analyzed the temperature 
distribution resulting from combined RF ablation with cryo-anchoring. Estimates for the 
onset of unwinding of the collagen triple helix vary and have been determined to be 
approximately 60°C in the bovine joint capsule [122] and 67.1°C in the bovine mitral valve 
[123]. Thus, we used 65°C as a threshold for permanent collagen denaturation and 
determined the area of tissue heated above this temperature. IR imaging reveals that while 
there is a distinct region of cryo-anchoring present through the full thickness of the leaflet, 
which stays relatively consistent across all RF energies, heating due to RF ablation 
dominates the leaflet temperature distribution. As a result, full thickness temperatures < 
0°C are confined to an area slightly larger than the cryo-anchor attachment area. Because 
thermal damage to the collagen matrix forms the basis of mechanical damage, we 
hypothesized that the tissue area heated above 65°C would correlate with changes in areal 
systolic deformation (Fig. 5.7). Indeed, this correlation is evident when % change in areal 
systolic deformation is plotted against tissue area above 65°C, demonstrating that 
biomechanical changes may be directly related to the amount of thermal tissue damage.  
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Fig. 5.7: Areal Shrinkage Deformation is Related to Area of Tissue Heating 
% change in areal systolic deformation vs. tissue area > 65°C, as determined by processing 
of IR thermal images at the end of ablation. Model fit: 
% change in areal systolic deformation = -10.54e0.60 * tissue area + 10.54 
 
 
Cryo-Anchor Attachment to MV Leaflets. Testing of the anchor strength of the cryo-anchor 
revealed that this attachment is sufficient to maintain contact, even with RF ablation, with 
stationary MV leaflets. While there are currently no direct estimates for the anchor strength 
required to maintain attachment to the MV during the cardiac cycle, one estimate can be 
made based on the atrial pressure during MV opening. Because the proposed catheter 
treatment involves access to the MV via the left atrium, and the peak atrial pressure is a 
representation of the force required to open the MV, this is an estimate for the minimum 
attachment force required to maintain adherence. Peak atrial pressure in normally 
functioning hearts is typically below 20 mmHg [12], or about 2.7 kPa. Thus, even if a much 
higher estimate for the atrial pressure is chosen, this value is considerably lower than the 
approximately 668 kPa of anchor strength recorded at 10 s of the 50 W RF ablation. 
Additionally, we speculate that cryo-anchoring and ablation of MV leaflets will occur with 
the MV kept partially open, with one leaflet kept anchored and the other moving freely. 
This may further reduce the force required to maintain cryo-anchoring. 
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Study Limitations. The data presented here indicate that RF ablation performed with cryo-
anchoring alters MV leaflet geometry and deformation in vitro; however, there are several 
limitations to this study. First, all treatments were performed on stationary leaflets in vitro. 
While this ensures robust delivery of RF energy, it is not realistic, particularly with regards 
to the anchor strength studies. Further work must be performed to verify the feasibility of 
cryo-anchoring on moving MV leaflets, both in vitro and in vivo. Additionally, ablations in 
the biomechanical and thermal imaging studies were performed on leaflets with the saline 
bath lowered, such that the maximum amount of RF energy would penetrate the leaflets. 
This provides a much more accurate measurement of the total energy delivered to the 
leaflet, but the in vivo environment is much more dynamic. Due to convective blood flow, 
in vivo treatments will require additional or prolonged RF energy delivery in order to 
produce the same biomechanical alterations, as demonstrated in a feasibility study utilizing 
a canine model [10]. Finally, these studies were performed on healthy porcine MV leaflets. 
It is unknown how leaflets with MVP might respond to RF ablation, due to their 
disorganized collagen architecture.  
 
Design Considerations for In Vivo Translation. In light of the results from this study, and 
what is previously known regarding RF ablation, we have identified several design 
considerations for in vivo translation of our combined RF ablation and cryo-anchoring 
catheter. First, we demonstrated in vitro that RF energy must be increased when used in 
conjunction with cryo-anchoring in order to achieve a similar therapeutic effect of RF alone. 
Because our biaxial mechanical analysis was performed on leaflets treated while only 
partially submerged, heat dissipation will likely increase when treatment is performed in 
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vivo, due to the surrounding hemodynamic environment. Thus, RF energy delivery will 
likely need to be increased in a similar manner and this will likely be accomplished by 
increasing either RF power or application time. Similarly, through placement in a dynamic 
hemodynamic environment and increases in application of RF energy, cryo-anchor strength 
may be reduced at the current liquid nitrogen delivery protocol, and liquid nitrogen 
delivery may need to be increased by increasing vacuum pressure and delivery time to 
compensate. Also, in order to decrease the amount of RF energy lost to the blood stream, 
RF electrode placement can be re-designed to allow for more direct delivery to the leaflets. 
One possible improvement is to replace the current, singular RF electrode, which encircles 
the entire 360º outer circumference of the catheter shaft, with three separate RF electrodes 
that are approximately 120º of the circumference and are insulated from each other. By 
having three separate electrodes, RF energy can be delivered to the electrode in direct 
contact with the leaflet, ensuring that the majority of RF energy enters the leaflet, as 
opposed to the bloodstream. These, and other potential modifications, will likely be 
necessary to translate this strategy into an integrated catheter that will be successful in 
vivo.  
 
Conclusions 
In this study, we demonstrate that RF ablation with a cryo-anchor may provide an 
alternative percutaneous treatment strategy for MVP. While it was previously shown that 
RF ablation alone reduces MV leaflet size, we have demonstrated the feasibility of cryo-
anchoring as a stability technique for secure attachment of a catheter to a MV leaflet. 
Additionally, cryo-anchoring may have possible uses in other applications involving RF 
ablation or in more general percutaneous catheters as a mechanism to enhance stability and 
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improve catheter contact in complex anatomies or hard-to-reach sites. Cryo-anchoring may 
be a particularly effective strategy in improving catheter stability during treatment of 
cardiac arrhythmias, given the dynamic environment of the heart. While we found here 
that cryo-anchoring reduces the effect of RF ablation, these effects can be mitigated by 
increasing RF power and duration. These in vitro results indicate that RF ablation with 
simultaneous cryo-anchoring reduces MV leaflet size and may be a viable clinical strategy 
for percutaneous treatment of myxomatous MVP.   
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Chapter 6  
 
AIM 2 – PART 2: BIAXIAL MECHANICAL CHARACTERIZATION OF NON-
UNIFORM THERMAL SHRINKAGE DEFORMATIONS 
 
 
Introduction 
We have shown in the previous chapter that RF ablation introduces thermal shrinkage and 
biomechanical changes to MV leaflets, and that thermal shrinkage of MV leaflets primarily 
occurs in the circumferential direction due to collagen fiber alignment. Further, cryo-
anchoring was shown to significantly reduce the amount of thermal shrinkage at a given 
RF power. However, this study was limited in that the experimental set-up was incapable 
of quantifying spatial variations in leaflet shrinkage. MV leaflet tissue does not uniformly 
deform in response to heat. Rather, the magnitude of thermal shrinkage varies throughout 
the treatment zone. 
One reason to quantify spatially-varying shrinkage of MV leaflet tissue in response 
to RFC catheter treatment is to generate data to develop patient-specific computational 
models of the MV, which are currently in development to aid in preoperative surgical and 
interventional planning [124-127]. Computational modeling of heart valves can offer the 
opportunity to interactively explore a repair strategy, allowing assessment of proposed 
structural changes to the valve [127]. Characterization of the tissue- and device-specific 
thermal shrinkage deformations resulting from the RFC catheter is an important first step 
in developing a computational model of the treatment strategy and for optimizing 
procedural planning. Previous studies on thermal shrinkage of collagenous tissues have 
used uniaxial and biaxial testing devices to characterize shrinkage deformations under a 
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variety of loading and temperature conditions [128-132]. Moreover, previous biaxial 
characterization of thermally-induced deformations have used a standard 2x2 marker 
tracking array, which is unable to characterize non-uniform shrinkage deformations that 
may arise due to ablation device configuration and tissue anisotropy.  
The objective of the work in this chapter was (1) to develop a biaxial mechanical 
testing method that more completely characterizes non-uniform tissue deformations that 
arise in thermal shrinkage of collagenous tissues and (2) to apply this method to 
characterize the shrinkage response resulting from RFC catheter treatment of MV leaflet 
tissue. Additionally, as mechanical loading conditions have been found to affect the 
thermal shrinkage response of collagenous tissues [130], we sought (3) to investigate the 
effect of varying preload on thermal shrinkage. Finally, pericardial tissue that has been 
treated with heat has been shown to dilate slightly within the first hour after treatment 
[128], thus we sought (4) to investigate the magnitude of post-treatment re-dilation of MV 
tissue. We hypothesize that tracking 16 markers on the MV leaflet surface will provide 
enhanced fidelity in measuring spatially-varying leaflet shrinkage induced by treatment 
with the RFC catheter and further, that increasing the applied preload on the MV leaflets 
prior to RFC catheter treatment will reduce the magnitude of thermal shrinkage.  
 
Materials and Methods 
Sample Preparation. Healthy porcine MV anterior leaflets were obtained from the local 
abattoir (Hampton Meats, Hopkinsville, KY). Anterior leaflets were chosen for this study 
due to their large and continuous surface area. The center portions of the leaflets were cut 
into rectangular sections and 16 markers were fixed to the atrial side of the tissue samples 
to allow optical tracking for strain calculations during mechanical loading. Four hooks 
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Fig. 6.1: Experimental Set-Up for 4x4 Marker Tracking 
A: Relative positioning of the 4x4 marker array on the surface of a MV anterior leaflet. B: 
4x4 marker array shown with catheter orientation and the relative sizes and positions of 
the RF electrode and cryo-anchors with respect to the sample. Also shown are the local 
coordinate axes, r=0 and s=0. C: Representative RFC catheter temperatures during ablation 
treatment in the biaxial mechanical tester showing RF electrode temperature (red dash) 
and cryo-anchor temperature (blue solid). 
 
 
where inserted into each side of a tissue sample and attached to sutures for mechanical 
loading. The circumferential (direction of collagen fiber alignment) and radial leaflet 
directions were aligned with the loading axes (Fig. 6.1A). Samples were tested in load 
control mode to equibiaxial membrane tension comparable to that experienced by healthy 
MV leaflets during systole (120 mmHg ≈ 90 N/m). All testing and treatment was performed 
with samples and catheter fully submerged in phosphate buffered saline at 37°C. For more 
details on the biaxial mechanical testing setup, see [9]. 
 
Mechanical Testing and Catheter Treatment. Samples were initially loaded 10 times to 90 
N/m of equibiaxial tension to pre-condition the tissue. Load was removed from the 
samples, the marker reference configuration, 𝑿, was acquired, and samples were again 
loaded 10 times to 90 N/m of equibiaxial tension to acquire the untreated loading curves. 
Following acquisition of untreated mechanical loading curves, samples were treated with 
the RFC catheter on the ventricular side according to one of four protocols (n=5 per group) 
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while submerged in phosphate buffered saline at a power of 50 W for 60 s (Fig. 6.1B-C). 
Either the samples were treated with 1) RF ablation without cryo-anchoring and no loading 
constraints (RF Only, No Preload), 2) RF ablation with cryo-anchoring with no loading 
constraints (RFC, No Preload), 3) RF ablation with cryo-anchoring with 1 N/m of 
equibiaxial preload (RFC, 1 N/m Preload), or 4) RF ablation with cryo-anchoring with 5 
N/m of equibiaxial preload (RFC, 5 N/m Preload). For treatments with no loading 
constraints, it was ensured that no load was applied to the sample edges during catheter 
treatment. For treatments with applied preload, samples were first loaded to the specified 
equibiaxial preload, the loading motors were held fixed in place, and no attempt was made 
to control or alter the applied load during catheter treatment.  Following catheter treatment, 
samples were pre-conditioned by loading 2-3 times to 90 N/m of equibiaxial tension, load 
was removed, and the treated unloaded configuration was acquired. Samples were again 
loaded 10 times to 90 N/m of membrane tension to acquire the treated mechanical loading 
curves. Pre-conditioning, unloaded marker position acquisition, and mechanical loading to 
90 N/m was repeated again after one hour, during which the samples sat traction-free, to 
examine any possible re-dilation effects. 
 
Deformation Characterization. Prior to analysis, the marker locations of all samples within 
each group were averaged together to form one average dataset per group. Additionally, 
radial symmetry was employed such that markers on either side of the local 𝑟 = 0 axis were 
mirrored and averaged together (Fig. 6.1B).  
Bilinear interpolation schemes are traditionally used to determine the deformation 
gradient from 2x2 marker arrays in biaxial mechanical testing of planar tissues [117, 133]. 
We sought a method to better characterize the non-uniform shrinkage deformations 
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induced by catheter treatment and used 16 tracking markers in a 4x4 marker array. Briefly, 
bicubic interpolation, with basis functions reported from [134], was used to form an 
isoparametric, curved-sided quadrilateral element from the 16 marker locations, from 
which, a 50x50 node grid was interpolated. Bicubic interpolation has the advantage of 
being C1 continuous to avoid discontinuities when determining the displacement and 
deformation gradients, and the curved sides enhance interpolation fidelity. The 
deformation gradient, 𝑭, was interpolated at each nodal location within the enclosed 4x4 
marker region, and directional deformations (circumferential – 𝐹11, radial – 𝐹22) and areal 
deformations (determinant of the deformation gradient tensor) are reported with respect to 
the pre-treatment, unloaded reference condition, 𝑿:  
 
𝑭 = 𝑰 +
𝜕𝒖
𝜕𝑿
 
 
Where 𝒖 is the displacement gradient.  In order to interpolate 𝑭 everywhere between 
each of the markers, it is necessary to introduce a local coordinate system (𝑟, 𝑠) that is 
centered about the origin and spans from -1 to 1 in each direction Fig. 6.2. The position 
within the element is then described in terms of the local coordinates 𝑟 and 𝑠, where 𝑖 is the 
marker number: 
 
𝑋(𝑟, 𝑠) =  ∑ 𝜙𝑖(𝑟, 𝑠)𝑋𝑖
16
𝑖=1
 
𝑌(𝑟, 𝑠) =  ∑ 𝜙𝑖(𝑟, 𝑠)𝑌𝑖
16
𝑖=1
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The displacements, 𝑢 and 𝑣, can be interpolated similarly: 
 
𝑢(𝑟, 𝑠) =  ∑ 𝜙𝑖(𝑟, 𝑠)𝑢𝑖
16
𝑖=1
 
𝑣(𝑟, 𝑠) =  ∑ 𝜙𝑖(𝑟, 𝑠)𝑣𝑖
16
𝑖=1
 
 
Given the marker positions (Fig. 6.2), the basis functions, 𝜙𝑖, are: 
 
𝜙1,2,3,4 =
1
256
(9𝑟2 − 1)(𝑟𝐿𝑟 + 1)(9𝑠
2 − 1)(𝑠𝐿𝑠 + 1), {𝑟𝐿 = ±1, 𝑠𝐿 = ±1} 
𝜙5,6,9,10 =
9
256
(9𝑠2 − 1)(𝑠𝐿𝑠 + 1)(1 − 𝑟
2)(1 + 9𝑟𝐿𝑟), {𝑟𝐿 = ±
1
3
, 𝑠𝐿 = ±1} 
𝜙7,8,11,12 =
9
256
(9𝑟2 − 1)(𝑟𝐿𝑟 + 1)(1 − 𝑠
2)(1 + 9𝑠𝐿𝑠), {𝑟𝐿 = ±1, 𝑠𝐿 = ±
1
3
} 
𝜙13,14,15,16 =
81
256
(1 − 𝑟2)(1 + 9𝑟𝐿𝑟)(1 − 𝑠
2)(1 + 9𝑠𝐿𝑠), {𝑟𝐿 = ±
1
3
, 𝑠𝐿 = ±
1
3
} 
 
 
Fig. 6.2: 4x4 Marker Positions for Bicubic Interpolation Scheme 
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However, we’re looking to find the displacement gradient, which requires finding 
the derivatives of the basis functions: 
 
𝜕𝒖
𝜕𝑿
= [
𝜕𝑢
𝜕𝑋
𝜕𝑢
𝜕𝑌
𝜕𝑣
𝜕𝑋
𝜕𝑣
𝜕𝑌
] 
 
Since the displacements are now written as functions of 𝑟 and 𝑠, the chain rule is 
needed to determine the gradient. For example: 
 
𝜕𝑢
𝜕𝑋
=
𝜕𝑢
𝜕𝑟
𝜕𝑟
𝜕𝑋
+
𝜕𝑢
𝜕𝑠
𝜕𝑠
𝜕𝑋
 
 
In matrix form, the displacement gradient is: 
 
[
𝜕𝑢
𝜕𝑋
𝜕𝑢
𝜕𝑌
𝜕𝑣
𝜕𝑋
𝜕𝑣
𝜕𝑌
] = [
𝜕𝑢
𝜕𝑟
𝜕𝑢
𝜕𝑠
𝜕𝑣
𝜕𝑟
𝜕𝑣
𝜕𝑠
] [
𝜕𝑟
𝜕𝑋
𝜕𝑟
𝜕𝑌
𝜕𝑠
𝜕𝑋
𝜕𝑠
𝜕𝑌
] 
 
As 𝑟 and 𝑠 are not explicit functions of 𝑋 and 𝑌, the last term must be inverted: 
 
[
𝜕𝑟
𝜕𝑋
𝜕𝑟
𝜕𝑌
𝜕𝑠
𝜕𝑋
𝜕𝑠
𝜕𝑌
] = [
𝜕𝑋
𝜕𝑟
𝜕𝑋
𝜕𝑠
𝜕𝑌
𝜕𝑟
𝜕𝑌
𝜕𝑠
]
−1
=
1
𝐽
𝑯 
 
Where: 
 
𝑯 = [
𝜕𝑢
𝜕𝑟
𝜕𝑌
𝜕𝑠
−
𝜕𝑢
𝜕𝑠
𝜕𝑌
𝜕𝑟
−
𝜕𝑢
𝜕𝑟
𝜕𝑋
𝜕𝑠
+
𝜕𝑢
𝜕𝑠
𝜕𝑋
𝜕𝑟
𝜕𝑣
𝜕𝑟
𝜕𝑌
𝜕𝑠
−
𝜕𝑣
𝜕𝑠
𝜕𝑌
𝜕𝑟
−
𝜕𝑣
𝜕𝑟
𝜕𝑋
𝜕𝑠
+
𝜕𝑣
𝜕𝑠
𝜕𝑋
𝜕𝑟
] 
 
𝐽 =
𝜕𝑋
𝜕𝑟
𝜕𝑌
𝜕𝑠
−
𝜕𝑋
𝜕𝑠
𝜕𝑌
𝜕𝑟
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The terms that compose 𝑯 and 𝐽 can be determined by differentiating the basis 
function, such as: 
 
𝜕𝑋
𝜕𝑟
= ∑
𝜕𝜙𝑖
𝜕𝑟
𝑋𝑖
16
𝑖=1
 
𝜕𝑋
𝜕𝑠
= ∑
𝜕𝜙𝑖
𝜕𝑠
𝑋𝑖
16
𝑖=1
 
 
The derivatives of the basis functions with respect to 𝑟: 
 
𝜕𝜙1,2,3,4
𝜕𝑟
=
1
256
(27𝑟2𝑟 + 18𝑟 − 𝑟𝐿)(9𝑠
2 − 1)(𝑠𝐿𝑠 + 1), {𝑟𝐿 = ±1, 𝑠𝐿 = ±1} 
𝜕𝜙5,6,9,10
𝜕𝑟
=
9
256
(9𝑠2 − 1)(𝑠𝐿𝑠 + 1)(−27𝑟
2𝑟 + 18𝑟 − 𝑟𝐿), {𝑟𝐿 = ±
1
3
, 𝑠𝐿 = ±1} 
𝜕𝜙7,8,11,12
𝜕𝑟
=
9
256
(27𝑟2𝑟 + 18𝑟 − 𝑟𝐿)(1 − 𝑠
2)(1 + 9𝑠𝐿𝑠), {𝑟𝐿 = ±1, 𝑠𝐿 = ±
1
3
} 
𝜕𝜙13,14,15,16
𝜕𝑟
=
81
256
(−27𝑟2𝑟 + 18𝑟 − 𝑟𝐿)(1 − 𝑠
2)(1 + 9𝑠𝐿𝑠), {𝑟𝐿 = ±
1
3
, 𝑠𝐿 = ±
1
3
} 
 
The derivatives of the basis functions with respect to 𝑠: 
 
𝜕𝜙1,2,3,4
𝜕𝑟
=
1
256
(27𝑠2𝑠 + 18𝑠 − 𝑠𝐿)(9𝑟
2 − 1)(𝑟𝐿𝑟 + 1), {𝑟𝐿 = ±1, 𝑠𝐿 = ±1} 
𝜕𝜙5,6,9,10
𝜕𝑟
=
9
256
(27𝑠2𝑠 + 18𝑠 − 𝑠𝐿)(1 − 𝑟
2)(1 + 9𝑟𝐿𝑟), {𝑟𝐿 = ±1, 𝑠𝐿 = ±
1
3
} 
𝜕𝜙7,8,11,12
𝜕𝑟
=
9
256
(9𝑟2 − 1)(𝑟𝐿𝑟 + 1)(−27𝑠
2𝑠 + 18𝑠 − 𝑠𝐿), {𝑟𝐿 = ±
1
3
, 𝑠𝐿 = ±1} 
𝜕𝜙13,14,15,16
𝜕𝑟
=
81
256
(−27𝑠2𝑠 + 18𝑠 − 𝑠𝐿)(1 − 𝑟
2)(1 + 9𝑟𝐿𝑟), {𝑟𝐿 = ±
1
3
, 𝑠𝐿 = ±
1
3
} 
 
And substituting into 𝑯 and 𝐽 produces: 
𝑭 = 𝑰 +
1
𝐽
𝑯 
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To analyze differences between treatment groups on the magnitude of thermal 
shrinkage deformation, the areal, circumferential, and radial deformations were averaged 
for each sample over all interpolated nodes in the unloaded state and at systolic loads. 
Differences between groups were assessed with one way ANOVA with a follow-up Holm-
Sidak method for multiple pairwise t-tests at significance level α=0.05. 
 
Results 
Averaged shrinkage deformations produced by RF ablation only (left column) and RFC 
catheter treatment at varying levels of preload are shown in the unloaded configuration 
(Fig. 6.3) and at systolic loads (Fig. 6.4). The approximate center of the RF ablation electrode 
in this study is at position (𝑟, 𝑠)  =  (0,0). In general, areal shrinkage deformations are 
greatest in the central RF ablation treatment region and on either side along the 
circumferential axis, leading to an hourglass-shaped shrinkage deformation. Cryo-anchor 
placement inhibits the formation of large shrinkage deformations along the border zones in 
the top and bottom of the radial axis.  Whereas areal shrinkage deformations vary relatively 
uniformly around the circumference of the ablation electrode in the RF only group, cryo-
anchors act to confine thermal shrinkage to the central region of the leaflet in the RFC 
catheter treatment groups. Interestingly, radial shrinkage magnitude is greatest in the 
tissue adjacent to the ablation electrode near the leaflet edges and not the leaflet tissue in 
direct contact with the ablation electrode. Further, as applied preload before treatment 
increases, the magnitude of areal shrinkage decreases and trends in directional differences 
between circumferential and radial deformation can be more fully appreciated.  
Areal and directional shrinkages are shown plotted along the local coordinate axes 
𝑟 = 0 (Fig. 6.5A) and 𝑠 = 0 for RFC catheter treatment at 1 N/m of preload (Fig. 6.5B). As 
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Fig. 6.3: Catheter Induced Shrinkage Deformations – Shown in the Unloaded State 
Shown are areal (top row), circumferential (middle row), and radial (bottom row) 
deformations, in the unloaded state,  induced by catheter treatment and averaged over n=5 
samples with radial symmetry.  
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Fig. 6.4: Catheter Induced Shrinkage Deformations – Shown at Systolic Loads 
Shown are areal (top row), circumferential (middle row), and radial (bottom row) 
deformations, shown at 90 N/m of equibiaxial load,  induced by catheter treatment and 
averaged over n=5 samples with radial symmetry. 
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expected, areal and circumferential shrinkage deformation magnitude becomes smaller at 
locations further away from the RF ablation electrode along the circumferential and radial 
axes (Fig. 6.5A-B). However, radial shrinkage deformation is larger towards the edges of 
the leaflet than in the immediate ablation zone when plotted along the circumferential axis 
(Fig. 6.5A).  
Thermal shrinkage deformation magnitudes were averaged over the 4x4 marker 
domain of each sample (Fig. 6.6). Differences in thermal shrinkage magnitude between RF 
ablation only and RFC catheter treatment groups with no preload were not significant. In 
general, preload on the MV leaflet samples significantly reduced the magnitude of 
shrinkage deformations. A preload of 5 N/m of membrane tension reduced shrinkage 
magnitude by approximately 50% compared to 1 N/m of preload (Fig. 6.6C). Additionally, 
shrinkage magnitude measured at systolic loading conditions was substantially lower than 
the shrinkage magnitude in the unloaded condition. Areal re-dilation was also measured 1 
hour after treatment, with maximum re-dilation of 8.53 ± 1.99% following RFC catheter 
treatment at no load (Fig. 6.6D). MV leaflet samples treated in combination with preload 
demonstrated no significant re-dilation. 
 
Discussion 
Characteristic Shape of RFC Catheter Thermal Shrinkage Lesions. The objective of this 
study was to quantify spatially-varying shrinkage deformations in collagenous tissues. A 
4x4 marker tracking grid on the atrial surface of the MV anterior leaflet captured the 
variations in tissue shrinkage that occur as a result of tissue anisotropy and ablation device 
geometry. The RFC catheter is a specialized tissue shrinkage device that uses two cryo-
anchoring elements placed on each side of an RF electrode to enable direct electrode-tissue 
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Fig. 6.5: Catheter-Induced Shrinkage Along Local Coordinate Axes 
Areal, circumferential, and radial shrinkage plotted along the local coordinate axes, r=0 (A) 
and s=0 (B), following catheter treatment at 1 N/m of preload. Local coordinate axes are 
shown plotted in Fig. 6.1 and Fig. 6.2 for reference. 
 
 
Fig. 6.6: Average Shrinkage at Varying Preloads 
Circumferential (A) and radial (B) shrinkage deformation induced by catheter treatment 
shown in the unloaded (black) and systolic (gray) loading conditions. C: Areal shrinkage. * 
significant different than all other groups, + significantly different than RF only, 0 N/m and 
RF+Cryo 5 N/m, ‡ significantly different than RF only, 0 N/m (p<0.05). D: Measured areal 
deformation taken in the unloaded state (black) and systolic loading condition (gray) 1 
hour post-treatment. + significantly different than both 0 N/m preload groups, (p<0.05). 
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contact. The result of treatment with the RFC catheter is a thermal shrinkage lesion that is 
affected by the cryogenic temperatures of the cryo-anchors. These sub-freezing 
temperatures appear to exist only on the ventricular surface, since marker positions on the 
atrial surface still experience shrinkage deformations with RF ablation, albeit reduced, in 
the areas of cryo-anchoring. Thus, cryo-anchoring reduces, but does not completely inhibit, 
thermal shrinkage in the vicinity. The characteristic hourglass shape of RFC catheter 
treatment can be fully appreciated in the no preload condition (Fig. 6.3) and is a result of 
collagen fiber alignment with the circumferential direction, as well as placement of the 
cryo-anchors relative to the RF ablation electrode.  
 
Preload Decreases the Magnitude of Thermal Shrinkage. A further aim of this study was to 
examine the variation in shrinkage magnitude and directionality as a result of increased 
preload on the leaflet. The native MV leaflet can be thought of as a membranous tissue that 
is constantly in some form of tension from both the fibrous, relatively rigid trigones around 
the annulus and the compliant chords that connect the leaflet free edge to the papillary 
muscles. Recent studies have demonstrated that the native MV is always under some 
amount of prestrain [75, 135, 136], and the belly region of MV leaflets has been found to 
contract by 18% and 30% in the circumferential and radial directions, respectively, 
following excision [75]. While no measurements for the corresponding preload exist, the 
measured prestrains likely fall within the toe region of the loading curves and implies that 
preload likely does not exceed 5-10 N/m of tension. Thus, to simulate prestrain in this 
study, 1 N/m or 5 N/m of preload was applied before the start of RFC catheter treatment. 
At 5 N/m of preload, the shrinkage lesion was fully contained within the 4x4 marker 
region, unlike the shrinkage lesions of the other groups (Fig. 6.3 and Fig. 6.4). Greater 
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applied preload seems to reduce the coverage of thermal shrinkage lesions, implying that a 
larger ablation electrode or more ablations are needed to thermally shrink an equivalent 
amount of tissue.  
 
Acute Re-Dilation of Thermal Shrinkage Lesions is Minimal. Re-dilation of thermal 
shrinkage lesions in pericardial tissue is known to occur over the first hour after treatment 
[130, 132], thus we sought to investigate this effect in MV leaflet tissue. In treatment groups 
with no preload, MV leaflet tissue was found to re-dilate slightly over one hour (Fig. 6.6D). 
However, when RFC catheter treatment was applied with 1 or 5 N/m of preload, no re-
dilation was measured. The absence of re-dilation following RFC catheter treatment with 
applied preload could be due to the reduced shrinkage magnitudes compared to those of 
the no preload groups. Regardless, the absence of re-dilation following RFC catheter 
treatment is beneficial to the MV repair strategy, as re-dilation will not need to be 
accounted for during treatment. 
 
Study Limitations. In this study, thermal shrinkage deformations were measured and 
quantified in the unloaded condition and at systolic loads (90 N/m of equibiaxial tension). 
Future work will examine how post-treatment leaflet mechanics are affected by examining 
the post-treatment  mechanical loading curves and determining the spatial variation of 
parameter estimates of a Fung-type hyperelastic constitutive model [137]. In order to cover 
a maximal amount of leaflet area, tracking markers were often placed near the sample 
edges. A further limitation of this study is occasional appearance of edge effects along the 
border of the 16 marker area due to the inhomogeneous strains in the vicinity of the loading 
attachments. 
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Conclusions. In this study, we developed a bicubic interpolation method to more fully 
characterize the non-uniform deformation response that results from the RFC catheter – a 
specialized ablation device that consists of an RF electrode surrounded on two sides by 
cryo-anchoring elements that inhibit thermal shrinkage. We found deformations that varied 
strongly depending on the direction of collagen fiber alignment and device alignment with 
the tissue. This analysis can be used to generate mechanical data for computational models 
to guide treatment therapy and to better understand spatially-varying tissue shrinkage 
dynamics. 
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Chapter 7  
 
AIM 2: RFC CATHETER ASSESSMENT IN A PHYSIOLOGIC FLOW ENVIRONMENT 
 
Text and figures for Chapter 7 taken from: 
Boronyak SM, Merryman WD: “In vitro assessment of a combined radiofrequency ablation and cryo-
anchoring catheter for treatment of mitral valve prolapse.” Journal of Biomechanics. Vol. 47. Issue 5, 
973-80, 2014. 
 
 
Introduction 
We have previously shown that when RF energy is applied to MV leaflets in a static 
environment with cryo-anchoring, leaflet size becomes significantly reduced, and infrared 
thermal imaging revealed that the cryo-anchor can be placed in close proximity to the RF 
electrode [11]. However, the effectiveness of this combined RF ablation and cryo-anchoring 
approach has yet to be tested in a physiologic flow environment. In particular, it is 
unknown whether a cryo-anchor can adhere to a moving MV leaflet and if this process 
negatively affects the flow and pressure across the MV.  
The purpose of this study was to develop and evaluate a combined RF ablation and 
cryo-anchoring catheter in a left heart flow simulation environment in order to optimize 
catheter performance and to determine procedure feasibility. We hypothesized that our 
combined RF ablation and cryo-anchoring catheter would adhere to moving porcine MV 
leaflets in a dynamic flow environment and effectively ablate the leaflet tissue with RF 
energy, mimicking surgical leaflet resection. To test this hypothesis, we constructed a left 
heart flow loop, similar to others [138, 139], in order to simulate the flow and pressure 
across healthy, excised porcine MVs. The data that follow support our hypothesis that the 
combined catheter prototype effectively adheres to and ablates MV leaflets in a physiologic 
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flow environment without negatively altering flow or pressure during the procedure, and 
that the changes induced by RF ablation remain durable over four weeks.  
 
Materials and Methods 
Left Heart Flow Loop. A left heart flow loop was developed in order to reproduce 
physiologic pressure and flow waveforms (Fig. 7.1A). Others have used similar flow 
simulators in an effort to study MV disease states and the effects of various repair strategies 
on MV mechanics [92, 140]. MVs were obtained from healthy pigs from a local abattoir 
(Hampton Meats, Hopkinsville, KY), and the entire MV apparatus was excised and kept 
intact. The MV annulus was sewn onto a silicone membrane, and the papillary muscles 
were sewn onto adjustable papillary muscle holders (Fig. 7.1B). LabView software 
(National Instruments, Austin, TX) was used to control the output pressure to a pump 
connected to the left ventricle, and an adjustable flow resistor and vessel compliance 
chamber were used to independently control the flow rate. Transmitral pressure and flow 
waveforms (Transonic Systems Inc., Ithaca, NY) were captured to assess the effect of 
catheter placement and cryo-anchoring on hemodynamics.  
 
RF Ablation and Cryo-Anchoring Catheter. A steerable catheter prototype was constructed 
utilizing components from a Freezer MAX Cardiac Cryoablation catheter (Medtronic, 
Minneapolis, MN). A RF electrode was placed in between two cryo-anchors on the tip of 
the catheter and was electrically insulated from the cryo-anchors (Fig. 7.1C). Liquid nitrous 
oxide delivery to the inside of the catheter tip, which is kept under vacuum, provides the 
cooling power for the cryo-anchor. A deflection wire was attached to a custom steering 
device to allow the catheter tip to be maneuvered. A viewing window on the left heart flow 
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Fig. 7.1: Left Heart Flow Simulator For Simulated Testing 
Left heart flow loop (A) used to test catheter performance consisting of, a: ventricle, b: 
atrium, c: Thoratec VAD bladder pump, d: compliance chamber, e: flow resistor, f: media 
reservoir for catheter access, g: catheter prototype, h: Transonic flow probe, and i: LabView 
input/output controller. B: A healthy MV mounted in the left heart flow loop with the 
catheter prototype placed on the anterior leaflet. Dotted lines represent regions targeted 
for cryo-anchoring and RF ablation. C: Catheter prototype with cryo-anchoring elements 
and RF electrode. 
 
 
loop allowed for precise spatial localization of the catheter tip to the desired areas of the 
MV. The cryo-anchor temperature was controlled automatically by monitoring the 
temperature of the cryo-anchor and varying the duty cycle of a cryogenic solenoid.  
 
Flow Loop Treatments. Two different treatments were tested on MVs placed in the left 
heart flow loop while under physiologic flow conditions. To determine the hemodynamic 
changes induced by cryo-anchoring, the cryo-anchoring procedure was performed without 
RF ablation on several locations of each MV leaflet for a total of 15 applications for 90 
seconds each at a temperature of approximately -30 to -35°C. The cryo-anchoring procedure 
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targeted the central portion of the anterior and posterior leaflets, as demonstrated in Fig. 
1B. In order to assess the ability to ablate the MV leaflets, RF ablation was performed 
during cryo-anchoring, also in the central portion of the anterior and posterior leaflets. RF 
ablation was applied while cryo-anchored to the MV at a power of 50 W for 90 seconds, 
with 15 applications. 
 
Parameter Fitting. Strain energy density was used to provide a quantitative measure of the 
extent of RF ablation, which allows post-treatment mechanical assessment of leaflets 
without any pre-treatment information. The strain energy density was determined by 
fitting post-treatment mechanical data to a three-parameter strain energy model using non-
linear regression [141]. After treatment in the left heart flow loop, MV anterior leaflets were 
excised, tracking markers were placed on the surface of the leaflet for strain tracking, and 
samples were placed into a biaxial mechanical test device and loaded to 90 N/m of 
membrane tension in each direction. For more details, see [9, 11]. 
Following mechanical testing, the strain energy density was determined by fitting 
the membrane tension and strain data to a three-parameter strain energy model [142], in 
order to determine the strain energy density (W): 
 
𝑇𝑖𝑗 =  
𝜕𝑊
𝜕𝐸𝑖𝑗
 
𝑊 = 𝑐[𝑒𝑄 − 1] 
Where:  
𝑄 =  𝐴1𝐸11
2 + 𝐴2𝐸22
2  
 
In which c, A1, and A2, are the parameters to be fit, Eij is the Green-Lagrange strain 
tensor, W is a strain energy density function, and Tij is a membrane tension representation 
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of the 2nd Piola-Kirchhoff stress tensor. Tij is a relation of membrane tension in the 
reference configuration to areas in the reference configuration and is defined as: 
 
𝑇11 =
𝑃1
𝐿2𝜆11
 
and: 
𝑇22 =
𝑃2
𝐿1𝜆22
 
 
Where P is the load in Newtons, L is the original length of the sample, and λ is the 
principal stretch ratio. Directions 1 and 2 correspond with the circumferential and radial 
directions of the MV leaflet, respectively. Experimental data was fit to the three parameter 
strain energy model using non-linear least squares regression with a trust-region-reflexive 
algorithm [143]. Boundary conditions were imposed such that all three parameters, c, A1, 
and A2, must be greater than zero. The results from mechanical testing, including the three 
parameter fits and the strain energy density, are displayed in the supplementary tables. 
In order to provide a control group for comparison, biaxial mechanical data that 
had previously been collected on untreated MV anterior leaflets (n=100) was fit to the above 
three parameter model. As the distribution of the residuals from model fitting was non-
normal, we used the results from parameter fitting these 100 samples to directly determine 
a 95% untreated confidence interval: the range that contained the middle 95 values. For 
additional control groups, we fit biaxial mechanical data from MV anterior leaflets treated 
in a static environment with 350 J, 850 J, and 1250 J of RF energy in combination with cryo-
anchoring [11]. n=5 anterior leaflets were used per control group. 
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Picrosirius Red Staining. Collagen morphology and birefringence were assessed with 
picrosirius red (PSR) staining, which is specific for collagen when viewed under polarized 
light [144]. Leaflets were sectioned along the circumferential direction at 7 µm, stained with 
sirius red 0.1% in saturated picric acid (Electron Microscopy Science, Hatfield, PA) for 1 
hour, and viewed between crossed polarizers at 200x magnification for morphological 
assessment (Eclipse E800, Nikon, Tokyo, Japan).  
Collagen birefringence is an indicator of thermal damage [145], so a relative 
measure of birefringence was obtained by determining the average image intensity [146]. 
MV sections were placed between crossed polarizers and images were taken with the long-
axis of each sample at 0°, 45°, and 90° relative to the polarizing axis. Average image 
intensity was calculated for a 250 µm x 250 µm area using images from each of the three 
orientations and normalized to the background light intensity. This process was repeated 
twice more for a total of 3 regions per MV leaflet.  
 
Durability Study. In order to test the durability of RF ablation treatment, MV anterior 
leaflets were excised from porcine hearts immediately after slaughter. Leaflets were then 
placed in the biaxial mechanical test device, mechanically tested to 90 N/m of membrane 
tension, and then either treated with 1250 J of RF energy with cryo-anchoring or were left 
untreated (n=6 per group). After treatments, leaflets were mechanically tested, placed in a 
tension bioreactor (Fig. 7.2) inside of a standard incubator (37°C, 5% CO2) and stretched to 
10% strain at 1 Hz.  During conditioning in the stretch bioreactor, samples were submerged 
in DMEM containing 10% FBS and 5% antibiotic/antimicotic (ABAM) for 3 days. ABAM 
was then reduced to 2% following the first three days of conditioning, and all samples were 
stretched continuously for four weeks. After four weeks of conditioning, mechanical testing 
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Fig. 7.2: Cyclic Stretch Bioreactor 
Cyclic stretch bioreactor used for the four week durability study. 
 
 
with parameter fitting and PSR staining were used to assess the state of the leaflets 
following four weeks of conditioning and to determine if leaflet size changes induced by RF 
ablation remained durable. 
 
Statistical Methods. For analysis of average image intensity of PSR-stained sections and 
leaflet size in the durability study, statistical significance was determined using a student’s 
t-test with α = 0.05. All error bars shown indicate standard error. For comparison of the 
parameters determined by non-linear regression, all data was compared to the 95% 
confidence interval determined directly from n=100 untreated MV anterior leaflets.  
 
Results 
Hemodynamics of Cryo-Anchoring. Fluid flow and pressure across the MV were monitored 
before (baseline) and during the cryo-anchoring procedure, and waveforms remain largely 
unaltered during cryo-anchoring (Fig. 7.3A and Fig. 7.3B). When the forward cardiac 
output was compared between baseline and during the cryo-anchoring procedure, no 
significant differences were observed (inset, Fig. 7.3B). Fig. 7.3C displays typical outputs to 
the catheter prototype’s cryo-anchor and RF ablation electrode during a combined RF 
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Fig. 7.3: Hemodynamics of Cryo-Anchoring and Typical Catheter Outputs 
Representative transmitral pressure (A) and flow (B) waveforms for a baseline flow 
condition (closed diamonds) and during cryo-anchoring (open circles). Inset: average 
forward cardiac output during baseline and cryo-anchoring flow conditions. No significant 
differences between groups. C: Catheter outputs for one representative ablation procedure 
performed in the left heart flow loop. 
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ablation procedure with cryo-anchoring. Videos of the cryo-anchoring procedure can be 
found in the supplemental data (Videos S1 and S2, not shown). 
 
Parameter Fitting. Fig. 7.4 shows a representative model fit to the biaxial mechanical data 
from both of the flow loop treatment groups. MV anterior leaflets treated with cryo-
anchoring alone produced mechanical responses similar to those that have been reported 
for native, untreated MV anterior leaflets (Fig. 7.4A) [11, 50]. Qualitative differences in the 
shape of the loading curves can be observed between the RF ablation with cryo-anchoring 
group and the cryo-anchoring only group. MV leaflets treated with RF ablation lack the toe 
region often seen in healthy, untreated MVs, and the absence of the toe region can be seen 
in Fig. 4B. The shaded regions of Figs. 4A and 4B are a graphical representation of the strain 
energy density. 
The strain energy density resulting from parameter fitting after treatment in the left heart 
flow loop is shown plotted alongside static controls treated with RF energy with cryo-
anchoring (Fig. 7.4C). The 0 J static control group is the average of 100 untreated MV 
anterior leaflets that were used to determine the 95% untreated confidence interval and was 
found to be 4.36 N/m with a 95% confidence interval of  (2.67, 7.11 N/m). The 350 J, 850 J, 
and 1250 J static control groups are a re-analysis of mechanical data previously presented 
for comparison purposes [11]. All MVs treated with RF ablation with cryo-anchoring in the 
flow loop have fitted parameters that fall well outside the 95% untreated confidence 
interval. All cryo-anchoring only MV leaflets have strain energy density similar to 
untreated controls, indicating that cryo-anchoring alone does not alter leaflet size or 
mechanical response. 
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Fig. 7.4: Model Fit Results to Treated and Untreated MV Leaflets 
Representative model fits to experimental mechanical data following treatment in the flow 
simulator following application of cryo-anchoring without RF energy (A) and following 
treatment with RF energy with cryo-anchoring (B). Circumferential direction, solid 
triangles. Radial direction, open circles. Model fits, dotted line. C: Strain energy density for 
static control leaflets and flow loop treated leaflets, an indicator of the extent of RF energy 
delivery. The shaded region represents the 95% untreated (0 J) confidence interval, 
determined from n=100 MV anterior leaflets not treated with the catheter prototype. Each 
of the static control leaflets (350, 850 and 1250 J) were treated with the amount of RF 
energy indicated combined with cryo-anchoring (n=5 per group). 
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Picrosirius Red Staining. Morphological analysis of MVs stained with PSR reveals the 
collagen crimp pattern typical of healthy MV leaflets (Fig. 7.5A). Cryo-anchoring alone does 
not modify collagen morphology (Fig. 7.5B); however, treatment with RF ablation 
denatures the collagen fibrils, and a distinct loss of collagen crimp occurs (Fig. 7.5C). 
Representative images of MVs treated in the left heart flow loop are also displayed in Fig. 
7.5, and PSR-stained sections of flow loop treatment with cryo-anchoring only (Fig. 7.5D) 
demonstrates morphologies similar to untreated valves. MVs treated in the flow loop with 
RF ablation with cryo-anchoring (Fig. 7.5E) reveal regions of thermal damage indicated by 
a loss of collagen crimp. Fig. 7.5E features a distinct border between ablated tissue and 
normal, untreated tissue.  
 
 
Fig. 7.5: Picrosirus Red Staining of RF Ablation-Treated MV Leaflets 
Representative images of PSR-stained sections sliced with the circumferential direction and 
viewed between crossed polarizers. Scale bars = 100 µm. A: Untreated, normal MV. B: 
Statically treated with cryo-anchoring only. C: Statically treated with RF ablation with 
cryo-anchoring. D: Flow loop treatment with cryo-anchoring only. E: Flow loop treatment 
with RF ablation with cryo-anchoring. Note the sharp demarcation between ablated and 
normal tissue. 
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Fig. 7.6: Quantification Polarized Light Intensity of PSR-Stained MV Sections 
Average normalized light intensity of PSR-stained sections viewed between crossed 
polarizers, a relative assessment of collagen birefringence. Average of n=3 MV anterior 
leaflets per group. + indicates a significant decrease (p < 0.05) from the static, untreated 
control leaflets. 
 
 
Average normalized light intensity is shown for static control valves and flow loop 
treated MVs in Fig. 7.6. Treatment with RF ablation results in a significant reduction in 
average light intensity (p < 0.05). Consistent with morphological image analysis and 
parameter fitting, MVs treated with cryo-anchoring alone have a collagen birefringence 
similar to normal, healthy MVs, and MVs treated with RF ablation with cryo-anchoring 
demonstrate a significant reduction in birefringence. 
 
Durability Study. Following static treatment of RF ablation with cryo-anchoring and four 
weeks in a stretch bioreactor, MV leaflets were reduced in size at all points in the loading 
cycle (Fig. 7.7A), similar to a typical acute post-treatment response [11]. Fig. 7.7B shows 
leaflet size changes, as measured at mechanical loading that mimics the systolic condition, 
immediately post-treatment and after four weeks of conditioning. Leaflets demonstrated 
size reductions in both the circumferential and radial directions that were maintained over 
Flow Loop Treatments
Cryo Only RF+Cryo
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Static Controls
Untreated RF + Cryo
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
0.0
0.5
1.0
1.5
2.0
2.5
3.0
+ +
101 
 
four weeks, with no significant difference between groups. Parameter fitting indicated that 
strain energy density for the RF ablation-treated MV leaflets remained outside the 95% 
untreated confidence interval over 4 weeks (Fig. 7.7C). Untreated and treated MV leaflets 
stained with PSR after four weeks of conditioning in a stretch bioreactor expressed similar 
morphologies to healthy and RF-treated leaflets, respectively (Fig. 7.7D and Fig. 7.7E).  
 
 
Fig. 7.7: Durability Testing of RF Ablation-Treated MV Leaflets 
Representative membrane tension vs. stretch ratio for one MV leaflet treated with 1250 J of 
RF energy with cryo-anchoring (A). Shown are the pre-treatment (circles) and four week 
post-treatment (squares) mechanical responses with all stretch ratios referenced to the 
untreated, unloaded configuration. B: % change in areal systolic deformation (leaflet size at 
90 N/m of membrane tension) immediately after treatment with 1250 J of RF energy with 
cryo-anchoring (black bars) and four weeks post-treatment (gray bars). No significant 
changes between groups (p > 0.05), n=6 for each group. C: Strain energy density for 
mechanical test data immediately after treatment (black bars) and four weeks post-
treatment (gray bars). n=6 for each group. D-E: Representative images of PSR-stained 
sections following four weeks in a stretch bioreactor. Scale bars = 100 µm. 
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Discussion 
Cryo-Anchoring Hemodynamics. As Video S1 (not shown) demonstrates, a steerable 
catheter can freely maneuver around the circumference of the MV apparatus, and 
placement of the catheter on or across the MV leaflet does not restrict motion. Cryo-
anchoring of the catheter to the surface of the MV apparatus can be performed in a variety 
of locations, allowing RF energy to be distributed where desired. Video S1 demonstrates a 
cryo-anchoring procedure in which both the anterior and posterior leaflets are anchored 
simultaneously, producing leaflet movement comparable to that of an edge-to-edge repair 
[84]. As demonstrated, cryo-anchoring provides robust attachment to both leaflets when 
each of the approximately 1.75 mm long cryo-anchors of the 7 French catheter are 
maintained at -30 to -35°C. Cryo-anchoring can also be confined to a single leaflet, such as 
that shown in Video S2, in which the anterior leaflet is anchored near the MV annulus and 
leaflet motion is largely unaltered. Thus, cryo-anchoring can be used to target specific 
regions of the MV apparatus for delivery of RF energy, and cryo-anchoring can be 
maintained over long periods of time (90 seconds or more) at temperatures around -30°C to 
allow for therapeutically meaningful doses of RF energy to be delivered (Fig. 7.3C). 
Importantly, the cryo-anchoring procedure does not significantly alter the hemodynamics 
of the left side of the heart (Fig. 7.3A-B).  
 
Assessment of RF Energy Delivery I: Strain Energy Density. As these experiments were 
performed on healthy MVs, flow measurements such as regurgitant volume, or geometric 
measurements such as the degree of leaflet prolapse, were not suitable indicators for 
treatment efficacy and an alternative method was necessary. In prior studies, we used 
biaxial mechanical testing to determine leaflet size and mechanical changes using pre- and 
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post-treatment mechanical data and demonstrated that changes in leaflet mechanics 
accompanied size changes [11]. However, pre-treatment mechanical data was unattainable 
in this study due to the need to use the intact MV apparatus in the left heart flow loop. 
Thus, our strain energy density approach permits quantitative assessment of mechanical 
changes induced by RF energy by comparing the results from model fitting to those of 
untreated and treated control valves.  
The robustness of strain energy density to predict alterations due to RF energy can 
be seen in the large differences between groups (Fig. 7.4C). The mechanical response and 
strain energy density of MV leaflets following cryo-anchoring are similar to the native, 
untreated response, confirming that cryo-anchoring does not affect leaflet mechanics. MVs 
treated in the flow loop with RF ablation were characterized by strain energy densities that 
fell well outside the 95% confidence interval, indicating that RF energy delivery to MV 
leaflets is still feasible in the presence of convective blood flow. As large (> 10 x 10 mm) 
sections of tissue are used for mechanical testing, strain energy density identifies large scale 
changes in the mechanics of the MV leaflets. A possible future application of this approach 
is for use with in vivo animal testing of the catheter prototype to verify RF energy delivery. 
As in vivo animal models of MV prolapse can be difficult to find, this will provide one 
method of testing successful delivery of RF energy in studies using healthy animals. 
 
Assessment of RF Energy Delivery II: PSR Staining. PSR staining is another method of 
assessing RF energy delivery, since the primary target of both our ablation treatment and 
PSR is collagen. The collagen structure of normal, healthy MV leaflets is characterized by a 
regular crimp pattern, shown in both the untreated and cryo-anchoring only treatments 
(Fig. 7.5A-B and Fig. 7.5D). Studies with cryoablation on the myocardium have concluded 
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that cryogenic temperatures, at least as low as -80°C, can be performed without structural 
damage to tissues [56]. MV leaflets that have been treated with RF ablation lose the collagen 
crimp pattern as they contract due to heat, and when stained with PSR, these same leaflets 
also demonstrate a significant reduction in collagen birefringence in areas of thermal 
damage (Fig. 7.6). In this study, we use the average light intensity of the sample as a 
relative measure of birefringence. The loss of birefringence manifests itself as regions of 
darkened tissue when viewed between crossed polarizing filters, and the difference in light 
intensity between ablated and untreated regions can be seen in Fig. 7.5E and Fig. 7.6.  
 
Durability of RF Energy-Induced Changes. The in vitro durability study was performed to 
determine whether size changes induced by RF ablation may be temporary and whether 
RF-treated leaflets become mechanically compromised over time, either of which would be 
detrimental to this treatment strategy. Previous studies have examined the use of RF 
ablation to reduce left ventricular volume size in patients with congestive heart failure and 
found that myocardium treated with RF energy re-dilated within four weeks [51]. In this 
study, after static treatment with an RF ablation and cryo-anchoring catheter prototype and 
four weeks of conditioning in a stretch bioreactor, MV leaflets remained durable (Fig. 7.7A). 
Following the four weeks of bioreactor conditioning, MV leaflet size actually reduced 
further in each direction when measured at systolic loads (Fig. 7.7B), albeit not 
significantly. The mechanism for this further reduction in leaflet size is unknown, but one 
possible explanation is that scarring causes stiffening of the tissue and further contraction. 
Others have reported that the first 2-3 months following ablation is a period of remodeling 
in which tissue mechanics and size may be altered [147, 148]. Additionally,  in vivo studies 
using RF ablation to shrink the MV annulus have reported that the annulus contracts to 
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diameters below the initial shrinkage at 3- and 6-months [54], following a trend similar to 
our durability results. While this study on the durability of RF ablation treatment of MVs is 
limited in that it was performed entirely in vitro, the results are promising in that leaflet 
size changes are maintained.  
 
Study Limitations. This study was somewhat limited in that healthy MVs were used, as 
there was not a reliable in vitro model for MV prolapse. A more precise determination of 
the efficacy of this percutaneous approach will be required using in vivo disease models. 
The procedure was also performed by direct visualization, which made accessing and 
treating the MV significantly easier than through echocardiographic image guidance. 
Lastly, ablation of the MV was confined to the leaflets, although the MV annulus and 
chords may also be ablated. Chordal elongation is often another target of MV repair, and 
further work may include ablation of the chords. However, there may be added risk of 
chordal rupture or of inducing arrhythmias, due to their location in the ventricle.  
 
Conclusions 
In this study, we have demonstrated that a combined RF ablation and cryo-anchoring 
catheter can reliably adhere to and ablate the MV in a dynamic hemodynamic environment. 
Cryo-anchoring provides robust, reversible attachment to the MV apparatus while RF 
ablation reduces MV leaflet size, effectively providing a percutaneous alternative for 
surgical leaflet resection. While in vitro results are promising, further study will be 
required to assess in vivo safety and efficacy.  
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Chapter 8  
 
AIM 3: TWO-DIMENSIONAL ECHOCARDIOGRAPHIC INDICATORS OF MV 
LEAFLET SHRINKAGE AND ASSESSMENT OF TREATMENT EFFICACY IN VIVO 
 
 
Introduction 
The objective of the present work is to evaluate the efficacy of the RFC catheter to 
approximate surgical leaflet resection using a non-survival porcine animal model. Initially, 
RFC catheter treatment efficacy criteria was identified using ex vivo testing of excised 
porcine MVs placed in a left heart flow simulation device. The primary goal of the ex vivo 
study was to use quantitative leaflet length measurements, obtained on echocardiographic 
views of the A2-P2 imaging plane, as a predictive imaging correlate for total leaflet area 
reductions. Leaflet area reductions of MVs in the left heart flow simulator were measured 
by tracking the positions of four suture markers placed on the MV anterior leaflet (AL) 
surface with echocardiography in an intercommissural imaging plane to capture all 
markers on 2-dimensional (2D) views. Corresponding leaflet length reductions were 
captured in the A2-P2 imaging plane and compared to directional and areal measurements 
obtained in the intercommissural plane.  
Following the establishment of efficacy criteria, five consecutive in vivo studies in 
healthy pigs were performed open-chest to test the efficacy of the RFC catheter to resect 
leaflet tissue. The data that follow demonstrate that RFC catheter treatment, guided by 
echocardiography, produces significant resection of MV leaflets without compromising 
hemodynamic function during treatment. Post-treatment echocardiographic images, 
quantification of leaflet length, as well as gross morphological, histological, and mechanical 
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analyses provide evidence that RF ablation can produce significant reductions in MV leaflet 
area.  
 
Materials and Methods 
Ex Vivo Establishment of Efficacy Criteria. Intact porcine MVs were excised from hearts 
obtained from the local abattoir (Hampton Meats, Hopkinsville, KY) within one hour of 
slaughter, including the annulus, leaflets, chords, and papillary muscles (PMs). Four 
tracking markers (3-0 braided polyester suture with 3-4 square knot throws) were sutured 
to the central region of the AL on the atrial surface with approximately 1 cm spacing to 
track leaflet size with echocardiography. Additionally, the outer margin of the AL was 
marked by staining with trypan blue to provide an estimate of leaflet area pre- and post-
treatment. The intact valves were then placed in a left heart flow simulator (Fig. 1A) 
capable of reproducing physiologic pressure and flow waveforms (average flow rate of 5 
L/min, heart rate of 70 beats/min, transmitral pressure of 100-120 mmHg), as described 
previously [149].  
Mock circulatory flow loops have been used to create models of MR and to study 
the hemodynamic response of MVs to various surgical treatments [150]. In this study, after 
a normal, baseline PM configuration was established, both PMs were displaced towards the 
MV annulus until significant leaflet billowing (greater than 4 mm beyond the annular line) 
was seen on echocardiography (Fig. 8.1). This provided an approximate simulation of bi-
leaflet prolapse to more easily visualize leaflet morphologic changes following treatment 
with the RFC catheter.  
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Fig. 8.1: Ex Vivo Methods 
A: MV positioned into the left heart flow simulator with adjustable PM attachments 
(arrows). B: Echocardiographic imaging planes used in the ex vivo study, surgical view. C: 
Change in MV morphology following treatment with the RFC catheter, shown in the A2-
P2 plane. Note the reduction of leaflet prolapse following treatment. D: Markers placed on 
the AL were tracked in the intercommissural imaging plane. E: Echocardiographic image 
of a porcine MV in the left heart flow simulator imaged in the A2-P2 plane with leaflet 
length measurements denoted in red. 
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To provide a clinically relevant assessment of RFC catheter treatment efficacy, two-
dimensional (2D) echocardiography (Acuson Antares, Siemens) was used to image MVs in 
the left heart flow simulator. Views of the MV apparatus were captured in two imaging 
planes: an intercommissural plane to track the four suture markers on the surface of the 
AL, and an A2-P2 plane to record leaflet morphology, length, and prolapse (Fig. 8.1B). 
Baseline echocardiographic recordings were captured, the PMs were displaced towards the 
annulus, and the prolapse condition was recorded (Fig. 8.1C). The AL was then treated 
several times with the RFC catheter with a cryo-anchor temperature of approximately -50°C 
and RF ablation power of 65W for 90 seconds each. The first five ablations were performed 
within the area constrained by the four tracking markers, and marker positions were 
recorded during mid-diastole after each ablation in the intercommissural plane (Fig. 8.1D). 
To determine reductions in marker area, circumferential length, and radial length, the 
deformation gradient tensor was calculated from the four marker positions and averaged 
over three repeated measurements (MATLAB, MathWorks, Inc.) [11, 117]. After the first 
five ablations, each AL and posterior leaflet (PL) was ablated up to 10 times, and post-
treatment echocardiographic recordings were captured. AL and PL lengths were measured 
during mid-diastole, from the base of the annulus to the leaflet free edge, and averaged 
over three measurements (MATLAB) (Fig. 8.1E), while corresponding leaflet prolapse 
measurements were taken during mid-systole (Showcase Premier, Trillium Technology) 
(Fig. 8.1C).  
 
In Vivo Investigational Protocol. Five consecutive studies in healthy pigs ranging in 
weight from 47 to 51 kg were carried out with a Vanderbilt University approved 
institutional animal care and use committee protocol to evaluate RFC catheter efficacy in 
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vivo. On the day of surgery, anesthesia was induced with ketamine (2.2 mg/kg), telazol (4.4 
mg/kg), xylazine (2.2 mg/kg), and atropine (0.04 mg/kg) via intramuscular injection, and 
isoflurane (1-3%) with O2 was administered under endotracheal intubation for 
maintenance. To prevent arrhythmias, animals were treated with an intravenous bolus 
loading dose of 2 mg/kg of amiodarone prior to the start of surgery and 1.2 mg/kg/hr via 
intravenous drip for maintenance thereafter. Heart rate, rhythm, and blood pressures were 
monitored throughout the procedures. 
A median sternotomy was performed and intervening fascial layers dissected to 
optimize visualization of the pericardium, heart and major blood vessels. An 18 gauge 
needle was utilized to cannulate the mid-to-distal anterior wall of the left ventricle through 
which a 0.035-inch J-wire was inserted for ventricular access. A 12 Fr short modified sheath 
was placed in the left ventricle (Fig. 8.2A-B) via an over-the-wire modified Seldinger 
technique followed by tandem removal of the wire and dilator. Sheath position on the left 
ventricular free wall and alignment with the MV apparatus was confirmed by direct 
echocardiographic guidance using an epicardial probe positioned superior to the access site 
on the pericardial-epicardial surface in an epicardial long-axis configuration. Fluoroscopy 
was available, if necessary, for sheath and catheter guidance but was used in only one 
animal in this study.  
The RFC catheter (10 Fr) was directed through the sheath and across the MV orifice 
under direct echocardiographic visualization. Once the RFC catheter tip was located in the 
vicinity of the AL, cryo-anchoring was obtained by intra-luminal delivery of nitrous oxide 
to securely cryo-anchor the catheter to the leaflet surface with a temperature of -50°C (Fig. 
8.2C-D). Once cryo-anchoring was achieved, RF energy was delivered to the AL for 60 
seconds (Fig. 8.2E-F). RF power output was regulated to maintain the RF electrode
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Fig. 8.2: In Vivo Methods 
A: Access to the MV was gained by placing a sheath midway up the left ventricular free 
wall, enabling direct access to the AL, shown post-mortem (B). Epicardial long-axis view of 
the RFC catheter cryo-anchored to the AL, while the PL moves freely. The diastolic view 
demonstrates the free PL (C), while the systolic view demonstrates that leaflet mobility is 
maintained, allowing valve closure (D). Dotted yellow line indicates the catheter shaft. E: 
Representative temperatures at the RF electrode (red, dash) and cryo-anchor (blue, solid) 
during one ablation. F: Representative ablation power output (black, solid) and measured 
impedance (red, dashed) corresponding to temperatures measured in E. LV: left ventricle. 
RV: right ventricle. 
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temperature within a calibrated range that was demonstrated to produce leaflet resection 
without significant impedance rise. Cryo-anchoring was then ceased after 60 seconds of 
ablation, the RFC catheter tip was re-positioned, and the cryo-anchoring and ablation 
process was repeated up to 20 times for each animal. 
 
In Vivo Study Evaluation Protocol. Echocardiographic examination of the MV and 
surrounding area was performed before and after RFC catheter treatment in long- and 
short-axis views of the heart. All echocardiographic imaging was performed epicardially 
using a custom-built scanner (Cephasonics, Santa Clara, CA) in B-mode with a 10 MHz 
linear array probe. Following catheter treatment and completion of the echocardiographic 
examination, each animal was euthanized according to protocol, and the heart was excised. 
At post-mortem, the entirety of the left heart, including the MV, ventricle, atrium and left 
ventricular outflow tract, was examined for signs of ablation. Gross leaflet morphology, as 
well as any off-target ablations, were noted. The belly region of each MV was then excised 
and mechanically tested to equibiaxial loads of 90 N/m in a biaxial mechanical testing 
device to assay for evidence of thermal alteration by fitting the mechanical loading curves 
to a Fung-type strain-energy model. Strain-energy measurements have previously been 
shown to provide a measure of thermal alteration and an estimate of resected leaflet area 
[130, 149]. Afterwards, leaflets were fixed in 10% formalin before histological staining with 
picrosirus red to assess collagen structure for characteristic markers of thermal alteration 
[145, 149]. Echocardiographic images of the AL in the long-axis view from pre- and post-
treatment were analyzed offline to measure leaflet length (MATLAB). Leaflet length 
measurements were repeated three times per image frame over 3-6 different frames for a 
total of 9-18 measurements per leaflet and were averaged together. 
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Statistical Analysis. All measurements are reported as mean ± standard error. One way 
ANOVA was conducted to examine statistical differences between groups with a follow-up 
Holm-Sidak method for multiple pairwise t-tests at significance level α=0.05. 
 
Results 
Ex Vivo Assessment. Maximum areal shrinkage within the marker region of interest was 
achieved after 4 ablations of 50W for 90 seconds (Fig. 8.3A-B) and shrinkage was greatest in 
the circumferential leaflet direction (Fig. 8.3C). After 15 ablations, spread over the entirety 
of the AL, areal leaflet shrinkage was 38 ± 2.7%, circumferential shrinkage was 30 ± 2.3%, 
and radial was 12 ± 2.2% (Fig. 8.3D). For comparison, leaflet area, as measured by the area 
enclosed by tissue dye markers before and after experiments, was found to have shrunk by 
32 ± 3.3% and 37 ± 5.9% in the AL and PL, respectively. Corresponding leaflet length 
reduction (9.2 ± 1.8%), measured on echocardiography in the A2-P2 imaging plane, was 
comparable to radial shrinkage. Overall, when leaflet length has been reduced by 9.2%, 
total leaflet area has decreased by 38%, which provides a quantitative target for 
determining leaflet resection efficacy in the in vivo study (Fig. 8.3D). PL length decreased 
by 12 ± 3%, and average leaflet lengths measured in the baseline, prolapse, and treated 
conditions are shown plotted in Fig. 8.4A-B. Leaflet prolapse decreased by 62 ± 17% and 50 
± 30% in the AL and PL, respectively (Fig. 8.4C-D). 
 
In Vivo Efficacy. The RFC catheter was able to selectively adhere to the AL, and valve 
closure was minimally inhibited during cryo-anchor formation. The maximum difference in 
heart rate during RFC catheter treatment from baseline averaged -2 ± 3.3 beats per minute, 
suggesting no adverse effects on cardiac function. Cryo-anchoring was successfully
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Fig. 8.3: Ex Vivo Leaflet Area Measurements 
A: MV leaflet circumferential (circ) and radial directions. B: Areal leaflet shrinkage over 
the course of 5 ablations within the 2x2 marker area, n=6. C: Corresponding directional 
shrinkage measurements in the circumferential (blue circles) and radial (red triangles) 
directions, n=6. D: Average final marker size reductions recorded in the intercommissural 
imaging plane (black bars) and corresponding leaflet length reduction measured in the A2-
P2 imaging plane (gray bar), n=9. 
 
 
 
Fig. 8.4: Ex Vivo Length and Prolapse Measurements 
A-B: AL and PL length measured in the baseline and prolapse configurations and 
following treatment with the RFC catheter. C-D: Corresponding reduction in prolapse of 
the AL (C) and PL (D) post-treatment. Lines above bars represent significant changes 
between groups (p<0.05). n=9 per group. 
 
# of ablations
0 1 2 3 4 5
%
 a
re
a
l 
s
h
ri
n
k
a
g
e
-40
-30
-20
-10
0
Area Circ Rad AL Length
%
 c
h
a
n
g
e
-50
-40
-30
-20
-10
0
DB
# of ablations
0 1 2 3 4 5
%
 s
h
ri
n
k
a
g
e
-40
-30
-20
-10
0
Circ
Radial C
R
a
d
ia
l
Circ
A
Baseline Prolapse Treated
A
L
 P
ro
la
p
s
e
 (
c
m
)
0.0
0.2
0.4
0.6
0.8
1.0
Baseline Prolapse Treated
P
L
 P
ro
la
p
s
e
 (
c
m
)
0.0
0.2
0.4
0.6
0.8
1.0
Baseline Prolapse Treated
A
L
 L
e
n
g
th
 (
c
m
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Baseline Prolapse Treated
P
L
 L
e
n
g
th
 (
c
m
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
All significant
A B
DC
115 
 
maintained throughout each ablation, and  between 15-21 ablations were attempted on each 
animal for a target time of 60 seconds (Table 8.1). One animal (Animal #5) developed atrial 
fibrillation after 15 ablation attempts and was successfully cardioverted to normal rhythm. 
Echocardiographic images taken of the AL post-treatment demonstrated apparent leaflet 
thickening, shortening of leaflet length (Fig. 8.5A-B), and altered leaflet motion throughout 
the cardiac cycle when compared to pre-treatment images. Measurements of leaflet length 
on echocardiographic long-axis views indicated an average 13.3 ± 4.6% reduction in AL 
length following RFC catheter treatment (Fig. 8.5C).  
 
 
Table 8.1: Average Ablation Output and Post-Treatment Morphological Assessment 
 
Animal 
# 
Ablations 
Attempted 
Average 
Duration 
(s) 
Average 
Power 
(W) 
Average 
RF Temp. 
(°C) 
Off-Target Ablations Morphologic Changes 
1 15 57 ± 2.5 50 ± 1.0 9.8 ± 0.4 2 – Near posteromedial 
commissure on 
ventricular wall 
 Significant char in belly region 
 Coagulum along annulus 
 Thickening throughout  
2 20 58 ± 1.8 50 ± 1.4 13 ± 0.6 1 - Near posteromedial 
commissure in atrium 
above annulus 
 Small amounts of char 
 Apparent thickening within 3-4 mm 
of free edge 
3 21 52 ± 2.8 33 ± 2.0 14 ± 0.6 0 - None could be 
identified 
 Significant char in A2 segment from 
annulus to leaflet free edge 
 Coagulum along annulus 
 Thickening throughout 
4 20 58 ± 1.3 28 ± 1.5 19 ± 0.7 0 - None could be 
identified 
 Moderate char, primarily in A2 
segment from leaflet belly region to 
free edge 
 Apparent thickening in leaflet central 
area 
5 15 56 ± 2.8 28 ± 0.7 16 ± 0.8 2 – Near posteromedial 
commissure on 
ventricular wall 
 Localized areas of leaflet thickening 
and light char on leaflet 
 Coagulum along annulus near both 
commissures 
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ALs treated with the RFC catheter demonstrated varying levels of char formation on 
the leaflet surface, coagulum formation around the annulus, and apparent leaflet 
thickening (Fig. 8.6A; Table 8.1). Most off-target ablations were located around the 
posteromedial commissure in either the ventricle or atrium Ablations located on the 
annulus immediately above the AL were not considered off-target. Strain energy values 
obtained for the n=5 ALs treated in the pig study are shown plotted alongside estimates for 
resected leaflet area (Fig. 8.6B). Resected leaflet area estimates were obtained from 
previously published findings in leaflets treated in a static bench environment, and strain 
energy values greater than 10 N/m have been found to correlate with significant resected 
leaflet areas [149]. Three out of five of the leaflets positively tested for strain energy values 
that indicate significant leaflet resection. Additionally, picrosirius red staining confirmed 
that the collagen structure of the ALs had been thermally altered in four of five leaflets (Fig. 
8.6C). 
 
Discussion 
Establishment of Leaflet Resection Efficacy Criteria. As healthy animals without MR were 
used for this study, a quantitative measurement was needed to appropriately evaluate the 
ability of the RFC catheter to shrink – or resect – MV leaflet tissue. Thus, we used a two-
part study to identify a measurement than can be used to assess the acute success of RFC 
catheter treatment in healthy animals: leaflet length measured on echocardiography.  
First, leaflet area and directional length measurements were taken in a physiologic 
ex vivo environment. These measurements were recorded in the intercommissural imaging 
plane (Fig. 8.1B), which cannot be sufficiently visualized without the placement of markers 
on the leaflet surface. Next, corresponding leaflet length measurements in the A2-P2 
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Fig. 8.5: Post-Treatment Echocardiographic AL Assessment 
Long-axis view of the AL before (A) and after (B) treatment with the RFC catheter. The 
post-treatment AL exhibits a characteristic increase in thickness and a decrease in radial 
length. C: AL length reduction (% decrease) as measured on epicardial echocardiography 
following treatment with the RFC catheter. Dashed line indicates efficacy criteria 
established in the ex vivo study. D: One representative leaflet length measurement 
(Animal #1). 
 
 
 
imaging plane, which is an easily obtainable measurement in vivo, were taken for 
comparison. As AL length (A2-P2 plane) and radial marker length (intercommissural 
plane) were found to agree and because the relationship between radial and circumferential 
shrinkage was found to remain the same across samples, leaflet length reductions 
measured on clinical 2D echocardiograms can be used to estimate total leaflet area 
shrinkage in healthy animals. Based on the ex vivo data, the target for in vivo RFC catheter 
treatment efficacy is approximately 10% reduction in leaflet length, which would indicate a 
total leaflet area reduction of approximately 40% (Fig. 8.3D). This is comparable to the 
average resected area of a typical PL quadrangular resection, which is 30% [73]. 
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Fig. 8.6: Post-Treatment Morphological, Mechanical, and Histological Assessment 
A: MV leaflets post-mortem. The AL is shown partially excised on the left and exhibits 
significant char and coagulum on the leaflet surface and at the base of the annulus (black 
arrows). Off-target ablations were seen in the posteromedial commissure (white arrows). 
The PL has been left untreated and is shown for comparison. B: Strain energy estimate on 
excised ALs following treatment with the RFC catheter. Values shown to the right are the 
corresponding estimates of resected leaflet area based on treated and untreated controls in 
a static bench environment [11, 149]. C: Representative picrosirius red stained section 
demonstrating the typical loss of collagen crimp following thermal shrinkage (Animal #1). 
An untreated control is shown on the right. Scale bar = 200µm. 
 
Ex vivo testing suggests that the MV leaflet shrinks relatively linearly with the 
number of 65W ablations, and it takes 4 ablations to maximally shrink a 1 cm square region 
of tissue by approximately 40% (Fig. 8.3B). Consistent with previous studies, the majority of 
leaflet shrinkage occurs in the circumferential direction, the primary direction of collagen 
fiber alignment (Fig. 8.3A). Thus, the total leaflet length, which is aligned radially, shrinks 
minimally (about 10%), while the leaflet shrinks approximately 30% in the circumferential 
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direction. The directional shrinkage response of diseased and myxomatous MV leaflets is 
currently unknown and warrants investigation.  
A secondary component of the ex vivo study was treatment of the prolapse model, 
enabling large changes to MV morphology to be more easily appreciated (Fig. 8.1C). One 
hallmark of Barlow’s disease is large, thickened, and billowing leaflets that prolapse 
significantly into the atrium during systole. In our ex vivo prolapse model, leaflet prolapse 
was reduced, on average, by over 50%. The large standard errors associated with the 
prolapse measurements (Fig. 8.4C-D) are likely an artifact of sample preparation (suturing 
of MV annulus). In some cases, leaflet prolapse was reduced by over 100% back to baseline.  
 
RFC Catheter Treatment is Acutely Efficacious In Vivo. RFC catheter leaflet resection was 
acutely successful in 4 of 5 animals according to the efficacy criteria established in the ex 
vivo study. Additionally, minor evidence of leaflet ablation was found in the unsuccessful 
animal, including small amounts of char formation on the leaflet surface and collagen 
thermal alteration visible on histology. This is the first study to demonstrate that MV leaflet 
area can be significantly reduced using a catheter-based strategy in vivo.  
Selective administration of thermal shrinkage to each MV leaflet is essential in the 
RFC catheter treatment strategy. Depending on the severity and presentation of 
degenerative MV disease, enlarged and myxomatous leaflet tissue could be confined to a 
single segment of a single leaflet or be present throughout both leaflets [20]. The AL was 
specifically targeted in this study due to the access route, and the AL was successfully 
adhered to independently of free motion of the un-targeted PL. An alternative access route, 
closer to the apex, was originally attempted, and it was found that the PL could be similarly 
targeted for cryo-anchoring (data not shown).  
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The ex vivo study indicates that leaflet length reductions of greater than 10% of the 
original length correlated with a resected area of ~40%. This benchmark was achieved in 4 
of 5 animals in the present study. Echocardiographic findings showed thickened and 
shortened leaflets post-treatment, characteristic of thermal alteration. Gross inspection of 
ALs post-mortem, picrosirius red staining, and mechanical testing, each verified successful 
RFC catheter treatment.  
Off-target ablations occurred in 3 of 5 animals. Epicardial echocardiography 
provides some guidance of catheter position, but probe maneuverability is limited and 
difficult to achieve reliably, which may have led to some of the off-target ablations 
observed here. Future studies will employ transesophageal echocardiography to more 
consistently and reliably guide catheter placement and transmitral positioning for ablation. 
Additionally, the catheter access route used in this study was advantageous in that it 
allowed direct access to the MV leaflets with little need for catheter steering, but the RFC 
catheter is intended to be used percutaneously, and thus approach the MV atrially through 
a trans-septal course. Future percutaneous studies will use the trans-septal approach with a 
steerable sheath and transesophageal echocardiography to more precisely target specific 
leaflets, which will likely reduce off-target ablations as a result 
 
Conclusion. This study demonstrates in vivo success of a catheter-based alternative to 
surgical leaflet resection for repair of degenerative MV disease. RF ablation with cryo-
anchoring stability can resect up to 40% of MV leaflet area. The RFC catheter cryo-anchor 
can selectively target each leaflet individually under echocardiographic guidance, allowing 
for RF delivery to specific leaflet segments. Efficacy criteria established ex vivo was used to 
confirm that RFC catheter treatment can be monitored on 2D echo and to confirm that 
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treatment was efficacious in healthy pigs. While further testing of safety and efficacy 
remain, short-term in vivo results indicate that the RFC catheter is a potential percutaneous 
alternative to surgical leaflet resection. 
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Chapter 9  
 
IMPACT AND FUTURE DIRECTIONS 
 
 
Investigational Summary and Impact of Results 
The overall goal of this research was to develop and refine a percutaneous MV repair 
device to provide an alternative to surgical leaflet resection and to investigate its 
effectiveness in reducing MV leaflet size. Several RFC catheter prototypes were designed 
and built throughout this investigation, and by the end of Aim 2 studies, a completed RFC 
catheter prototype was built for in vivo use. The current iteration of the RFC catheter is 
capable of controllably cryo-anchoring to MV leaflets in the beating heart, without 
cardiopulmonary bypass, at temperatures of -50°C, and RF ablation has been successfully 
delivered at powers of up to 70W in vivo. The RFC catheter interfaces with a commercially 
available RF generator, a custom-built nitrous oxide delivery system, and Arduino and 
LabView control and data acquisition software, providing a complete RFC catheter system 
that is ready for percutaneous studies.  
We began our investigation of RFC catheter efficacy in Aim 1 by examining the 
thermal and mechanical effects of RF ablation and cryo-anchoring within close proximity 
on a catheter in a static ex vivo setup. We found that MV leaflet area could be reduced by 
approximately 40% or more during cryo-anchoring and demonstrated that cryo-anchoring 
remains robust during RF ablation, as measured on IR imaging and anchor strength testing. 
We also found that leaflet shrinkage magnitude varies spatially in relation to RF electrode 
and cryo-anchor location, and not simply according to the radial distance from the 
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electrode, with the greatest leaflet shrinkage occurring in the direction of the 
circumferential axis. 
In Aim 2, the RFC catheter was tested in a physiologic flow environment and it was 
shown that cryo-anchoring can independently adhere to moving MV leaflets while 
transmitral flow and pressure remain unchanged during cryo-anchoring. Additionally, we 
identified two techniques to assess successful delivery of RF energy to MV leaflets: 
mechanical model fitting and picrosirus red staining. Importantly, it was also shown that 
MV shrinkage deformations induced by the RFC catheter remain durable and do not re-
dilate over 4 weeks.  
Finally, in Aim 3, we developed echocardiographic efficacy criteria to assess RFC 
catheter treatment in vivo by directly measuring leaflet shrinkage before and after RFC 
catheter treatment and by comparing areal shrinkage measurements to measurements of 
leaflet length. The effectiveness of the RFC catheter to thermally shrink MV leaflets was 
then demonstrated in a large animal model, open-chest without cardiopulmonary bypass, 
by using echocardiographic efficacy criteria – leaflet length measurements – developed in 
the left heart flow simulator. The RFC catheter successfully reduced anterior leaflet size in 
four out of five animals with no compromising procedural complications. These promising 
results imply that the RFC catheter is a possible percutaneous alternative to surgical MV 
leaflet resection. With efficacy demonstrated in a small cohort of animals using an open-
chest approach, further testing using a percutaneous approach is clearly justified.  
The RFC catheter is not intended as a universal MV repair device. Instead, the RFC 
catheter is intended to be used as part of an armamentarium of percutaneous MV repair 
devices, with specific devices chosen to target specific lesions. Currently, percutaneous or 
minimally invasive approaches are in development to perform annuloplasty and chordal 
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replacement. However, there are no devices, other than the RFC catheter, that are able to 
perform MV leaflet resection. In the future, the interventional cardiologist may have the 
tools to perform an effective MV repair without the need for cardiopulmonary bypass or 
general anesthesia, which will improve post-operative recovery times, decrease procedural 
cost, and significantly increase the percentage of patients amenable to repair [4].  
 
Future Directions 
While we have developed the RFC catheter system from concept to functioning 
prototype and have demonstrated its effectiveness to adhere to and resect MV leaflet tissue, 
there is still much testing to be done before this approach can be used in the clinic. The first 
step is to refine the RFC catheter treatment strategy for percutaneous delivery. The 
proposed percutaneous access route is to enter the right heart through the vena cava and 
use trans-septal puncture to access the left atrium. Trans-septal puncture is relatively 
common and is used in a variety of procedures such as ablation of left-sided arrhythmias 
and in MitraClip placement [151, 152]. Thus, there are already commercially available 
steerable sheaths that would enable our current RFC catheter prototypes to be used in the 
trans-septal approach. Transesophageal echocardiography will be needed to provide 
percutaneous guidance of the RFC catheter and will be available for these studies shortly. 
Additionally, 3D echocardiography has the potential to more completely visualize the MV 
leaflets and to provide a quantitative measurement of MV leaflet area, which would 
provide a significant improvement over 2D measurements. 3D echocardiography may also 
be crucial to the RFC catheter treatment strategy in the future, as it can more readily 
identify prolapsing leaflet segments.  
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Once the RFC catheter treatment strategy has been refined for percutaneous 
delivery and shrinkage of MV leaflets in a non-survival porcine animal model, the next step 
will be to treat MR in a diseased animal model and to follow the animal status for several 
months after treatment. Middle to small size canines commonly develop degenerative MR 
as they age, and thus, are an ideal pre-clinical model to test RFC catheter effectiveness [10]. 
With successful treatment of MR in a canine survival model, the RFC catheter will be 
poised for first-in-man studies of RF ablation to treat enlarged MV leaflets. By using the 
RFC catheter to resect prolapsing segments in degenerative MR, and by combining one of 
the several percutaneous annuloplasty approaches in development, a fully percutaneous 
and efficacious repair for degenerative MR may someday be realized. 
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APPENDIX A: RFC CATHETER BUILD INSTRUCTIONS 
 
 
A. Machine a groove in the catheter cryogen applicator: 
The purpose of this part is to remove as much material as possible from the cryo applicator tip 
underneath where the RF electrode will sit in order to provide insulation between the cryo 
applicator and RF electrode. With a felt marker, mark the middle portion of the cryogen applicator 
where the groove will be cut. Place the catheter, wrapped in something to protect it, in a vise. Use a 
1/16” end mill to cut the groove, rotating the tip every so often and moving the catheter tip forward 
and back as needed to widen the groove. Place a 1/32” end mill in a Dremel and hand cut the groove 
deeper, taking care to make the edges as square as possible. Use a small file to cut the edges deeper 
and smooth inconsistencies. Use the Dremel steel brush tool to remove sharp edges, if necessary. 
 
Approximate groove diameter at smallest point: 1.75 mm 
Approximate length of groove: 2.75 mm 
 
 
 
Fig. A.1 – Left: Catheter in vise for machining of cryo tip. Right: Finished cryo tip with insulating groove for RF 
electrode. 
 
 
 
B. Remove the coaxial cryogen/vacuum connector: 
Trim the connector where it meets the blue tubing, being careful to preserve as much of the tubing 
coming out of the catheter handle as possible. Carefully cut away the outer blue tubing lining. Near 
the location where the coaxial connector meets the clear vacuum tubing, there will be a strong 
adhesive bond between the flexible clear tubing with the outer blue tube lining. 
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Fig. A.2 – Catheter with coaxial connector removed, prior to removal of blue lining. 
 
 
 
C. Extend the cryogen delivery tube: 
First, trim some of the clear vacuum line that attaches to the catheter handle in order to expose some 
of the cryogen delivery tube (this is the orange, polyimide tubing). Slide a slightly larger polyimide 
tube (0.0159” ID/0.0179” OD) of several inches of length over the cryogen delivery tube and set with 
epoxy. Care should be taken to ensure there is epoxy within the inner mating surface of the larger 
and smaller diameter polyimide tubes, as well as a layer encapsulating the junction along the 
outside. Keep a 0.005” diameter wire inside the cryogen delivery tube to ensure no epoxy blocks the 
tube. Let this set for at least 4 hours, until it sets and is workable. 
 
Polyimide tube: Amazon, 26 AWG, B00212Q0FY 
Nitinol wire: Amazonsupply, 0.005” nitinol, B001385FJE 
Epoxy: McMaster, Loctite 1C, 1813A221 
 
 
Fig. A.3 – Large cryogen delivery tube extension epoxied to smaller cryogen delivery tube. 
 
 
 
D. Remove the cryo applicator tip and trim the cryogen delivery tube: 
Carefully remove the cryo applicator tip from the catheter tubing by grabbing the tip with pliers and 
rocking back and forth. Pull the cryo applicator out just enough to expose the polyimide tube for 
grasping. Pull a length (6-10 cm) of the polyimide tube out of the catheter body. Some force will be 
needed here, and the polyimide tube may stretch significantly, especially near the distal tip. Thread 
the 0.005” diameter wire all the way down the cryogen delivery tube to check for any blockages. 
Trim the cryogen delivery tube to remove any damaged sections and to remove any blockages, 
leaving approximately 1 cm of tubing hanging outside of the catheter body. Carefully apply 
cyanoacrylate to the outside of the cryogen delivery tube, just inside of the catheter body, in order to 
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glue it to the translucent plastic linear inside the catheter body. This helps to prevent it sliding away 
from the distal end of the catheter tip. 
 
Cyanoacrylate adhesive: McMaster, Permabond 910, 7580A52 
 
 
Fig. A.4 –Cryo tip detached from catheter body with polyimide cryogen delivery tube exposed. 
 
 
 
E. Add a vacuum/cryogen connection to the catheter handle: 
A corner barb to quick-disconnect adapter was placed in the flexible vacuum line tubing, with the 
polyimide tube sticking out of a hole that was 1/16” hole that was drilled in the connector. A 1/16” 
OD stainless steel tube was placed over the polyimide tube and slid into the connector for additional 
support. The stainless steel tube was glued with epoxy at the location where it entered the connector 
and where the polyimide lumen leaves the stainless steel tube. After epoxy sets, carefully trim excess 
polyimide tubing so that the end of the polyimide tube is approximately flush with the stainless steel 
tube. Add 1/16” compression fitting components to this stainless steel tube when ready to use 
catheter. 
 
Epoxy: McMaster, Loctite 1C, 1813A221  
Stainless steel tube: McMaster, 0.062” OD, 0.052” ID, 8988K36  
Quick-disconnect adapter: McMaster, polypropylene, 51545K82 
Compression fitting nut: McMaster, stainless steel, 5182K672  
Compression fitting front sleeve: McMaster, stainless steel, 5182K65  
Compression fitting back sleeve: McMaster, stainless steel, 5182K66  
 
 
Fig. A.5 – New cryo delivery tube and vacuum connector completed with compression fitting components. 
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F. Return cryo applicator tip to catheter: 
Trim polyimide tube at distal end of the catheter such that approximately 4-5 mm of length remains 
outside of the catheter body. Carefully place polyimide tube into the cryo applicator with tweezers 
or other tool. Apply cyanoacrylate adhesive to the circumference of the cryo applicator – the portion 
that will return to the main part of the catheter. Return the cryo applicator tip to the blue catheter 
body. If necessary, pull back on the deflection mechanism to guide the tip back into the tube. Gently 
twist back and forth slightly to spread the adhesive. Let tip set overnight. 
 
Cyanoacrylate adhesive: McMaster, Permabond 910, 7580A52  
 
 
Fig. A.6 – Catheter tip prior to being glued to the distal catheter body. 
 
 
 
G. Place a layer of epoxy on the cryo applicator were the metal material was machined: 
Place epoxy in the space of the cryo applicator to provide additional insulation. Let set for 24 hours, 
at least, and remove excess with a Dremel brush or fine metal file. 
 
Epoxy: McMaster, Loctite 1C, 1813A221 
 
 
Fig. A.7 – Thermally and electrically insulating epoxy placed on cryo applicator tip to separate RF electrode and cryo-
anchor. 
 
 
 
H. Protect electrodes: 
Drip cyanoacrylate adhesive over each of the three ring electrodes found near the distal tip of the 
catheter. Allow to sit for several seconds, and then remove excess with a brush or similar tool. 
Repeat 2-3 times. These steps are to plug any small holes which may otherwise allow nitrous oxide 
gas to escape during catheter operation. 
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Cyanoacrylate adhesive: McMaster, Permabond 910, 7580A52  
 
 
Fig. A.8 – Sealing ring electrodes near tip with cyanoacrylate adhesive to prevent nitrous oxide gas leakage. 
 
 
 
I. Fabricate the copper RF electrode: 
Place a few inch length of 4 mm OD copper tube in the drill (as one would a drill bit), to create a 
makeshift lathe. Better yet, use a lathe if available. Turn the drill on at a moderate speed, and using a 
cutting blade on the Dremel, carefully thin the copper tube until the thickness of the tube is small, 
but great enough so as not to break under light-moderate finger pressure. Cut the copper tube into 
lengths that roughly match the length of the groove cut on the cryo applicator tip (approximately 
2.75 mm). Use a file and/or smooth grinding wheel to remove burrs and smooth and thin the 
electrode. Cut the copper ring once, lengthwise, so that it can be bent open. Size the open copper 
ring using the cryo applicator tip. Trim any excess copper ring with wire cutters. Solder a thin 
enamel-coated wire (approximately two meters long, for trimming later) to the inside of the copper 
ring. The enamel-coated wire can be stripped by placing in a flame and then by removing the 
charred enamel with sandpaper. 
 
Copper tubing: McMaster, 5/32” x 0.014,  
Cutting blade: McMaster, 15/16” dia, 0.04” thick, 1257A75  
Enamel-coated wire: McMaster, 32 gauge, 7588K89  
 
 
Fig. A.9 – Left: Drill-Dremel lathe setup for reducing the OD of 4mm diameter hollow copper rod. Center: Completed RF 
electrodes. Right: RF electrode cut lengthwise with RF wire soldered. 
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J. Assemble the RF thermocouple: 
Use either (a) a thermocouple wire taken from the inside of another cryo catheter or (b) a small 
thermocouple (40 gauge wire). Strip the end, wrap wires together and solder, then place thin layer of 
quickset epoxy over the exposed wire leads. If using a thermocouple wire taken from the inside of a 
second cryo catheter, it will have to be extended. Strip both wires from the other end of the catheter 
thermocouple wire, as well as the two wires from the extension wire and solder to extend. Insulate 
with epoxy (1C). Place a thermocouple connector on the other end of the wire and check for 
functionality using thermocouple thermometer, Type K. Thermocouple wires taken from another 
cryo catheter can be stripped using sandpaper. 40 gauge thermocouple wires can be stripped with a 
razor blade. 
 
+: copper colored wire (if taken from another catheter), yellow insulation (Omega 40 gauge) 
-: silver colored wire (if taken from another catheter), red insulation (Omega 40 gauge) 
 
Thermocouple wire: Omega Engineering, Type-K, TT-K-40-SLE 
Epoxy: McMaster, general purpose 3-6 min, 7541A76  
Epoxy: McMaster, Loctite 1C, 1813A221 
Thermocouple connector: McMaster, Type-K flat-pin, 3869K35  
 
 
Fig. A.10 – Left: Thermocouple tip with insulating epoxy at the measurement junction. Right: Thermocouple wire taken 
from a CryoCath catheter extended with a 40 gauge thermocouple extension wire. 
 
 
 
K. Assembly of RF components with cryo catheter: 
Trim a length of heat shrink tubing that runs from the base of the catheter to just before the 
deflectable portion of the catheter tip. Heat shrink tubing should not cover the deflectable portion of 
the catheter body, as it will inhibit motion. Place RF thermocouple wire all the way down the heat 
shrink tubing, and leave both ends hanging out of the heat shrink tube. Place a several inch length of 
polyimide tube over the thermocouple wire, on the end with the measurement junction Slide RF 
electrode wire through the polyimide tube and through the heat shrink tubing towards the base of 
the catheter handle. Slide catheter down the heat shrink tube. Glue the RF thermocouple wire, with 
cyanoacrylate adhesive, to the inside of the RF electrode, near the RF wire solder point. Place a layer 
of epoxy over the dried epoxy layer already on the cryo applicator. Place RF electrode, with 
superglued-thermocouple wire over the epoxy layer and use pliers to secure tightly around the cryo 
applicator. Use a multimeter to ensure that current will not flow between the RF eletrode and cryo 
applicator tip. Remove any excess epoxy from the cryo applicator. Wait overnight to proceed 
further. Use a lighter to shrink the heat shrink tubing along the length of the catheter shaft. Once 
heat shrink tubing is set, use high viscosity cyanoacrylate to seal the end of the heat shrink tubing 
closest to the catheter tip.  
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Shrink wrap: McMaster, FEP, 8703K117 
Polyimide tube: AmazonSupply, 0.0285” ID, B00212GAYU  
Cyanoacrylate adhesive: McMaster, Permabond 910, 7580A52 
Cyanoacrylate adhesive (high viscosity): McMaster, Permabond 240, 7580A85 
 
 
 
Fig. A.11– Top, from left: (1) RF wire and RF thermocouple wire within heat shrink tubing, (2) Catheter body with RF 
electrode wire, RF thermocouple wire, and heat shrink tubing in place, (3) RF electrode with RF wire and RF thermocouple 
wire attached and ready for attachment to cryo applicator, (4) Polyimide tubing containing RF electrode and thermocouple 
wires, along with completed catheter tip. Bottom: Catheter with heat shrink tubing ready for RF electrode attachment.  
 
 
 
L. Assembly of Cryo Delivery Tube Umbilical: 
Cut two 4 cm lengths of 0.062” OD stainless steel tubing. Trim polyimide tube to desired length. 
Bond one stainless steel tube to each end of the polyimide tubing with epoxy. Let set over night. 
Slide polyimide with stainless steel ends through a length of nylon tubing to protect the polyimide 
from kinks. Epoxy stainless steel sections to nylon tube. Add compression nut and sleeves to each 
stainless steel tube and a compression coupler to one.  
 
Polyimide tube: AmazonSupply, 0.0285” ID, B00212GAYU  
Epoxy: McMaster, Loctite 1C, 1813A221 
Stainless steel tube: McMaster, 0.062” OD, 0.052” ID, 8988K36  
Compression fitting nut: McMaster, stainless steel, 5182K672  
Compression fitting front sleeve: McMaster, stainless steel, 5182K65  
Compression fitting back sleeve: McMaster, stainless steel, 5182K66  
Compression fitting coupler: McMaster, stainless steel, 5182K716 
Tube protector: McMaster, nylon tubing, 5112K42 
 
 
134 
 
 
Fig. A.12– Left: Stainless steel tube bonded to polyimide tube end. Right: Nylon tubing added and bonded to stainless 
steel tube for protection of polyimide tube. 
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APPENDIX B: RF ELECTRODE TEMPERATURE CALIBRATION 
 
 
RF Ablation Temperature Range 
During RF ablation, it is important to maintain ablation power such that tissue temperatures are 
raised sufficiently to induce shrinkage (>65°C). On the other hand, charring around the RF electrode 
from very high ablation temperatures (>100°C) leads to a rapid impedance rise and a significant 
reduction in RF power delivery to the tissue. Thus, RF electrode power output must be throttled to 
maintain tissue temperatures between 65°C-100°C to generate significant thermal shrinkage.  
 
Rationale for RFC Catheter Temperature Calibration 
The RFC catheter contains an RF electrode that sits over cryo-anchors, and the RF electrode is 
separated from the cryo-anchors by only a thin layer of insulation. A thermocouple measures the RF 
electrode temperature and sits between the RF electrode and thin insulating layer. Thus, the 
measured RF electrode temperature is many degrees cooler than the RF electrode-tissue interface 
temperature and many degrees cooler than the surrounding tissue temperature (assuming RF 
ablation is currently raising the tissue temperature). This is not a significant problem when using the 
RFC catheter ex vivo in a flow simulator filled with saline, as there are no proteins in saline to 
coagulate that will char and raise the impedance (significant char of the tissue itself can occur ex 
vivo, but given the large heat convection due to fluid flow, the threshold of tissue charring is rarely 
reached). However, in vivo, blood can coagulate, char, and disrupt RF energy delivery. Therefore, 
the RFC catheter electrode temperature must be calibrated such that tissue temperatures of between 
65°C-100°C can be generated without charring.  
 
RFC Catheter Temperature Calibration Experiment 1: Myocardial Measurements 
Calibration of the RF electrode has been performed with two different experiments. In the first 
experiment, small sections (very roughly: 2 cm x 2cm x 1 cm thick) of myocardium were excised 
from a heart and sutured to a plastic bracket (metal materials are not used as they will affect current 
distribution) fixed to the atrial-ventricular wall of the left heart flow simulator. A mechanical valve 
was placed in the atrial-ventricular wall, and the myocardial tissue was placed directly in the flow 
path, on the atrial side, to simulate MV flow rates. Myocardial tissue was used as the stationary 
nature of the tissue permits tissue temperature measurements, which is not easily performed on 
moving MV leaflets. A thermocouple was carefully placed approximately 1-2 mm below the 
myocardial surface. The left heart flow simulator was run at 5 L/min and transmitral pressures of 
120 mmHg. The RFC catheter was placed on the surface of the myocardium, directly above the 
myocardial thermocouple placement (Fig. B.1). An indifferent electrode (wire attached to aluminum 
foil) was placed between the atrium and fluid reservoir of the left heart flow simulator, and its 
position relative to the catheter was varied to vary impedance. Three different treatments were then 
performed to hone in on the ideal RF electrode temperature range: 
 
Test 1: Cryo-anchoring on, RF power of 50W, impedance high (250-300Ω) 
Test 2: Cryo-anchoring on, RF power of 50W, impedance low (50-75Ω) 
Test 3: Cryo-anchoring on, RF power of 80W, impedance low (50-75Ω) 
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Test 1 was used to demonstrate that no or minimal temperature increases may occur at high ablation 
powers. Test 2 and Test 3 were used to generate significant tissue temperature rises to determine the 
matching RF electrode temperature. Results from testing Catheter Prototype #07 on 2015-02-10 are 
shown below (Fig. B2). 
 
 
 
Fig. B.1. Myocardial RF Electrode Temperature Calibration Test – Experimental Set-Up 
 
 
 
 
Fig. B.2: Results from Myocardial Temperature Calibration Test 
RF electrode calibration on Catheter Prototype #07. Recorded on 2015-02-10. During Test 3, popping of the tissue 
occurred, which indicated rapid boiling/expansion of the fluid contained within the myocardium.  
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Myocardial Temperature Calibration Test Conclusions 
We conclude from the above results that RF electrode temperatures, on Catheter Prototype #07 
specifically, of between 5-10°C are sufficient to generate tissue temperatures that will create tissue 
shrinkage. However, we can also conclude that there is a fine line between significant (tissue 
shrinkage causing) and insignificant (no tissue shrinkage causing) temperatures measured on the RF 
electrode, as temperatures below 0°C do not cause thermal shrinkage lesions. Further, RF electrode 
temperature must be carefully throttled to avoid excessive (>10°C) tissue temperature in this catheter 
prototype, as conditions were favorable for char to occur past this point.  
 
 
 
 
RFC Catheter Temperature Calibration Experiment 2: Excised MV Test 
The myocardial temperature calibration test above confirmed that low measured RF electrode 
temperatures do not necessary imply low tissue temperatures, and the test above can be used to 
calibrate the desired RF electrode temperature range. However, the test above takes significant time 
to execute. A simpler test can be performed that takes much less time, if a sewn excised MV is 
already available. An excised porcine MV can be placed in the left heart flow simulator with flow 
and pressure conditions as described above. An indifferent electrode (wire attached to aluminum 
foil) can be placed in the left heart flow simulator on the atrial chamber floor, which results in 
impedances of around 60Ω during ablation of the MV leaflets.  RF electrode temperature is then 
measured in two different testing conditions: 
 
Test A: Cryo-anchoring on, RF ablation at 50W, catheter positioned just in front of MV leaflets (in 
atrium) with no leaflet attachment 
Test B: Cryo-anchoring on, RF ablation at 50W, catheter attached to MV leaflets 
 
 
 
 
 
 
Fig. B.3. RF Electrode Calibration Test Using an Excised Porcine MV 
RF electrode temperatures measured during cryo-anchoring and ablation with no leaflet attachment (black, dotted) and 
with direct leaflet attachment of cryo-anchor and RF electrode (red, solid). Catheter Prototype #07. Recorded on 2015-02-
03. 
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Excised MV Calibration Test Conclusions 
Assuming that MV tissue temperatures that correspond with thermal leaflet shrinkage are being 
generated in Test B, this test can be used to determine the RF electrode temperature target for in vivo 
ablations. Test A is a control test, demonstrating temperature that can be expected when RF ablation 
is on, but no thermal shrinkage is being produced. The difference in measured RF electrode 
temperature between these two tests is small (Fig. B.3): with no leaflet attachment, the averaged 
measured RF electrode temperature was 4.5°C and with leaflet attachment, the averaged measured 
RF electrode temperature was 8°C. The 8°C measured RF electrode temperature corresponds with 
the calibrated range in the myocardial temperature calibration test. The excised MV calibration test 
provides the target RF electrode temperature during RF ablation in vivo – in this case the target RF 
electrode temperature is 8°C – however, the excised MV calibration test will likely not provide the 
upper limit of RF electrode temperatures that produce charring in vivo. 
 
Additional Conclusion 
The above calibration test(s) should be performed frequently. It was found after several months 
during an in vivo procedure that the calibrated range for the Catheter Prototype #07 RF electrode 
had shifted upwards by about 10°C, to 10°C-20°C from 0°C-10°C.  
 
RF Electrode Temperature Calibrations as of 2015-05-22 
Catheter Prototype #06: -5°C to 5°C 
Catheter Prototype #07: 10° C to 20°C 
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APPENDIX C: RFC CATHETER SYSTEM – NITROUS OXIDE DELIVERY HARDWARE 
 
 
The nitrous oxide delivery system (Fig. C.1) provides the cooling power for the RFC catheter. Liquid 
nitrous oxide is pulled out of a nitrous oxide tank with dip tube. A pressure regulator is available to 
regulate the nitrous oxide pressure, if necessary, but full tank pressure (750-800psi, depending on 
room temperature) is used with the current iteration of the RFC catheter prototype. A solenoid valve 
compatible with cryogenic liquids is used to turn cryogen flow on and off. The solenoid valve is 
switched on when supplied with 120VAC and switched off when current is removed.  
 
The combined weight of the nitrous oxide tank and nitrous oxide is 47lbs when full. After the tank 
plus nitrous oxide weight measures 35lbs or below, cryo-anchor cooling power is inconsistent and a 
new tank is needed. 
 
 
 
Fig. C.1: Nitrous Oxide Delivery System Hardware 
Nitrous oxide delivery system hardware. Letters correspond to parts list below. 
 
 
Table C.1. Nitrous Oxide Delivery System Parts List 
ITEM ITEM DESCRIPTION SUPPLIER PART NUMBER 
A Nitrous Oxide, 20 lbs., with Dip Tube A-L Compressed   
B 
Regulator Fitting Inlet Nipple, 1/4" NPT Male, CGA #326, 2.5" 
Length 
McMaster 79215A673 
B 
Regulator Fitting Female Thread Inlet Nut, CGA #326, 0.952" 
Length 
McMaster 79215A672 
C Pressure Regulator, Tescom BB-1 Series  Tescom BB-13AH2KVA4 
D Pressure Gauge, 0-1200 psi Tescom 62500-2000N 
E 
Hex Nipple,Precision Extreme-Pressure 316 Stainless Steel 
Pipe Fitting, 1/4 x 1/4 Pipe Size, 1-7/16" Length 
McMaster 48805K81 
F 
Adapter, Precision Extreme-Pressure 316 Stainless Steel Pipe 
Fitting, 1/4 x 1/8 Pipe Size, Female x Male 
McMaster 48805K252 
G 
Cryo Solenoid, Clean & Bagged Cryogenic Brass Solenoid 
Valve 1/8 NPT Female, 120 VAC 
McMaster 50585K21 
H 
Yor-Lok Adapter, Type 316 Stainless Steel, Straight Adapter for 
1/16" Tube OD x 1/8 NPT Male 
McMaster 5182K435 
 
Precision Extreme-Pressure 316 Stainless Steel Pipe Fitting, 
1/4 Pipe Size, Hex Head Solid Plug 
McMaster 48805K28 
A: Nitrous 
Oxide Tank
B: Regulator 
Fitting
C: Pressure 
Regulator
E: Hex 
Nipple
F: Adapter
G: Cryo
Solenoid
H: Yor-Lok
Adapter
D: Pressure 
Gauge
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APPENDIX D: RFC CATHETER SYSTEM – CONTROL SYSTEM CODE 
 
 
The following code was developed to control the RFC catheter system using an Arduino Uno. This 
code reads in the temperatures of the catheter cryo-anchor and RF electrode from a serial connection 
to a commericially available thermocouple measurement device (EA15, Extech Instruments, Nashua, 
NH), and then the code throttles a cryo solenoid based upon the measured cryo-anchor temperature. 
If the cryo-anchor temperature is above -20°C, the cryo solenoid is set to full on. If the cryo-anchor 
temperature is below -20°C, the cryo-anchor is switched on/off with a duty cycle controlled by the 
user (default is 0.2) and a cycle period of 2 seconds. The cryo-anchor temperature, RF electrode 
temperature, cryo solenoid duty cycle, and cryo solenoid on/off state are then passed to LabView for 
data acquisition. 
 
 
// Steve Boronyak 
// July 02, 2014 
 
/* This program also the user to manually control the duty cycle of the cryo 
solenoid for 
controlling the cryo cath temperature */ 
 
// DOES NOT measure RESISTANCE or RF POWER OUTPUT 
// DOES NOT include temperature compensation for filter induced offsets (this is 
done in LabView) 
 
/* USB Host to PL2303-based USB Thermocouple Thermometer */ 
/* Extech EasyView 15 */ 
 
 
/* USB Host Libraries and associated code from Oleg */ 
/* http://www.circuitsathome.com/arduino_usb_host_shield_projects */ 
 
 
// DEFINE PINS //////////////////////////////////////////////////////////////// 
#define cryoINPUT 2            // Cryo input switch 
#define cryoIND 3              // Cryo indicator LED line 
#define RFinput 4              // RF input switch 
#define cryoOUTPUT 5           // Cryo output line, to 5V SSR 
#define RFoutput 6             // RF output line, to TIP120 and solenoid valve 
#define RFind  A0              // RF indicator LED line 
#define buttUP  A1 
#define buttDOWN  A2 
 
 
// ADD LIBRARIES ////////////////////////////////////////////////////////////// 
 
/* USB support */ 
#include <avrpins.h> 
#include <max3421e.h> 
#include <usbhost.h> 
#include <usb_ch9.h> 
#include <Usb.h> 
#include <usbhub.h> 
#include <avr/pgmspace.h> 
#include <address.h> 
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/* CDC support */ 
#include <cdcacm.h> 
#include <cdcprolific.h> 
 
/* Debug support */ 
#include <printhex.h> 
#include <message.h> 
#include <hexdump.h> 
#include <parsetools.h> 
 
 
// INITILIZE VARIABLES 
///////////////////////////////////////////////////////////////////////// 
int count = 0;              // Count of total bytes received to the buffer 
int buffer[9];              // Storage buffer for thermocouple data 
int tempbuffer[9]; 
int sign = LOW;             // LOW means + sign, HIGH means - sign 
int connection = LOW;       // HIGH means open line; 
int value_CRYO = 0;         // Digital input from cryoINPUT 
int PWMod = 0;              // Indicator variable: 1 if PWM pedal is active 
int CRYOout = 0;            // Indicator variable: 1 if cryo solenoid out is on 
int RFstate = LOW;          // Current state of the RF input switch 
float cycleDELAY = 400;     // Used for switching between on and off timing 
float cyclePERIOD = 2000;   // Cycle period 
float DUTY = 0.2;           // Duty cycle of PWM signal to cryo solenoid 
float deltaDUTY = 0;        // Duty cycle of PWM signal to cryo solenoid 
float Tcryo = 25;           // Cryo temperature 
float TcryoLAST = 25;       // Previously measured cryo temperature 
float timeSTAMP;            // Time of temperature measurement 
float deltaT = 0;           // Absolute value of change in temperature between 
measurements 
byte STATE = B00000000;     // Indicates the state of the cryo solenoid/RF output 
boolean REC = false;        // When TRUE, thermocouple data ready to analyze 
unsigned long timeZERO;     // Time of first received byte of thermocouple data 
unsigned long timeF;        // Time of last received byte of thermocouple data 
unsigned long OFFtime;      // Millisecond time, last time switch was off 
unsigned long readTIME = 0; 
unsigned long PWtimer = 0;  // Timer value: the last time the cryo solenoid was 
switched on or off 
unsigned long RFoff = 0;    // millisecond timer, last time RF switch was off 
 
int valueUP = LOW; 
int valueDOWN = LOW; 
unsigned long buttLAST; 
int duty1 = 4; 
 
   
 
// INITLIZE USB HOST DEVICE ////////////////////////////////////////////////// 
class PLAsyncOper : public CDCAsyncOper 
{ 
public: 
    virtual uint8_t OnInit(ACM *pacm); 
}; 
 
// Continue to initilize USB Host device, I guess 
uint8_t PLAsyncOper::OnInit(ACM *pacm) 
{ 
    uint8_t rcode; 
     
    // Set DTR = 1 - I don't know what this means 
    rcode = pacm->SetControlLineState(1); 
 
142 
 
    if (rcode) // Still don't know 
    { 
        ErrorMessage<uint8_t>(PSTR("SetControlLineState"), rcode); 
        return rcode; 
    } 
 
    LINE_CODING lc; 
    lc.dwDTERate  = 9600;   // default serial speed of unit 
    lc.bCharFormat  = 0;    // i have no idea what this means 
    lc.bParityType  = 0;    // default parity of the unit 
    lc.bDataBits  = 8;      // number of data bits 
   
    rcode = pacm->SetLineCoding(&lc); // Don't know 
 
    if (rcode)      // Still don't know 
        ErrorMessage<uint8_t>(PSTR("SetLineCoding"), rcode); 
             
    return rcode; 
} 
 
 
// I have no idea what this does, I guess start communicating??? 
USB     Usb; 
PLAsyncOper  AsyncOper; 
PL2303       Pl(&Usb, &AsyncOper); 
 
 
// SET UP CODE //////////////////////////////////////////////////////////// 
void setup() 
{ 
  // Set pin 7 HIGH for serial communication to work: 
  pinMode(7, OUTPUT);              // Pin 7 must be set HIGH, active low reset 
  digitalWrite(7, HIGH);           // So set Pin 7 dammit 
   
  // Cryo and RF I/O: 
  pinMode(cryoINPUT, INPUT);       // Set pin 2, as cryo input 
  pinMode(cryoIND, OUTPUT);        // Cryo LED output indicator 
  pinMode(cryoOUTPUT, OUTPUT);     // Cryo output line to SSR 
  pinMode(RFinput, INPUT);         // RF input switch 
  pinMode(RFind, OUTPUT);          // RF LED output indicator 
  pinMode(RFoutput, OUTPUT);       // RF output line to TIP120 and solenoid 
  pinMode(buttUP, INPUT);          // Button high increases duty cycle 
  pinMode(buttDOWN, INPUT);        // Button high decreases duty cycle 
   
  digitalWrite(cryoIND, LOW); 
  digitalWrite(cryoOUTPUT, LOW); 
  digitalWrite(RFind, LOW); 
  digitalWrite(RFoutput, LOW); 
   
  tempbuffer[0] = 0; 
  tempbuffer[1] = 0; 
  tempbuffer[2] = 0; 
  tempbuffer[3] = 0; 
  tempbuffer[4] = 0; 
  tempbuffer[5] = 0; 
  tempbuffer[6] = 0; 
  tempbuffer[7] = 0; 
  tempbuffer[8] = 0; 
 
   
  Serial.begin(9600);              // Set baud rate of Arduino serial monitor, 
must match LabView program 
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  if (Usb.Init() == -1)            // Error message, if USB Host fails to 
initilize 
      Serial.println("OSCOKIRQ failed to assert"); 
       
  delay(200);  
 
} 
 
 
void loop() 
{ 
  
//////////////////////////////////////////////////////////////////////////////////
///////// 
  // READ THERMOCOUPLE TEMPERATURE 
////////////////////////////////////////////////////////// 
  
//////////////////////////////////////////////////////////////////////////////////
///////// 
   
  // INITLIZE SOME MORE VARIABLES //////////////////////////// 
  REC = false; 
  uint8_t rcode;      // what does the rcode do??? 
  uint8_t  buf[9];    // serial buffer equals Max.packet size of thermocouple 
output       
  uint16_t rcvd = 9;  // same as line above 
   
  Usb.Task(); 
     
    if( Pl.isReady()) {   
       /* reading the thermometer */ 
       rcode = Pl.RcvData(&rcvd, buf); 
        if (rcode && rcode != hrNAK) 
           ErrorMessage<uint8_t>(PSTR("Ret"), rcode);             
            if( rcvd ) { //more than zero bytes received 
               
              // Time stamps to check if it takes an unexpected amount of time to 
get all 9 bytes 
              if (count == 0){ 
                timeZERO = millis(); 
              } 
              if (count == 8){ 
                timeF = millis(); 
              } 
               
              for (uint16_t i=0; i < rcvd; i++) { 
                   
                  buffer[count] = buf[i];  // For every byte received, write to 
the buffer 
                  count++;                 // Increment byte count 
                   
                  if (count >= 9){         // Return byte count to zero; 
                    count = 0; 
                     
                    if (timeF - timeZERO > 100){    // Check for timeout error 
                      Serial.println("Timeout ERROR"); 
                    } 
                     
                    if (timeF - timeZERO <= 100){  // If no timeout error, 
everything is good 
                      REC = true; 
                    }//if (timeF - timeZERO <= 100 
                  }//if (count >= 9... 
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              }//for( uint16_t i=0; i < rcvd; i++... 
            }//if( rcvd..   
      tempbuffer[1] = buffer[1]; 
      tempbuffer[2] = buffer[2]; 
      tempbuffer[3] = buffer[3]; 
      tempbuffer[4] = buffer[4]; 
      tempbuffer[5] = buffer[5]; 
      tempbuffer[6] = buffer[6]; 
    }//if( Pl.isReady())..   
    
///////////////////////////////////////////////////////////////////////////////// 
     
     
    
///////////////////////////////////////////////////////////////////////////////// 
    // DETERMINE/THROTTLE CRYO SOLENOID OUTPUT 
////////////////////////////////////// 
    
///////////////////////////////////////////////////////////////////////////////// 
 
    value_CRYO = digitalRead(cryoINPUT); 
    valueUP = digitalRead(buttUP); 
    valueDOWN = digitalRead(buttDOWN); 
     
    if (valueUP == HIGH && millis() - buttLAST > 200){ 
      DUTY = DUTY + 0.05; 
      buttLAST = millis(); 
    } 
    if (valueDOWN == HIGH && millis() - buttLAST > 200){ 
      DUTY = DUTY - 0.05; 
      buttLAST = millis(); 
    } 
     
    if (DUTY > 0.9){ 
      DUTY = 1; 
    } 
    if (DUTY < 0.1){ 
      DUTY = 0; 
    } 
     
    if (value_CRYO == HIGH && Tcryo < -15){ 
       
      if (DUTY == 1){ 
        if (millis() - OFFtime > 200){ 
          CRYOout = HIGH; 
          digitalWrite(cryoIND, HIGH); 
          digitalWrite(cryoOUTPUT, HIGH); 
        } 
      } 
      if (DUTY == 0){ 
        CRYOout = LOW; 
        digitalWrite(cryoIND, LOW); 
        digitalWrite(cryoOUTPUT, LOW); 
        } 
      if (DUTY < 1 && DUTY > 0){ 
        if (CRYOout == LOW){ 
          cycleDELAY = (1 - DUTY)*cyclePERIOD; 
        }//if (CRYOout == LOW... 
        if (CRYOout == HIGH){ 
          cycleDELAY = DUTY*cyclePERIOD; 
        }//if (CR 
        if (millis() - PWtimer > cycleDELAY){ 
          CRYOout = !CRYOout; 
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          digitalWrite(cryoIND, CRYOout); 
          digitalWrite(cryoOUTPUT, CRYOout); 
          PWtimer = millis(); 
        }//if (millis() - PWtimer... 
      } 
    }  
    else if (value_CRYO == HIGH && Tcryo >= -15){ 
      CRYOout = HIGH; 
      digitalWrite(cryoIND, CRYOout); 
      digitalWrite(cryoOUTPUT, CRYOout); 
    } else { 
      OFFtime = millis(); 
      digitalWrite(cryoIND, LOW); 
      digitalWrite(cryoOUTPUT, LOW); 
      CRYOout = LOW; 
    } 
     
    if (DUTY == 1){ 
      DUTY = 0.9; 
    } 
    if (DUTY == 0){ 
      DUTY = 0.1; 
    } 
 
    /////////////////////////////////////////////////////////////////////////// 
     
     
    /////////////////////////////////////////////////////////////////////////// 
    // RECORD DATA: TEMPERATURE & SOLENOID OUTPUT STATE /////////////////////// 
    /////////////////////////////////////////////////////////////////////////// 
    if (REC == true){ 
       
      TcryoLAST = Tcryo; 
       
      // Thermocouple CH1 - CRYO // 
      // Byte 2: CH1 Status Byte 
      // Bytes 3 and 4: CH1 Temperature Bytes 
      connection = bitRead(buffer[1],6); // Byte 2, bit 6: OL determination 
      if (connection == HIGH){ 
        Serial.write(255); 
         
      }//if (connection == HIGH... 
       
      if (connection == LOW){ 
        sign = bitRead(buffer[1],7);    // Byte 2, bit 7: negative sign 
determination 
        if (sign == LOW){               // If byte 2, bit 7 LOW: + sign 
          Tcryo = (((float)buffer[2]*256) + (float)buffer[3])/10; 
        }//if (sign == LOW... 
        if (sign == HIGH){              // If byte 2, bit 7 HIGH: - sign 
          Tcryo = -(((float)buffer[2]*256) + (float)buffer[3])/10; 
        }//if (sign == HIGH... 
         
        deltaT = Tcryo - TcryoLAST; 
        timeSTAMP = (float)timeF/1000; 
         
         
        bitWrite(STATE,0,value_CRYO); 
        bitWrite(STATE,1,RFstate); 
         
        duty1 = int(DUTY*100); 
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        //This order must stay the same for the LabView program to process 
correctly 
        Serial.write(128); 
        Serial.write(buffer[1]); 
        Serial.write(buffer[2]); 
        Serial.write(buffer[3]); 
        Serial.write(buffer[4]); 
        Serial.write(buffer[5]); 
        Serial.write(buffer[6]); 
        Serial.write(STATE); 
        Serial.write(duty1); 
        Serial.write(255); 
      }//if (connection == LOW... 
      // END CH1 - Cryo // 
       
    }//if (REC == true... 
     
    if (REC == false){ 
      if (millis() - readTIME > 200){ 
        Serial.write(128); 
        Serial.write(tempbuffer[1]); 
        Serial.write(tempbuffer[2]); 
        Serial.write(tempbuffer[3]); 
        Serial.write(tempbuffer[4]); 
        Serial.write(tempbuffer[5]); 
        Serial.write(tempbuffer[6]); 
        Serial.write(STATE); 
        Serial.write(duty1); 
        Serial.write(255); 
         
        readTIME = millis(); 
      } 
    } 
    
/////////////////////////////////////////////////////////////////////////////// 
     
} 
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APPENDIX E: RFC CATHETER SYSTEM – DATA ACQUISITION CODE 
 
 
All data acquisition from the RFC catheter system is done in LabView. Data is read in from the RF 
generator directly to a National Instruments DAQ and the catheter control system via the Arduino 
program in Appendix D. The front panel shown below is used to display catheter temperature, 
impedance, and power information during the procedure. The corresponding wire diagram is 
shown on the next page. 
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APPENDIX F: RFC CATHETER SYSTEM – CONTROL SYSTEM ELECTRICAL 
SCHEMATIC  
 
 
The essential components for constructing the RFC catheter electrical control system are shown on 
the next page. Also of note, not indicated on the drawings, are the USB connections: 1) from the USB 
host shield to the EA15 thermocouple measurement device, and 2) from the Arduino Uno to the 
computer running the LabView data acquisition software. Non-trivial components are listed in the 
table below. 
 
Table F.1. Non-Trivial Components of the RFC Catheter Control System 
Description Supplier Cat No 
USB Host Shield Sparkfun DEV-09947 
Foot Switch with Front Pivot Steel, Maintained, SPST-NO, 6' Cord McMaster 7717K22 
Long-Life Relay 5 DC Control Voltage, 5 Amps @ 100-240V AC, G3NE-
205T-US McMaster 8192K211 
ProtoBoard - Wombat (PTH) Sparkfun PRT-08619 
Arduino Uno Sparkfun DEV-1102 
IC REG LDO 9V 2A TO-220 DigiKey 497-6038-5-ND 
BOX ABS 9.84X7.09X1.97" GREY DigiKey HM1099-ND 
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APPENDIX G: RFC CATHETER SYSTEM ELECTRICAL SCHEMATIC 
 
 
The RF generator (EPT-1000, Boston Scientific) measurement lines were connected to a LabView 
DAQ to record RF power and RF impedance during the procedure. A ground line must also be 
connected from the rear of the RF generator to the LabView DAQ. 
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APPENDIX H: RFC CATHETER SYSTEM – THERMOCOUPLE FILTERS 
 
 
Significant noise is present on the RFC catheter thermocouple measurements when RF power is 
actively being delivered. In order to reduce noise and obtain accurate temperature measurements, a 
passive low-pass filter was employed on each thermocouple (Fig. H.1 and Fig. H.2). The low-pass 
filters were placed just prior to the thermocouple measurement device. Ground, indicated below, is 
the thermocouple measurement device ground accessed in the battery compartment.  
 
 
 
                 
 
Fig. H.1. RFC Catheter Thermocouple Filter Design 
Circuit shown is adapted from the datasheet for the AD8494 instrumentation amplifier. Values selected for 𝑅, 
𝐶𝐶, and 𝐶𝐷, along with the cut-off frequencies, are shown to the right. 
 
 
 
Values for 𝑅, 𝐶𝐶, and 𝐶𝐷 were selected to obtain a low cut-off frequency for differential voltage, 𝑓𝑑𝑖𝑓𝑓  , 
and a relatively high cut-off frequency for common mode voltage, 𝑓𝐶𝑀: 
 
𝑓𝑑𝑖𝑓𝑓 =
1
2𝜋𝑅(2𝐶𝐷 + 𝐶𝐶)
 
 
𝑓𝐶𝑀 =
1
2𝜋𝑅𝐶𝐶
 
 
 
 
Fig. H.2. RFC Catheter Thermocouple Filter 
+
_
R
R
CC
CC
CD
R 4.7 kΩ 
CD 1 µF 
CC 0.1 µF 
fDIFF 16.1 Hz 
fCD 339 Hz 
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APPENDIX I: BIAXIAL MECHANICAL TESTING ANALYSIS CODE 
 
 
Basic Biaxial Mechanical Testing (2x2 Marker Grid) Analysis 
The following MATLAB code was used to perform all mechanical and geometrical data analysis in 
Aim 1 and in the durability study in Aim 2. The program reads in data files output from the biaxial 
mechanical tester, which includes marker position data used to determine the deformation gradient 
tensor with a bilinear interpolation. 
 
The input data files for this program must be formatted as follows, where X1q and X2q refer to 
marker positions in the axis 1 and axis 2 directions and q refers to the marker number: 
 
Column # Value 
1 Time (s) 
2 Load 1 
3 Load 2 
4 F11 
5 F12 
6 F21 
7 F22 
8 E11 
9 E12 
10 E22 
11 X11 
12 X12 
13 X13 
14 X14 
15 X21 
16 X22 
17 X23 
18 X24 
 
 
% Biax Data Processing 
  
% Steve Boronyak 
% 08-16-2011 
  
clear 
clc 
  
  
%% User Input %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% Sample Number 
sample = 'Sample 149'; 
  
% Sample Test Date: 10-10-2012 
  
% Sample dimensions 
radial = 11.1;  % mm 
circ = 11.3;    % mm 
  
% Reference Marker Files 
untreated_ref = load('Treated-4wk_ref.txt'); 
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cryo_ref = load('Treated-4wk_ref.txt'); 
treated_ref = load('Treated-4wk_ref.txt'); 
  
% Load Test Data 
untreated = importdata('Treated-4wk(10).txt','\t',1); 
cryo = importdata('Treated-4wk(10).txt','\t',1); 
treated = importdata('Treated-4wk(10).txt','\t',1); 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
  
%% Extract Data %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% Convert to membrane tension - units of N/m: 
C_load_untreated = untreated.data(:,2).*(9.81/radial); 
R_load_untreated = untreated.data(:,3).*(9.81/circ); 
  
C_load_cryo = cryo.data(:,2).*(9.81/radial); 
R_load_cryo = cryo.data(:,3).*(9.81/circ); 
  
C_load_treated = treated.data(:,2).*(9.81/radial); 
R_load_treated = treated.data(:,3).*(9.81/circ); 
  
  
% Shift first data point to equal 1: 
C_stretch_untreated = untreated.data(:,4) - (untreated.data(1,4)-1); 
R_stretch_untreated = untreated.data(:,7) - (untreated.data(1,7)-1); 
  
C_stretch_cryo = cryo.data(:,4) - (cryo.data(1,4)-1); 
R_stretch_cryo = cryo.data(:,7) - (cryo.data(1,7)-1); 
  
C_stretch_treated = treated.data(:,4) - (treated.data(1,4)-1); 
R_stretch_treated = treated.data(:,7) - (treated.data(1,7)-1); 
  
  
% Find the max load: 
[n1,m1] = max(C_load_untreated); 
[n2,m2] = max(R_load_untreated); 
  
[n3,m3] = max(C_load_cryo); 
[n4,m4] = max(R_load_cryo); 
  
[n5,m5] = max(C_load_treated); 
[n6,m6] = max(R_load_treated); 
  
  
%% Determine Strain Differences %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% After data has been trimmed to include only the loading curve, find the 
% data point closet to 90 N/m of membrane tension (because sometimes the  
% biax overshoots this target): 
  
[~,r1] = min( abs(90 - C_load_untreated(1:m1) ) ); 
max_load(1) = C_load_untreated(r1); 
max_stretch(1) = C_stretch_untreated(r1); 
  
[~,r2] = min( abs(90 - R_load_untreated(1:m2) ) ); 
max_load(2) = R_load_untreated(r2); 
max_stretch(2) = R_stretch_untreated(r2); 
  
[~,r3] = min( abs(90 - C_load_cryo(1:m3) ) ); 
max_load(3) = C_load_cryo(r3); 
max_stretch(3) = C_stretch_cryo(r3); 
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[~,r4] = min( abs(90 - R_load_cryo(1:m4) ) ); 
max_load(4) = R_load_cryo(r4); 
max_stretch(4) = R_stretch_cryo(r4); 
  
[~,r5] = min( abs(90 - C_load_treated(1:m5) ) ); 
max_load(5) = C_load_treated(r5); 
max_stretch(5) = C_stretch_treated(r5); 
  
[~,r6] = min( abs(90 - R_load_treated(1:m6) ) ); 
max_load(6) = R_load_treated(r6); 
max_stretch(6) = R_stretch_treated(r6); 
  
max_strain = max_stretch - 1; 
  
% Determine areal strain: 
areal_strain_untreated = max_stretch(1)*max_stretch(2); 
areal_strain_cryo = max_stretch(3)*max_stretch(4); 
areal_strain_treated = max_stretch(5)*max_stretch(6); 
  
% All change in strain data compiled into one matrix: 
change_in_strain = [ (max_strain(3)-max_strain(1))/max_strain(1)*100 ... 
                     (max_strain(5)-max_strain(1))/max_strain(1)*100 ... 
                     (max_strain(5)-max_strain(3))/max_strain(3)*100;... 
                     (max_strain(4)-max_strain(2))/max_strain(2)*100 ... 
                     (max_strain(6)-max_strain(2))/max_strain(2)*100 ... 
                     (max_strain(6)-max_strain(4))/max_strain(4)*100;... 
                     (areal_strain_cryo - 
areal_strain_untreated)/areal_strain_untreated*100 ... 
                     (areal_strain_treated - 
areal_strain_untreated)/areal_strain_untreated*100 ... 
                     (areal_strain_treated - 
areal_strain_cryo)/areal_strain_cryo*100]; 
  
% Determine % change in stretch, RFA to Untreated: 
change_circ_stretch_RFA = ((max_stretch(5) - max_stretch(1))/max_stretch(1))*100; 
change_rad_stretch_RFA = ((max_stretch(6) - max_stretch(2))/max_stretch(2))*100; 
  
% Determine % change in stretch, Cryo Only to Untreated: 
change_circ_stretch_cryo = ((max_stretch(3) - max_stretch(1))/max_stretch(1))*100; 
change_rad_stretch_cryo = ((max_stretch(4) - max_stretch(2))/max_stretch(2))*100; 
  
% Determine % change in stretch, RFA to Cryo Only: 
change_circ_stretch_RFAcryo = ((max_stretch(5) - 
max_stretch(3))/max_stretch(3))*100; 
change_rad_stretch_RFAcryo = ((max_stretch(6) - 
max_stretch(4))/max_stretch(4))*100; 
  
  
disp('----------------------------------------------------------------------------
-') 
disp('    COMPLIANCE CHANGES                                                       
') 
disp('----------------------------------------------------------------------------
-') 
fprintf('\n') 
  
  
disp('PERCENT CHANGE IN STRETCH:') 
fprintf('\n') 
disp('          Cryo to Untreated        RFA to Untreated        RFA to Cryo') 
156 
 
fprintf('Circ         \t%+7.2f \t\t\t\t %+6.2f \t\t\t 
%+7.2f',change_circ_stretch_cryo,change_circ_stretch_RFA,change_circ_stretch_RFAcr
yo) 
fprintf('\n') 
fprintf('Radial       \t%+7.2f \t\t\t\t %+6.2f \t\t\t %+7.2f  
',change_rad_stretch_cryo,change_rad_stretch_RFA,change_rad_stretch_RFAcryo) 
fprintf('\n') 
fprintf('Areal           %+7.2f \t\t\t    %+7.2f \t\t\t %+7.2f  
',change_in_strain(3,1),change_in_strain(3,2),change_in_strain(3,3)) 
fprintf('\n') 
fprintf('\n') 
fprintf('\n') 
  
disp('PERCENT CHANGE IN STRAIN:') 
fprintf('\n') 
disp('          Cryo to Untreated        RFA to Untreated        RFA to Cryo') 
fprintf('Circ         \t%+7.2f \t\t\t\t %+6.2f \t\t\t 
%+7.2f',change_in_strain(1,1),change_in_strain(1,2),change_in_strain(1,3)) 
fprintf('\n') 
fprintf('Radial       \t%+7.2f \t\t\t\t %+6.2f \t\t\t %+7.2f  
',change_in_strain(2,1),change_in_strain(2,2),change_in_strain(2,3)) 
fprintf('\n') 
fprintf('\n') 
fprintf('\n') 
  
COMPLIANCE = [change_circ_stretch_cryo change_rad_stretch_cryo 
change_in_strain(3,1) 0 change_in_strain(1,1) change_in_strain(2,1);... 
              change_circ_stretch_RFA change_rad_stretch_RFA change_in_strain(3,2) 
0 change_in_strain(1,2) change_in_strain(2,2);... 
              change_circ_stretch_RFAcryo change_rad_stretch_RFAcryo 
change_in_strain(3,3) 0 change_in_strain(1,3) change_in_strain(2,3)]; 
           
  
%% Plot Membrance Tension v Stretch %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% Determine max stretch, of all samples: 
total_stretch = [C_stretch_untreated(1:r1); R_stretch_untreated(1:r2); 
C_stretch_cryo(1:r3);... 
                 R_stretch_cryo(1:r4); C_stretch_treated(1:r5); 
R_stretch_treated(1:r6)]; 
              
maximum_S = max(total_stretch); 
  
% Set the maximum x-axis stretch on plot to 1.5 if, stretch is less than 
% 1.5: 
if (maximum_S > 1.5) 
    % DO NOTHING 
else 
    maximum_S = 1.5; 
end 
  
fig1 = figure(1); 
% Plot UNTREATED, CIRC and RADIAL: 
plot(C_stretch_untreated(1:r1),C_load_untreated(1:r1),'ko','MarkerSize',6) 
hold on 
plot(R_stretch_untreated(1:r2),R_load_untreated(1:r2),'kv','MarkerSize',6) 
% Plot CRYO ONLY, CIRC and RADIAL: 
plot(C_stretch_cryo(1:r3),C_load_cryo(1:r3),'bo','MarkerSize',6) 
plot(R_stretch_cryo(1:r4),R_load_cryo(1:r4),'bv','MarkerSize',6) 
% Plot TREATED, CIRC and RADIAL: 
plot(C_stretch_treated(1:r5),C_load_treated(1:r5),'ro','MarkerSize',6) 
plot(R_stretch_treated(1:r6),R_load_treated(1:r6),'rv','MarkerSize',6) 
grid on 
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axis([1 maximum_S 0 95]) 
xlabel('Stretch Ratio') 
ylabel('Membrane Tension (N/m)') 
ptitle1 = [sample,' - Membrane Tension vs. Stretch']; 
title(ptitle1,'FontWeight','bold') 
legend('Circ: Untreated','Radial: Untreated','Circ: Cryo','Radial: Cryo','Circ: 
Cryo + RFA','Radial: Cryo + RFA') 
hold off 
filename = [sample,' - Membrane Tension vs Stretch.jpg']; 
saveas(fig1,filename) 
  
  
%% Stretch Data Referenced to Original Untreated Marker Reference %%%%%%%%% 
  
% REFERENCE STATE, UNTREATED marker data: 
X1 = untreated_ref(1,:); 
X2 = untreated_ref(2,:); 
  
% dX/dS: 
dX1_dS1 = (1/4)*( X1(1) - X1(2) - X1(3) + X1(4) ); 
dX1_dS2 = (1/4)*( X1(1) + X1(2) - X1(3) - X1(4) ); 
dX2_dS1 = (1/4)*( X2(1) - X2(2) - X2(3) + X2(4) ); 
dX2_dS2 = (1/4)*( X2(1) + X2(2) - X2(3) - X2(4) ); 
  
% Determine which frame to use, closest to 90 N/m 
if r1 > r2 
    L1 = r2; 
elseif r2 > r1 
    L1 = r1; 
else 
    L1 = r2; 
end 
  
if r3 > r4 
    L2 = r4; 
elseif r4 > r3 
    L2 = r3; 
else 
    L2 = r3; 
end 
  
if r5 > r6 
    L3 = r6; 
elseif r6 > r5 
    L3 = r5; 
else 
    L3 = r5; 
end 
  
untreated_F11 = untreated.data(1:L1,4); 
untreated_F22 = untreated.data(1:L1,7); 
untreated_k1 = untreated.data(1:L1,5); 
untreated_k2 = untreated.data(1:L1,6); 
  
cryo_F11 = zeros(L2,1); 
cryo_F22 = zeros(L2,1); 
cryo_k1 = zeros(L2,1); 
cryo_k2 = zeros(L2,1); 
  
treated_F11 = zeros(L3,1); 
treated_F22 = zeros(L3,1); 
treated_k1 = zeros(L3,1); 
treated_k2 = zeros(L3,1); 
158 
 
  
% CRYO ONLY F11 and F22, wrt to UNTREATED REFERENCE LOCATIONS: 
for i = 1:L2 
     
    % DEFORMED MARKER POSITIONS, frame 'i': 
    xx1_treated = cryo.data(i,11:14); 
    xx2_treated = cryo.data(i,15:18); 
     
    % Displacement Field: 
    u1 = xx1_treated - X1; 
    u2 = xx2_treated - X2; 
     
    % dU/dS: 
    dU1_dS1 = (1/4)*( u1(1) - u1(2) - u1(3) + u1(4) ); 
    dU1_dS2 = (1/4)*( u1(1) + u1(2) - u1(3) - u1(4) ); 
    dU2_dS1 = (1/4)*( u2(1) - u2(2) - u2(3) + u2(4) ); 
    dU2_dS2 = (1/4)*( u2(1) + u2(2) - u2(3) - u2(4) ); 
     
    % Matrix for H: 
    compH = zeros(2,2); 
    compH(1,1) =  dU1_dS1 * dX2_dS2 - dU1_dS2 * dX2_dS1; 
    compH(1,2) = -dU1_dS1 * dX1_dS2 + dU1_dS2 * dX1_dS1; 
    compH(2,1) =  dU2_dS1 * dX2_dS2 - dU2_dS2 * dX2_dS1; 
    compH(2,2) = -dU2_dS1 * dX1_dS2 + dU2_dS2 * dX1_dS1; 
     
    % Jacobian: 
    J = dX1_dS1 * dX2_dS2 - dX1_dS2 * dX2_dS1; 
  
    % Deformation Gradient Tensor: 
    F = eye(2,2) + (1/J)*compH; 
     
    cryo_F11(i) = F(1,1); 
    cryo_F22(i) = F(2,2); 
    cryo_k1(i) = F(1,2); 
    cryo_k2(i) = F(2,1); 
     
end 
  
% TREATED F11 and F22, wrt to UNTREATED REFERENCE LOCATIONS: 
for i = 1:L3 
     
    % DEFORMED MARKER POSITIONS, frame 'i': 
    xx1_treated = treated.data(i,11:14); 
    xx2_treated = treated.data(i,15:18); 
     
    % Displacement Field: 
    u1 = xx1_treated - X1; 
    u2 = xx2_treated - X2; 
     
    % dU/dS: 
    dU1_dS1 = (1/4)*( u1(1) - u1(2) - u1(3) + u1(4) ); 
    dU1_dS2 = (1/4)*( u1(1) + u1(2) - u1(3) - u1(4) ); 
    dU2_dS1 = (1/4)*( u2(1) - u2(2) - u2(3) + u2(4) ); 
    dU2_dS2 = (1/4)*( u2(1) + u2(2) - u2(3) - u2(4) ); 
     
    % Matrix for H: 
    compH = zeros(2,2); 
    compH(1,1) =  dU1_dS1 * dX2_dS2 - dU1_dS2 * dX2_dS1; 
    compH(1,2) = -dU1_dS1 * dX1_dS2 + dU1_dS2 * dX1_dS1; 
    compH(2,1) =  dU2_dS1 * dX2_dS2 - dU2_dS2 * dX2_dS1; 
    compH(2,2) = -dU2_dS1 * dX1_dS2 + dU2_dS2 * dX1_dS1; 
     
    % Jacobian: 
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    J = dX1_dS1 * dX2_dS2 - dX1_dS2 * dX2_dS1; 
  
    % Deformation Gradient Tensor: 
    F = eye(2,2) + (1/J)*compH; 
     
    treated_F11(i) = F(1,1); 
    treated_F22(i) = F(2,2); 
    treated_k1(i) = F(1,2); 
    treated_k2(i) = F(2,1); 
     
end 
  
  
Jacobian_cryo = cryo_F11(L2) * cryo_F22(L2) - cryo_k1(L2 )* cryo_k2(L2); 
Jacobian_RFA = treated_F11(L3) * treated_F22(L3) - treated_k1(L3) * 
treated_k2(L3); 
Jacobian_untreated = untreated_F11(L1) * untreated_F22(L1) - untreated_k1(L1) * 
untreated_k2(L1); 
  
% Percent change in the Jacobian (area): 
Change_J_cryo = ( (Jacobian_cryo - Jacobian_untreated)/Jacobian_untreated)*100; 
Change_J_RFA = ( (Jacobian_RFA - Jacobian_untreated)/Jacobian_untreated)*100; 
Change_J_RFA_cryo = ( (Jacobian_RFA - Jacobian_cryo)/Jacobian_cryo)*100; 
  
% Change in F11: 
Change_F11_cryo = ( (cryo_F11(L2) - untreated_F11(L1))/untreated_F11(L1))*100; 
Change_F11_RFA = ( (treated_F11(L3) - untreated_F11(L1))/untreated_F11(L1))*100; 
Change_F11_RFA_cryo = ( (treated_F11(L3) - cryo_F11(L2))/cryo_F11(L2))*100; 
  
% Change in F22: 
Change_F22_cryo = ( (cryo_F22(L2) - untreated_F22(L1))/untreated_F22(L1))*100; 
Change_F22_RFA = ( (treated_F22(L3) - untreated_F22(L1))/untreated_F22(L1))*100; 
Change_F22_RFA_cryo = ( (treated_F22(L3) - cryo_F22(L2))/cryo_F22(L2))*100; 
  
disp('----------------------------------------------------------------------------
-') 
disp('    DEFORMATION CHANGES                                                      
') 
disp('----------------------------------------------------------------------------
-') 
fprintf('\n') 
  
disp('PERCENT CHANGE:') 
fprintf('\n') 
disp('          Cryo to Untreated        RFA to Untreated        RFA to Cryo') 
fprintf('Circ         \t%+7.2f \t\t\t\t %+6.2f \t\t\t 
%+7.2f',Change_F11_cryo,Change_F11_RFA,Change_F11_RFA_cryo) 
fprintf('\n') 
fprintf('Radial       \t%+7.2f \t\t\t\t %+6.2f \t\t\t %+7.2f  
',Change_F22_cryo,Change_F22_RFA,Change_F22_RFA_cryo) 
fprintf('\n') 
fprintf('Areal           %+7.2f \t\t\t    %+7.2f \t\t\t %+7.2f  
',Change_J_cryo,Change_J_RFA,Change_J_RFA_cryo) 
fprintf('\n') 
fprintf('\n') 
fprintf('\n') 
  
  
DEFORMATION = [Change_F11_cryo Change_F22_cryo Change_J_cryo;... 
               Change_F11_RFA Change_F22_RFA  Change_J_RFA;... 
               Change_F11_RFA_cryo Change_F22_RFA_cryo Change_J_RFA_cryo]; 
  
%% Plot Membrane Tension v Stretch %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
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% Of treated data referenced to the original untreated marker reference 
  
% Determine MAX & MIN stretch, of all samples: 
total_stretch = [untreated_F11; untreated_F22; cryo_F11;... 
                 cryo_F22; treated_F11; treated_F22]; 
              
maximum_S = max(total_stretch); 
minimum_S = min(total_stretch); 
  
% Set the maximum x-axis stretch on plot to 1.5 if, stretch is less than 
% 1.5: 
if (maximum_S > 1.5) 
    % DO NOTHING 
else 
    maximum_S = 1.5; 
end 
  
% Set the minimum x-axis stretch on plot to 1 if, stretch is greater than 
% 1: 
if (minimum_S < 1) 
    % DO NOTHING 
else 
    minimum_S = 1; 
end 
  
fig2 = figure(2); 
  
% Plot UNTREATED, CIRC and RADIAL: 
plot(untreated_F11,C_load_untreated(1:L1),'ko','MarkerSize',6) 
hold on 
plot(untreated_F22,R_load_untreated(1:L1),'kv','MarkerSize',6) 
  
% Plot CRYO ONLY, CIRC and RADIAL: 
plot(cryo_F11,C_load_cryo(1:L2),'bo','MarkerSize',6) 
plot(cryo_F22,R_load_cryo(1:L2),'bv','MarkerSize',6) 
  
% Plot TREATED, CIRC and RADIAL: 
plot(treated_F11,C_load_treated(1:L3),'ro','MarkerSize',6) 
plot(treated_F22,R_load_treated(1:L3),'rv','MarkerSize',6) 
  
grid on 
axis([minimum_S maximum_S 0 95]) 
xlabel('Stretch Ratio') 
ylabel('Membrane Tension (N/m)') 
ptitle4 = [sample,' - Tenson v Stretch - Original Reference']; 
title(ptitle4,'FontWeight','bold') 
legend('Circ: Untreated','Radial: Untreated','Circ: Cryo','Radial: Cryo','Circ: 
Cryo + RFA','Radial: Cryo + RFA') 
hold off 
  
filename = [sample,' - Tenson v Stretch - Orig Reference.jpg']; 
saveas(fig2,filename) 
  
  
%% Determine GEOMETRY Changes %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
untreated_ref_T = transpose(untreated_ref); 
untreated_ref_T(5,1) = untreated_ref_T(1,1); 
untreated_ref_T(5,2) = untreated_ref_T(1,2); 
  
cryo_ref_T = transpose(cryo_ref); 
cryo_ref_T(5,1) = cryo_ref_T(1,1); 
cryo_ref_T(5,2) = cryo_ref_T(1,2); 
161 
 
  
treated_ref_T = transpose(treated_ref); 
treated_ref_T(5,1) = treated_ref_T(1,1); 
treated_ref_T(5,2) = treated_ref_T(1,2); 
  
  
% Areal Changes: 
untreated_area = polyarea(untreated_ref_T(:,1),untreated_ref_T(:,2)); 
cryo_area = polyarea(cryo_ref_T(:,1),cryo_ref_T(:,2)); 
treated_area = polyarea(treated_ref_T(:,1),treated_ref_T(:,2)); 
  
% Percent Change - Areal: 
cryo_area_change = ((cryo_area - untreated_area)/untreated_area)*100; 
treated_area_change = ((treated_area - untreated_area)/untreated_area)*100; 
treated_cryo_area = ((treated_area - cryo_area)/cryo_area)*100; 
  
% Circumferential & Radial Directions: 
C_untreated = 0.5*(sqrt( (untreated_ref(1,1)-untreated_ref(1,2))^2 + 
(untreated_ref(2,1)-untreated_ref(2,2))^2 )... 
    + sqrt( (untreated_ref(1,4)-untreated_ref(1,3))^2 + (untreated_ref(2,4)-
untreated_ref(2,3))^2 ) ); 
R_untreated = 0.5*(sqrt( (untreated_ref(1,1)-untreated_ref(1,4))^2 + 
(untreated_ref(2,1)-untreated_ref(2,4))^2 )... 
    + sqrt( (untreated_ref(1,2)-untreated_ref(1,3))^2 + (untreated_ref(2,2)-
untreated_ref(2,3))^2 ) ); 
  
C_cryo = 0.5*(sqrt( (cryo_ref(1,1)-cryo_ref(1,2))^2 + (cryo_ref(2,1)-
cryo_ref(2,2))^2 )... 
    + sqrt( (cryo_ref(1,4)-cryo_ref(1,3))^2 + (cryo_ref(2,4)-cryo_ref(2,3))^2 ) ); 
R_cryo = 0.5*(sqrt( (cryo_ref(1,1)-cryo_ref(1,4))^2 + (cryo_ref(2,1)-
cryo_ref(2,4))^2 )... 
    + sqrt( (cryo_ref(1,2)-cryo_ref(1,3))^2 + (cryo_ref(2,2)-cryo_ref(2,3))^2 ) ); 
  
C_treated = 0.5*(sqrt( (treated_ref(1,1)-treated_ref(1,2))^2 + (treated_ref(2,1)-
treated_ref(2,2))^2 )... 
    + sqrt( (treated_ref(1,4)-treated_ref(1,3))^2 + (treated_ref(2,4)-
treated_ref(2,3))^2 ) ); 
R_treated = 0.5*(sqrt( (treated_ref(1,1)-treated_ref(1,4))^2 + (treated_ref(2,1)-
treated_ref(2,4))^2 )... 
    + sqrt( (treated_ref(1,2)-treated_ref(1,3))^2 + (treated_ref(2,2)-
treated_ref(2,3))^2 ) ); 
  
% Percent Change - Circ and Radial: 
cryo_circ_change = (C_cryo-C_untreated)/C_untreated*100; 
cryo_radial_change = (R_cryo-R_untreated)/R_untreated*100; 
  
treated_circ_change = (C_treated-C_untreated)/C_untreated*100; 
treated_radial_change = (R_treated-R_untreated)/R_untreated*100; 
  
treated_cryo_C = (C_treated-C_cryo)/C_cryo*100; 
treated_cryo_R = (R_treated-R_cryo)/R_cryo*100; 
  
change_in_geom = [cryo_circ_change treated_circ_change treated_cryo_C;... 
                  cryo_radial_change treated_radial_change treated_cryo_R;... 
                  cryo_area_change treated_area_change treated_cryo_area]; 
       
disp('----------------------------------------------------------------------------
-') 
disp('    GEOMETRY CHANGES                                                         
') 
disp('----------------------------------------------------------------------------
-') 
fprintf('\n') 
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disp('PERCENT CHANGE:') 
fprintf('\n') 
disp('          Cryo to Untreated        RFA to Untreated        RFA to Cryo') 
fprintf('Circ         \t%+7.2f \t\t\t\t %+6.2f \t\t\t 
%+7.2f',change_in_geom(1,1),change_in_geom(1,2),change_in_geom(1,3)) 
fprintf('\n') 
fprintf('Radial       \t%+7.2f \t\t\t\t %+6.2f \t\t\t %+7.2f  
',change_in_geom(2,1),change_in_geom(2,2),change_in_geom(2,3)) 
fprintf('\n') 
fprintf('Areal           %+7.2f \t\t\t    %+7.2f \t\t\t %+7.2f  
',change_in_geom(3,1),change_in_geom(3,2),change_in_geom(3,3)) 
fprintf('\n') 
fprintf('\n') 
fprintf('\n') 
fprintf('\n') 
  
GEOMETRY = [cryo_circ_change cryo_radial_change cryo_area_change;... 
            treated_circ_change treated_radial_change treated_area_change;... 
            treated_cryo_C treated_cryo_R treated_cryo_area]; 
  
%% Marker Geometry Plot - UNSTRAINED %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
Xdet(1:5) = untreated_ref_T(:,1); 
Xdet(6:10) = treated_ref_T(:,1); 
Ydet(1:5) = untreated_ref_T(:,2); 
Ydet(6:10) = treated_ref_T(:,2); 
  
min_markerX = min(Xdet); 
min_markerY = min(Ydet); 
max_markerX = max(Xdet); 
max_markerY = max(Ydet); 
  
figure(3) 
plot(untreated_ref_T(:,1),untreated_ref_T(:,2),'ko--
','LineWidth',1,'MarkerSize',5,'MarkerFaceColor','k') 
hold on 
plot(cryo_ref_T(:,1),cryo_ref_T(:,2),'bo--
','LineWidth',1,'MarkerSize',5,'MarkerFaceColor','b') 
plot(treated_ref_T(:,1),treated_ref_T(:,2),'ro--
','LineWidth',1,'MarkerSize',5,'MarkerFaceColor','r') 
ptitle4 = [sample,' - Marker Locations - UNSTRAINED']; 
title(ptitle4,'FontWeight','bold') 
legend('Untreated','Cryo Only','RFA + Cryo') 
axis([min_markerX-25 max_markerX+25 min_markerY-25 max_markerY+25]) 
hold off 
  
%% Marker Geometry Plot - STRAINED %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
untreated_strained = [untreated.data(r1,11) untreated.data(r1,15);... 
                      untreated.data(r1,12) untreated.data(r1,16);... 
                      untreated.data(r1,13) untreated.data(r1,17);... 
                      untreated.data(r1,14) untreated.data(r1,18);... 
                      untreated.data(r1,11) untreated.data(r1,15)]; 
           
cryo_strained = [cryo.data(r3,11) cryo.data(r3,15);... 
                 cryo.data(r3,12) cryo.data(r3,16);... 
                 cryo.data(r3,13) cryo.data(r3,17);... 
                 cryo.data(r3,14) cryo.data(r3,18);... 
                 cryo.data(r3,11) cryo.data(r3,15)]; 
                   
treated_strained = [treated.data(r5,11) treated.data(r5,15);... 
                    treated.data(r5,12) treated.data(r5,16);... 
                    treated.data(r5,13) treated.data(r5,17);... 
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                    treated.data(r5,14) treated.data(r5,18);... 
                    treated.data(r5,11) treated.data(r5,15)]; 
                 
Xdet(1:5) = untreated_strained(:,1); 
Xdet(6:10) = treated_strained(:,1); 
Ydet(1:5) = untreated_strained(:,2); 
Ydet(6:10) = treated_strained(:,2); 
  
min_markerX = min(Xdet); 
min_markerY = min(Ydet); 
max_markerX = max(Xdet); 
max_markerY = max(Ydet); 
  
figure(4) 
plot(untreated_strained(:,1),untreated_strained(:,2),'ko--
','LineWidth',1,'MarkerSize',5,'MarkerFaceColor','k') 
hold on 
plot(cryo_strained(:,1),cryo_strained(:,2),'bo--
','LineWidth',1,'MarkerSize',5,'MarkerFaceColor','b') 
plot(treated_strained(:,1),treated_strained(:,2),'ro--
','LineWidth',1,'MarkerSize',5,'MarkerFaceColor','r') 
ptitle5 = [sample,' - Marker Locations - STRAINED']; 
title(ptitle5,'FontWeight','bold') 
legend('Untreated','Cryo Only','RFA + Cryo') 
axis([min_markerX-25 max_markerX+25 min_markerY-25 max_markerY+25]) 
hold off 
 
 
 
 
Biaxial Mechanical Testing Analysis: Fung-Type Strain Energy Model 
The following MATLAB code was used to perform the fits of mechanical data to the Fung-type 
hyperelastic strain energy model presented in Aim 2. 
 
% Parameter fitting for model of biaxial test data 
 
% Steve Boronyak 
% April 17, 2013 
  
clear 
clc 
close all 
  
%% LOAD TEST DATA %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% SAMPLE DIMENSIONS 
L1 = 15;     % mm - circ 
L2 = 12;   % mm - radial 
  
test_data = importdata('Treated(10).txt','\t',1); 
  
LOAD1 = test_data.data(:,2);    % grams 
LOAD2 = test_data.data(:,3);    % grams 
  
% MAX LOAD 
[n1,m1] = max(LOAD1); 
[n2,m2] = max(LOAD2); 
  
if m1 > m2                  % Determine the length of the dataset 
    length = m2; 
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else 
    length = m1; 
end 
  
E11 = test_data.data(1:length,8);   % From Green-Lagrangian Strain Tensor 
E22 = test_data.data(1:length,10); 
  
F11 = test_data.data(1:length,4);   % From deformation gradient tensor 
F22 = test_data.data(1:length,7); 
  
LOAD1 = LOAD1(1:length); 
LOAD2 = LOAD2(1:length); 
  
  
%% CALCULATE S %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
S11 = (LOAD1.*9.81)./(L2.*F11);  % 2nd Piola-Kirchhoff Stress, without 
S22 = (LOAD2.*9.81)./(L1.*F22);  % thickness 
  
  
%% MODEL FITTING %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% INITIAL GUESSES 
c = 0.1;                 % N/m 
A1 = 100;                % Unitless 
A2 = 10;                 % Unitless 
beta = [c;A1;A2]; 
  
Nfit = 3;                % Number of parameters to fit 
  
% LOWER BOUNDS 
LB = [0;0;0];            % Model makes no sense of coeffs below 0 
  
fop = optimset('Algorithm','levenberg-marquardt');  % Doesn't use Marquardt due to 
lower bounds 
[betaE,RESNORM,residuals,exflag,outp,lambda,JACOBIAN] = 
lsqnonlin(@biax_function_4,beta,LB,[],fop,S11,S22,E11,E22); 
beta_ci = nlparci(betaE,residuals,'jacobian',JACOBIAN); 
  
  
%% GENERATE FUNCTION FROM CALCULATED PARAMETERS %%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
S11_CALC = betaE(1).*( 2.*betaE(2).*E11 ).*exp( betaE(2).*E11.^2 + 
betaE(3).*E22.^2 ); 
S22_CALC = betaE(1).*( 2.*betaE(3).*E22 ).*exp( betaE(2).*E11.^2 + 
betaE(3).*E22.^2 ); 
  
W = betaE(1).*(exp( betaE(2).*E11.^2 + betaE(3).*E22.^2 ) - 1);    % Strain-energy 
function 
W_loading = betaE(1)*(exp( betaE(2)*E11(length)^2 + betaE(3)*E22(length)^2 ) - 1); 
  
SStot = sum((S11 - mean(S11)).^2); 
SSerr = sum((S11 - S11_CALC).^2); 
R_Squared_11 = 1 - SSerr/SStot;         % R^2 of circ fit 
  
SStot = sum((S22 - mean(S22)).^2); 
SSerr = sum((S22 - S22_CALC).^2); 
R_Squared_22 = 1 - SSerr/SStot;         % R^2 of radial fit 
  
  
% PLOT RESIDUALS HISTOGRAM 
figure(1) 
hist(residuals) 
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% PLOT THE MODEL FIT 
figure(2) 
plot(F11,S11.*F11,'bo') 
hold on 
plot(F22,S22.*F22,'rd') 
plot(F11,S11_CALC.*F11,'k-','LineWidth',2) 
plot(F22,S22_CALC.*F22,'k-','LineWidth',2) 
xlabel('Stretch Ratio') 
ylabel('Membrane Tension (N/m)') 
legend('Circ','Radial') 
title('Model Fits') 
hold off 
  
  
%% ERROR ANALYSIS %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
  
JACOBIAN = full(JACOBIAN); 
  
% Sigma^2: 
weight_sq = (residuals'*residuals)/(length-Nfit+1); 
  
% Curvature matrix: 
alphaS = JACOBIAN'*JACOBIAN./weight_sq; 
  
% Covariance matrix: 
covariance = inv(alphaS); 
  
% SigmaP 
sigmaP = diag(sqrt(covariance)); 
  
% Correlation matrix: 
correlation = covariance ./ (sigmaP*sigmaP');    
CORRELATE = det(correlation); 
  
% Chi^2 statistic: 
chisq2 = 1/weight_sq*sum(residuals.^2); 
chi_critical = chi2inv(0.95,length-Nfit); 
  
  
%% COMPILE DATA FOR EASY EXPORT %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
ALL_DATA = [betaE(1);betaE(2);betaE(3);R_Squared_11;R_Squared_22;... 
    W_loading;outp.iterations;chisq2;chi_critical;CORRELATE]; 
  
PLOT_DATA = [F11 S11.*F11 F22 S22.*F22 F11 S11_CALC.*F11 F22 S22_CALC.*F22]; 
 
function F = biax_function_4(beta,S11,S22,E11,E22) 
  
F = [ S11 - beta(1).*( 2.*beta(2).*E11 ).*exp( beta(2).*E11.^2 + beta(3).*E22.^2 ) 
      S22 - beta(1).*( 2.*beta(3).*E22 ).*exp( beta(2).*E11.^2 + beta(3).*E22.^2 
)]; 
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Basic Biaxial Mechanical Testing 16 Marker Analysis 
The following MATLAB code was used to perform the Aim 1 – Part 2 studies in Chapter 6. 
 
The data is input from a .mat file, which contains four variables: X1, X2, xx1, and xx2. X1 and X2 are 
the marker reference positions and xx1 and xx2 are the deformed marker positions, where 1 and 2 
correspond to axis 1 and axis 2. Each variable is arranged as a 1x16 matrix, with the column number 
corresponding to the marker numbers shown in the code below. 
 
%% BIAX 16 MARKER DEFORMATION GRADIENT AND ANALYSIS 
  
% Steve Boronyak 
% Department of Biomedical Engineering 
% Vanderbilt University 
% January 5, 2015 
  
% This code only works with the AVERAGE marker positions obtained after 
% using "biax_16_average_markers.m" or "biax_16_average_markersRF.m". The 
% file loads in the X1, X2, xx1, and xx2 marker positions in units of cm. 
  
% This code performs a bicubic interpolation in order to calculate the 
% displacement gradient and deformation gradient within a 4x4 bicubic 
% element. The spatially varying deformation gradient and maximum principal 
% strain are plotted on the reference and deformed grids. The grids were 
% determined using the bicubic interpolation of the 16 tracking markers. 
  
% Marker numbering for this implementation of the bicubic interpolation 
% (for X1 and X2 below): 
% 04---10---09---03 
% ||   ||   ||   || 
% 11---16---15---08 
% ||   ||   ||   || 
% 12---13---14---07 
% ||   ||   ||   || 
% 01---05---06---02 
  
% This program loads the marker positions assuming the following 
% configuration (this is the marker order of X1uo and X2uo): 
% 04---03---02---01 
% ||   ||   ||   || 
% 08---07---06---05 
% ||   ||   ||   || 
% 12---11---10---09 
% ||   ||   ||   || 
% 16---15---14---13 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
clear 
close all 
clc 
colordef white              % Set figures for black background 
  
  
%% USER INPUT %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% REFERENCE and DEFORMED Marker File 
disp('Select DATA file'); 
[datafile,ImageFolder,~] = uigetfile('*.mat'); 
xxx = [ImageFolder datafile]; 
load(xxx) 
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%% EXTRACT DATA %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% Displacement Field: 
u1 = xx1 - X1; 
u2 = xx2 - X2; 
  
% Rearrange X1/2 and xx1/2 arrays for marker outline: 
jj = [1,5,6,2,7,8,3,9,10,4,11,12,1]; 
for i = 1:13 
    X1_outline(i) = X1(jj(i)); 
    X2_outline(i) = X2(jj(i)); 
    xx1_outline(i) = xx1(jj(i)); 
    xx2_outline(i) = xx2(jj(i)); 
end 
  
%% CALCULATE DEFORMED GRADIENT AT r=0, s=0 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
r = 0; 
s = 0; 
  
% Marker locations in the local (r,s) coordinate system: 
rL = [-1,1,1,-1,-1/3,1/3,1,1,1/3,-1/3,-1,-1,-1/3,1/3,1/3,-1/3]; 
sL = [-1,-1,1,1,-1,-1,-1/3,1/3,1,1,1/3,-1/3,-1/3,-1/3,1/3,1/3]; 
  
% dX/dS: 
dX1_dS1 = bicubic_derivative_r(r,s,rL,sL,X1); 
dX1_dS2 = bicubic_derivative_s(r,s,rL,sL,X1); 
dX2_dS1 = bicubic_derivative_r(r,s,rL,sL,X2); 
dX2_dS2 = bicubic_derivative_s(r,s,rL,sL,X2); 
  
% dU/dS: 
dU1_dS1 = bicubic_derivative_r(r,s,rL,sL,u1); 
dU1_dS2 = bicubic_derivative_s(r,s,rL,sL,u1); 
dU2_dS1 = bicubic_derivative_r(r,s,rL,sL,u2); 
dU2_dS2 = bicubic_derivative_s(r,s,rL,sL,u2); 
  
% Matrix for H: 
compH = zeros(2,2); 
compH(1,1) =  dU1_dS1*dX2_dS2 - dU1_dS2*dX2_dS1; 
compH(1,2) = -dU1_dS1*dX1_dS2 + dU1_dS2*dX1_dS1; 
compH(2,1) =  dU2_dS1*dX2_dS2 - dU2_dS2*dX2_dS1; 
compH(2,2) = -dU2_dS1*dX1_dS2 + dU2_dS2*dX1_dS1; 
  
% Jacobian: 
J = dX1_dS1*dX2_dS2 - dX1_dS2*dX2_dS1; 
  
% Deformation Gradient Tensor: 
F = eye(2,2) + (1/J)*compH; 
  
F11 = F(1,1); 
F22 = F(2,2); 
k1 = F(1,2); 
k2 = F(2,1); 
  
%% GENERATE MESH GRID - DEFORMED AND UNDEFORMED %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
node_width = 50;                            % Number of nodes in each direction 
r = linspace(-1,1,node_width);              % Generate vector of points in r-space 
s = linspace(-1,1,node_width);              % Generate vector of points in s-space 
  
[rr,ss] = meshgrid(r,s); 
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% Generate REFERENCE and DEFORMED grids 
for i = 1:node_width 
    for j = 1:node_width 
        X_grid(i,j) = bicubic_basis(rr(i,j),ss(i,j),rL,sL,X1); 
        Y_grid(i,j) = bicubic_basis(rr(i,j),ss(i,j),rL,sL,X2); 
        u_grid(i,j) =  bicubic_basis(rr(i,j),ss(i,j),rL,sL,u1); 
        v_grid(i,j) = bicubic_basis(rr(i,j),ss(i,j),rL,sL,u2); 
        xx_grid(i,j) = X_grid(i,j) + u_grid(i,j); 
        yy_grid(i,j) = Y_grid(i,j) + v_grid(i,j); 
    end 
end 
  
  
%% CALCULATE DEFORMATION GRADIENT EVERYWHERE %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
for i = 1:node_width 
    for j = 1:node_width 
        % dX/dS: 
        dX1_dS1 = bicubic_derivative_r(rr(i,j),ss(i,j),rL,sL,X1); 
        dX1_dS2 = bicubic_derivative_s(rr(i,j),ss(i,j),rL,sL,X1); 
        dX2_dS1 = bicubic_derivative_r(rr(i,j),ss(i,j),rL,sL,X2); 
        dX2_dS2 = bicubic_derivative_s(rr(i,j),ss(i,j),rL,sL,X2); 
         
        % dU/dS: 
        dU1_dS1 = bicubic_derivative_r(rr(i,j),ss(i,j),rL,sL,u1); 
        dU1_dS2 = bicubic_derivative_s(rr(i,j),ss(i,j),rL,sL,u1); 
        dU2_dS1 = bicubic_derivative_r(rr(i,j),ss(i,j),rL,sL,u2); 
        dU2_dS2 = bicubic_derivative_s(rr(i,j),ss(i,j),rL,sL,u2); 
         
        % Matrix for H: 
        compH = zeros(2,2); 
        compH(1,1) =  dU1_dS1*dX2_dS2 - dU1_dS2*dX2_dS1; 
        compH(1,2) = -dU1_dS1*dX1_dS2 + dU1_dS2*dX1_dS1; 
        compH(2,1) =  dU2_dS1*dX2_dS2 - dU2_dS2*dX2_dS1; 
        compH(2,2) = -dU2_dS1*dX1_dS2 + dU2_dS2*dX1_dS1; 
         
        % Jacobian: 
        J = dX1_dS1*dX2_dS2 - dX1_dS2*dX2_dS1; 
         
        % Deformation Gradient Tensor: 
        zF = eye(2,2) + (1/J)*compH; 
         
        zF11(i,j) = zF(1,1);            % Axis 1 deformation 
        zF22(i,j) = zF(2,2);            % Axis 2 deformation 
        zFdet(i,j) = det(zF);           % Areal deformation 
         
        E_star = 0.5*(transpose(zF)*zF - eye(2,2)); 
        [v,d] = eig(E_star); 
        zMAXp(i,j) = min(min(d));       % Minimum principal strain 
%         zMAXp(i,j) = max(max(d));       % Minimum principal strain 
        zInv1(i,j) = sum(sum(d));       % 1st Invariant 
    end 
end 
  
for i = 1:node_width 
    % dX/dS: 
    dX1_dS1 = bicubic_derivative_r(r(i),0,rL,sL,X1); 
    dX1_dS2 = bicubic_derivative_s(r(i),0,rL,sL,X1); 
    dX2_dS1 = bicubic_derivative_r(r(i),0,rL,sL,X2); 
    dX2_dS2 = bicubic_derivative_s(r(i),0,rL,sL,X2); 
     
    % dU/dS: 
    dU1_dS1 = bicubic_derivative_r(r(i),0,rL,sL,u1); 
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    dU1_dS2 = bicubic_derivative_s(r(i),0,rL,sL,u1); 
    dU2_dS1 = bicubic_derivative_r(r(i),0,rL,sL,u2); 
    dU2_dS2 = bicubic_derivative_s(r(i),0,rL,sL,u2); 
     
    % Matrix for H: 
    compH = zeros(2,2); 
    compH(1,1) =  dU1_dS1*dX2_dS2 - dU1_dS2*dX2_dS1; 
    compH(1,2) = -dU1_dS1*dX1_dS2 + dU1_dS2*dX1_dS1; 
    compH(2,1) =  dU2_dS1*dX2_dS2 - dU2_dS2*dX2_dS1; 
    compH(2,2) = -dU2_dS1*dX1_dS2 + dU2_dS2*dX1_dS1; 
     
    % Jacobian: 
    J = dX1_dS1*dX2_dS2 - dX1_dS2*dX2_dS1; 
     
    % Deformation Gradient Tensor: 
    zF = eye(2,2) + (1/J)*compH; 
     
    F11s0(i) = zF(1,1);            % Axis 1 deformation 
    F22s0(i) = zF(2,2);            % Axis 2 deformation 
    Fdets0(i) = det(zF);           % Areal deformation 
     
    XposS0(i) = bicubic_basis(r(i),0,rL,sL,X1); 
    YposS0(i) = bicubic_basis(r(i),0,rL,sL,X2); 
    u_grid0(i) =  bicubic_basis(r(i),0,rL,sL,u1); 
    v_grid0(i) = bicubic_basis(r(i),0,rL,sL,u2); 
    xx_posS0(i) = XposS0(i) + u_grid0(i); 
    yy_posS0(i) = YposS0(i) + v_grid0(i); 
end 
  
for i = 1:node_width 
    % dX/dS: 
    dX1_dS1 = bicubic_derivative_r(0,s(i),rL,sL,X1); 
    dX1_dS2 = bicubic_derivative_s(0,s(i),rL,sL,X1); 
    dX2_dS1 = bicubic_derivative_r(0,s(i),rL,sL,X2); 
    dX2_dS2 = bicubic_derivative_s(0,s(i),rL,sL,X2); 
     
    % dU/dS: 
    dU1_dS1 = bicubic_derivative_r(0,s(i),rL,sL,u1); 
    dU1_dS2 = bicubic_derivative_s(0,s(i),rL,sL,u1); 
    dU2_dS1 = bicubic_derivative_r(0,s(i),rL,sL,u2); 
    dU2_dS2 = bicubic_derivative_s(0,s(i),rL,sL,u2); 
     
    % Matrix for H: 
    compH = zeros(2,2); 
    compH(1,1) =  dU1_dS1*dX2_dS2 - dU1_dS2*dX2_dS1; 
    compH(1,2) = -dU1_dS1*dX1_dS2 + dU1_dS2*dX1_dS1; 
    compH(2,1) =  dU2_dS1*dX2_dS2 - dU2_dS2*dX2_dS1; 
    compH(2,2) = -dU2_dS1*dX1_dS2 + dU2_dS2*dX1_dS1; 
     
    % Jacobian: 
    J = dX1_dS1*dX2_dS2 - dX1_dS2*dX2_dS1; 
     
    % Deformation Gradient Tensor: 
    zF = eye(2,2) + (1/J)*compH; 
     
    F11r0(i) = zF(1,1);            % Axis 1 deformation 
    F22r0(i) = zF(2,2);            % Axis 2 deformation 
    Fdetr0(i) = det(zF);           % Areal deformation 
     
%     YposR0(i) = bicubic_basis(0,s(i),rL,sL,X2); 
     
    XposR0(i) = bicubic_basis(0,s(i),rL,sL,X1); 
    YposR0(i) = bicubic_basis(0,s(i),rL,sL,X2); 
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    u_grid0(i) =  bicubic_basis(0,s(i),rL,sL,u1); 
    v_grid0(i) = bicubic_basis(0,s(i),rL,sL,u2); 
    xx_posR0(i) = XposR0(i) + u_grid0(i); 
    yy_posR0(i) = YposR0(i) + v_grid0(i); 
end 
  
  
%% PLOT MARKERS 
  
% Determine boundaries of plots, so all are uniform 
xMIN = min([min(min(X_grid)) min(min(xx_grid))]); 
xMAX = max([max(max(X_grid)) max(max(xx_grid))]); 
yMIN = min([min(min(Y_grid)) min(min(yy_grid))]); 
yMAX = max([max(max(Y_grid)) max(max(yy_grid))]); 
  
%% PLOTS OF DEFORMATION GRADIENT %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% Determine boundaries of plots, so all are uniform 
xMIN = min([min(min(X_grid)) min(min(xx_grid))]); 
xMAX = max([max(max(X_grid)) max(max(xx_grid))]); 
yMIN = min([min(min(Y_grid)) min(min(yy_grid))]); 
yMAX = max([max(max(Y_grid)) max(max(yy_grid))]); 
  
  
fig5 = figure(5); 
pcolor(xx_grid,yy_grid,zFdet) 
hold on 
plot(xx1,xx2,'ko','MarkerSize',5,'MarkerFaceColor','k') 
% title('Areal Deformation - DEFORMED Configuration','FontSize',14) 
xlim([xMIN-0.05 xMAX+0.05]) 
ylim([yMIN-0.05 yMAX+0.05]) 
colorbar 
set(colorbar,'fontsize',14); 
% set(gcf, 'Color', [0,0,0]); 
set(gcf, 'Color', [1,1,1]); 
set(gca,'FontSize',14) 
% caxis([FMIN2 FMAX2]) 
xlabel('(cm)') 
ylabel('(cm)') 
hold off 
 
fig5 = figure(8); 
pcolor(xx_grid,yy_grid,zF11) 
hold on 
plot(xx1,xx2,'ko','MarkerSize',5,'MarkerFaceColor','k') 
% title('F11 - DEFORMED Configuration','FontSize',14) 
% plot(xx_posS0,yy_posS0,'k-','LineWidth',2) 
% plot(xx_posR0,yy_posR0,'k-','LineWidth',2) 
xlim([xMIN-0.05 xMAX+0.05]) 
ylim([yMIN-0.05 yMAX+0.05]) 
% caxis([FMIN FMAX]) 
colorbar 
set(colorbar,'fontsize',14); 
% set(gcf, 'Color', [0,0,0]); 
set(gcf, 'Color', [1,1,1]); 
set(gca,'FontSize',14) 
xlabel('(cm)') 
ylabel('(cm)') 
hold off 
 
figure(9) 
pcolor(X_grid,Y_grid,zF22) 
hold on 
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plot(X1,X2,'ko','MarkerSize',5,'MarkerFaceColor','k') 
plot(XposS0,YposS0,'k-','LineWidth',2) 
plot(XposR0,YposR0,'k-','LineWidth',2) 
% title('F22 - REFERENCE Configuration','FontSize',14) 
% caxis([FMIN FMAX]) 
colorbar 
set(colorbar,'fontsize',14); 
% set(gcf, 'Color', [0,0,0]); 
set(gcf, 'Color', [1,1,1]); 
set(gca,'FontSize',14) 
xlabel('(cm)') 
ylabel('(cm)') 
hold off 
  
fig5 = figure(10); 
pcolor(xx_grid,yy_grid,zF22) 
hold on 
plot(xx1,xx2,'ko','MarkerSize',5,'MarkerFaceColor','k') 
% title('F22 - DEFORMED Configuration','FontSize',14) 
xlim([xMIN-0.05 xMAX+0.05]) 
ylim([yMIN-0.05 yMAX+0.05]) 
% plot(xx_posS0,yy_posS0,'k-','LineWidth',2) 
% plot(xx_posR0,yy_posR0,'k-','LineWidth',2) 
% caxis([FMIN FMAX]) 
colorbar 
set(colorbar,'fontsize',14); 
% set(gcf, 'Color', [0,0,0]); 
set(gcf, 'Color', [1,1,1]); 
set(gca,'FontSize',14) 
xlabel('(cm)') 
ylabel('(cm)') 
hold off 
 
figure(13) 
plot(XposS0,Fdets0,'k-.','LineWidth',2) 
hold on 
set(gca,'LineWidth',2); 
plot(XposS0,F11s0,'b-','LineWidth',2) 
set(gca,'FontSize',14) 
plot(XposS0,F22s0,'r--','LineWidth',2) 
xlabel('X11 Position (cm)') 
ylabel('Deformation') 
legend('Areal','Circ - F11','Radial - F22') 
xlim([-.7 .7]) 
% ylim([0.3 1.4]) 
hold off 
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APPENDIX J: AIM 2 SUPPLEMENTAL DATA – ESTIMATED MODEL PARAMETERS 
 
 
This section of the Appendix contains the estimated model parameters for all samples analyzed in 
the Aim 2 study of strain energy model fits. 
 
 
Table J.1. Parameter fitting results for untreated MV anterior leaflets. 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
92 0.10 106.67 22.48 4.56 0.995 0.996 
93 0.03 89.22 35.68 3.52 0.996 0.997 
94 0.01 243.43 31.78 3.03 0.995 0.993 
91 0.04 607.16 21.67 3.58 0.984 0.993 
83 0.04 176.96 11.32 4.49 0.992 0.989 
82 0.08 54.61 8.57 5.95 0.993 0.992 
86 0.06 551.91 95.91 2.64 0.980 0.987 
81 0.01 50.63 23.60 3.93 0.995 0.992 
80 0.03 58.24 17.52 4.31 0.993 0.992 
79 0.01 244.73 13.47 3.63 0.992 0.990 
78 0.10 31.05 10.71 5.11 0.987 0.988 
77 0.05 57.38 21.18 4.48 0.994 0.992 
76 0.05 67.95 14.41 5.06 0.992 0.991 
75 0.05 62.04 6.40 6.10 0.996 0.991 
74 0.05 90.93 22.04 4.36 0.995 0.994 
73 0.19 110.56 36.89 4.17 0.991 0.992 
72 0.07 250.95 79.96 2.68 0.995 0.992 
71 0.22 89.47 55.56 4.15 0.996 0.995 
70 0.06 59.32 21.74 4.47 0.994 0.992 
69 0.04 152.21 14.30 4.22 0.995 0.994 
68 0.02 46.74 22.24 4.19 0.994 0.992 
67 0.00 71.99 24.60 3.01 0.979 0.971 
66 0.09 60.70 17.16 5.25 0.996 0.996 
65 0.06 187.89 30.37 3.63 0.995 0.996 
64 0.06 136.58 44.86 3.48 0.995 0.995 
63 0.04 131.87 17.85 3.96 0.995 0.994 
62 0.07 100.49 29.29 3.98 0.995 0.995 
61 0.06 87.13 16.12 4.54 0.998 0.996 
60 0.04 47.42 9.43 5.37 0.993 0.990 
59 0.01 58.79 39.29 3.51 0.992 0.991 
58 0.11 24.26 4.09 7.11 0.990 0.982 
57 0.13 155.57 12.48 4.87 0.993 0.994 
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56 0.09 67.37 25.05 4.44 0.994 0.992 
55 0.18 75.04 6.64 6.41 0.998 0.991 
54 0.07 132.86 8.85 4.86 0.994 0.983 
53 0.04 74.21 14.44 4.62 0.993 0.992 
52 0.05 168.59 15.23 4.31 0.994 0.992 
51 0.24 285.50 48.44 3.73 0.980 0.991 
49 0.05 94.55 26.80 3.97 0.995 0.996 
48 0.16 65.57 16.33 5.13 0.996 0.997 
45 0.12 93.19 30.80 4.16 0.998 0.997 
43 0.06 184.65 17.75 4.57 0.986 0.993 
42 0.05 416.00 57.58 2.82 0.993 0.996 
43 0.04 168.37 48.80 2.92 0.995 0.995 
95 0.07 240.39 33.54 3.55 0.997 0.994 
96 0.14 67.47 9.49 6.08 0.996 0.993 
97 0.04 91.43 25.24 4.07 0.995 0.992 
98 0.12 69.68 17.56 4.77 0.996 0.996 
99 0.10 45.97 9.15 5.47 0.995 0.992 
100 0.14 162.98 36.60 3.71 0.993 0.997 
101 0.21 136.42 76.56 3.58 0.995 0.995 
103 0.03 154.97 33.40 3.48 0.988 0.986 
104 0.20 44.04 8.52 6.64 0.992 0.983 
105 0.04 258.22 38.12 3.32 0.984 0.985 
106 0.33 55.40 6.79 7.38 0.994 0.977 
107 0.13 186.35 24.23 3.98 0.996 0.993 
108 0.14 83.86 26.39 4.41 0.995 0.993 
109 0.17 152.64 53.33 3.84 0.993 0.995 
110 0.15 160.30 60.48 3.54 0.991 0.994 
125 0.06 114.39 16.24 4.50 0.994 0.992 
127 0.14 91.13 23.50 4.67 0.998 0.996 
129 0.34 61.05 8.44 7.12 0.998 0.994 
145 0.17 154.65 13.03 5.87 0.996 0.995 
146 0.09 230.41 39.17 3.64 0.996 0.997 
147 0.02 526.90 27.44 3.39 0.990 0.990 
124 0.08 82.06 17.41 4.79 0.996 0.994 
126 0.15 51.12 25.01 5.09 0.997 0.997 
128 0.05 158.85 47.72 2.48 0.996 0.995 
142 0.03 386.66 37.21 3.15 0.955 0.982 
143 0.16 146.41 13.42 5.34 0.996 0.994 
144 0.06 168.88 26.36 3.91 0.996 0.995 
111 0.04 146.25 61.71 3.11 0.987 0.990 
112 0.00 276.11 37.01 2.43 0.975 0.985 
113 0.05 32.52 9.92 5.78 0.986 0.988 
114 0.05 152.65 34.42 3.66 0.995 0.995 
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115 0.04 419.26 56.39 2.67 0.995 0.996 
116 0.04 437.05 56.27 2.68 0.995 0.996 
137 0.00 118.16 22.48 3.09 0.993 0.991 
138 0.01 119.28 24.53 3.57 0.992 0.991 
139 0.02 76.01 26.34 3.92 0.995 0.995 
140 0.01 74.87 30.87 3.52 0.994 0.992 
141 0.06 58.47 18.88 4.83 0.997 0.996 
87 0.01 711.96 31.84 2.82 0.982 0.984 
41 0.04 168.37 48.80 2.92 0.995 0.995 
40 0.19 215.39 31.59 4.20 0.991 0.994 
39 0.11 161.01 18.94 4.72 0.996 0.996 
38 0.08 68.82 16.56 4.79 0.998 0.995 
37 0.11 104.71 16.47 4.65 0.995 0.994 
36 0.05 157.64 38.10 3.61 0.995 0.994 
35 0.14 95.36 62.74 3.78 0.997 0.996 
33 0.02 92.65 35.68 3.23 0.994 0.995 
34 0.14 64.90 21.37 4.95 0.997 0.996 
31 0.17 60.90 36.08 4.71 0.995 0.994 
30 0.72 17.05 3.42 10.65 0.998 0.992 
29 0.14 48.10 10.11 6.12 0.995 0.993 
27 0.06 64.05 19.77 4.49 0.994 0.993 
26 0.13 76.28 28.52 4.54 0.998 0.997 
25 0.08 65.00 18.82 4.93 0.997 0.995 
24 0.11 54.21 28.00 4.71 0.996 0.997 
23 0.09 57.48 11.11 5.82 0.997 0.996 
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Table J.2. Parameter fitting results from static control, RF-treated leaflets. 
STATICALLY TREATED: 350 J 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
106 0.75 21.80 8.66 7.98 0.994 0.987 
107 0.15 125.72 29.02 4.29 0.994 0.994 
108 0.78 31.72 14.79 7.39 0.998 0.998 
109 0.71 55.47 31.17 5.48 0.998 0.998 
110 0.51 95.21 59.97 4.32 0.998 0.997 
       STATICALLY TREATED: 850 J 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
100 5.73 3.70 4.91 15.59 0.998 0.998 
101 1.55 11.00 5.67 11.08 0.998 0.997 
103 11.81 2.94 2.71 18.96 0.998 0.998 
104 5.48 2.59 2.47 18.06 0.998 0.995 
105 1.45 0.00 18.73 5.62 -0.838 0.980 
       STATICALLY TREATED: 1250 J 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
95 0.94 2.93 4.51 11.39 0.354 0.176 
96 6.38 2.33 3.61 17.56 0.998 0.998 
97 2.91 2.07 4.21 15.61 0.699 0.708 
98 3.92 3.56 3.84 15.54 0.998 0.997 
99 11.64 1.58 1.27 24.21 0.998 0.998 
 
 
  
176 
 
Table J.3. Parameter fitting results from flow loop treated MV leaflets. 
FLOW LOOP TREATED: CRYO ONLY 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
157 0.14 95.21 28.11 4.29 0.999 0.998 
160 0.06 74.29 23.90 4.44 0.998 0.994 
 163 0.08 66.10 16.89 5.31 0.997 0.993 
       FLOW LOOP TREATED: RF ONLY 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
158 3.25 5.73 4.07 14.05 0.999 0.999 
161 2.50 6.00 3.62 14.28 0.999 0.998 
162 2.75 11.94 8.60 11.30 0.990 0.990 
       FLOW LOOP TREATED: RF+CRYO 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
155 6.50 4.25 2.41 18.22 0.998 0.997 
156 13.67 5.24 5.46 14.27 0.996 0.998 
159 7.40 5.50 3.21 15.83 0.995 0.994 
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Table J.4. Parameter fitting results from durability study leaflets. 
UNTREATED: ACUTE 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
125 0.06 114.39 16.24 4.50 0.994 0.992 
127 0.14 91.13 23.50 4.67 0.998 0.996 
129 0.34 61.05 8.44 7.12 0.998 0.994 
145 0.17 154.65 13.03 5.87 0.996 0.995 
146 0.09 230.41 39.17 3.64 0.996 0.997 
147 0.02 526.90 27.44 3.39 0.990 0.990 
       UNTREATED: WEEK 4 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
131 0.47 81.01 31.14 5.40 0.996 0.996 
133 0.31 49.23 39.41 4.87 0.998 0.998 
135 0.36 57.82 13.17 6.33 0.997 0.995 
149 0.13 1685.22 43.46 4.04 0.943 0.936 
151 0.20 183.25 33.29 4.18 0.974 0.970 
153 0.17 470.44 23.57 4.38 0.993 0.988 
       TREATED: ACUTE 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
124 10.74 3.38 2.33 18.74 0.995 0.993 
126 1.93 9.17 4.92 12.39 0.995 0.997 
128 3.35 11.50 5.16 12.33 0.999 0.999 
142 4.26 3.03 4.36 16.00 0.972 0.980 
143 1.99 14.23 4.30 11.61 0.998 0.993 
144 0.43 36.18 15.34 6.54 0.993 0.989 
       TREATED: WEEK 4 
Sample Number c (N/m) A1 A2 W (N/m) R2circ R2rad 
130 3.87 13.07 7.71 11.19 0.994 0.996 
132 1.51 13.18 9.88 9.35 0.996 0.995 
134 3.01 19.25 11.57 8.97 0.998 0.998 
148 2.87 7.44 8.53 12.06 0.982 0.989 
150 2.79 21.21 4.84 11.45 0.997 0.998 
152 0.95 60.30 14.16 6.88 0.998 0.996 
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APPENDIX K: LEFT HEART FLOW SIMULATOR 
 
 
Essential accessory components for the left heart flow simulator, pinout diagrams for the LabView 
DAQ cards, pressure sensor calibrations, and the pneumatic system schematic are shown below. 
CAD drawings to reproduce the left heart flow simulator follow on the remaining pages. 
 
 
Essential Components, Left Heart Flow Simulator 
PART PART NUMBER MANUFACTURER 
Proportional Pressure Regulator PS120000-020-010 Hoerbiger 
Pressure Sensors 19C003PG1L Honeywell 
Flow Meter 400 Series Transonic 
Solenoid Valve 3-Way, 8003G/H, 8202 G/H Asco 
DAQ Chassis NI-cDAQ 9178 National Instruments 
DAQ: Analog In NI-9205 National Instruments 
DAQ: Analog Out NI-9263 National Instruments 
 
 
Pinouts for DAQ Cards 
NI 9205 
ACH0+ Pressure Sensor, Ventricle, OUT+ 
ACH0- Pressure Sensor, Ventricle, OUT- 
ACH1+ Pressure Sensor, Atrium, OUT+ 
ACH1- Pressure Sensor, Atrium, OUT- 
ACH3+ Flow Meter, Slot 1, Pin 1 
ACH3- GND 
ACH4+ Flow Meter, Slot 1, Pin 2 
ACH4- GND 
ACH5+ RF Generator, RF Power Measurement, + 
ACH5- RF Generator, RF Power Measurement, - 
ACH6+ RF Generator, RF Impedance Measurement, + 
ACH6- RF Generator, RF Impedance Measurement, - 
NI 9263 
AO0 Proportional Regulator, Set Value 
COM GND 
AO1 Transistor to Solenoid Valve 
COM GND 
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Pressure Sensor Calibration: Ventricle 
 
 
 
 
Pressure Sensor Calibration: Atrium 
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Left Heart Flow Simulator Pneumatic System Diagram 
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